What is A@@ cla@@ sta@@ ?
A@@ cla@@ sta is a solution for in@@ fusion (@@ dri@@ p into a v@@ ein@@ ) containing the active substance z@@ ole@@ dr@@ onic acid (@@ 5 m@@ g@@ / 100 m@@ l@@ )@@ .
What is A@@ cla@@ sta used for@@ ?
A@@ cla@@ sta is used for the treatment of the following dise@@ as@@ es@@ : • o@@ ste@@ op@@ or@@ o@@ sis (@@ a disease that makes bones fra@@ gi@@ le@@ )@@ , both in women who have been through the men@@ op@@ ause and in men@@ .
It is used in patients who are at risk of fra@@ cture (@@ bone break@@ s@@ )@@ , including patients who have recently broken their hip in a minor trau@@ ma@@ , such as a fall@@ ; • Pa@@ get@@ ’ s disease of the bon@@ e@@ , a disease where the normal process of bone growth is ch@@ ange@@ d.
The medicine can only be obtained with a prescri@@ p@@ tion@@ .
How is A@@ cla@@ sta use@@ d@@ ?
A@@ cla@@ sta is given as a 100 ml in@@ fu@@ sion@@ , lasting at least 15 min@@ ut@@ es@@ .
This can be repeated once a year in patients being treated for o@@ ste@@ op@@ or@@ o@@ si@@ s.
Pati@@ ents who have broken their hip should receive A@@ cla@@ sta at least two weeks after the operation to repair the frac@@ ture@@ .
For Pa@@ get@@ ’ s dise@@ as@@ e@@ , only one in@@ fusion of A@@ cla@@ sta is gi@@ ven@@ .
The effect of the in@@ fusion la@@ sts for a year or mor@@ e@@ .
Pati@@ ents must have adequate flu@@ ids before and after treat@@ ment@@ .
A@@ de@@ qu@@ ate supp@@ lements of vit@@ amin D and cal@@ ci@@ um are also recommended for all patients receiving A@@ cla@@ sta@@ .
In addi@@ tion@@ , patients with Pa@@ get@@ ’ s disease should take at least 500 mg cal@@ ci@@ um twice a day for at least 10 days following treat@@ ment@@ , and patients who have broken their hip should receive a large dose of vit@@ amin D (@@ 50,000 to 12@@ 5,000 international un@@ it@@ s@@ ) by mouth or by in@@ jection into a muscle before their first in@@ fu@@ sion@@ .
Using par@@ ac@@ et@@ am@@ ol or i@@ bu@@ pro@@ fen (@@ anti@@ -@@ infl@@ amm@@ ation medi@@ cin@@ es@@ ) shortly after A@@ cla@@ sta can reduce symptoms such as fe@@ ver@@ , muscle pain@@ , flu@@ -@@ like symp@@ tom@@ s@@ , joint pain and hea@@ da@@ che in the three days following the in@@ fu@@ sion@@ .
A@@ cla@@ sta is not recommended for use in patients who have severe problems with their ki@@ d@@ ne@@ y@@ s.
In the treatment of Pa@@ get@@ ’ s disease of the bon@@ e@@ , A@@ cla@@ sta must only be used by a doctor who has experience in the treatment of the dise@@ as@@ e@@ .
In wom@@ en@@ , o@@ ste@@ op@@ or@@ o@@ sis is more common after the men@@ op@@ au@@ se@@ , when the levels of the female hor@@ mone o@@ est@@ ro@@ gen 7 West@@ fer@@ ry Cir@@ cus@@ , Can@@ ary W@@ har@@ f@@ , London E@@ 14 4@@ HB@@ , UK Tel@@ .
(@@ 44@@ -@@ 20@@ ) 74 18 84 00 Fax (@@ 44@@ -@@ 20@@ ) 74 18 84 16 E@@ -@@ mail@@ : mail@@ @@@ eme@@ a. europa@@ . e@@ u htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . e@@ u
© European Medic@@ ines Agen@@ cy@@ , 200@@ 8.
Re@@ production is author@@ ised provided the source is acknowle@@ dge@@ d. fall@@ .
In Pa@@ get@@ ’ s disease the bone breaks down more quick@@ ly@@ , and when it gro@@ ws back@@ , it is we@@ aker than normal@@ .
The active substance in A@@ cla@@ sta@@ , z@@ ole@@ dr@@ onic aci@@ d@@ , is a bi@@ sph@@ osph@@ on@@ ate@@ .
It stops the action of the o@@ ste@@ o@@ cla@@ st@@ s@@ , the cells in the body that are involved in breaking down the bone tis@@ su@@ e@@ .
This leads to less bone loss in o@@ ste@@ op@@ or@@ o@@ sis and less disease activity in Pa@@ get@@ ’ s dise@@ as@@ e@@ .
How has A@@ cla@@ sta been studi@@ ed@@ ?
Because the active substance in A@@ cla@@ sta is the same as the active substance in Z@@ omet@@ a@@ , some of the data presented for Z@@ omet@@ a were taken into account when asse@@ ssing A@@ cla@@ sta@@ .
For the treatment of o@@ ste@@ op@@ or@@ o@@ si@@ s@@ , the effects of A@@ cla@@ sta given once a year have been compared with those of pla@@ c@@ eb@@ o (@@ a dum@@ my treat@@ ment@@ ) in two main stu@@ dies@@ .
The first involved almost 8,000 elderly women with o@@ ste@@ op@@ or@@ o@@ si@@ s@@ , looking at the number of sp@@ ine and hip frac@@ tures over three ye@@ ar@@ s.
The second involved 2,@@ 12@@ 7 men and women with o@@ ste@@ op@@ or@@ o@@ sis who were aged over 50 years and had recently broken their hi@@ p@@ , and looked at the number of frac@@ tures over up to five ye@@ ar@@ s.
In both stu@@ dies@@ , the patients were allowed to take other medic@@ ines for o@@ ste@@ op@@ or@@ o@@ si@@ s@@ , but not other bi@@ sph@@ osph@@ on@@ at@@ es@@ .
In Pa@@ get@@ ’ s dise@@ as@@ e@@ , A@@ cla@@ sta has been studied in a total of 3@@ 57 patients in two stu@@ dies@@ , where it was compared with ri@@ se@@ dr@@ onate (@@ another bi@@ sph@@ osph@@ on@@ ate@@ ) over six mon@@ th@@ s.
The patients received one in@@ fusion of A@@ cla@@ sta or they received ri@@ se@@ dr@@ onate once a day for two mon@@ th@@ s.
The main measure of effec@@ tiveness was whether blood levels of ser@@ um al@@ kal@@ ine ph@@ osp@@ hat@@ ase (@@ an enz@@ y@@ me involved in the breakdown of bon@@ e@@ ) returned to normal or fell by at least 75@@ % of the way back to normal level@@ s.
What benefit has A@@ cla@@ sta shown during the stu@@ dies@@ ?
In o@@ ste@@ op@@ or@@ o@@ si@@ s@@ , A@@ cla@@ sta was more effective than pla@@ c@@ eb@@ o at reducing the number of frac@@ tu@@ res@@ .
In the study of elderly wom@@ en@@ , the risk of sp@@ ine frac@@ tures was reduced by 70@@ % in patients taking A@@ cla@@ sta (@@ without any other medic@@ ines for o@@ ste@@ op@@ or@@ o@@ si@@ s@@ ) over three ye@@ ar@@ s@@ , compared with those taking pla@@ c@@ ebo@@ .
There was a 4@@ 1@@ % risk reduction in hip frac@@ tu@@ res@@ , when compar@@ ing all women taking A@@ cla@@ sta (@@ with or without other o@@ ste@@ op@@ or@@ o@@ sis medi@@ cin@@ es@@ ) with those taking pla@@ c@@ ebo@@ .
In the study of men and women who had broken their hi@@ p@@ , 9@@ % of the patients receiving A@@ cla@@ sta had a fra@@ cture (@@ 92 out of 1,@@ 06@@ 5@@ )@@ , compared with 13@@ % of the patients receiving pla@@ c@@ eb@@ o (@@ 13@@ 9 out of 1,@@ 06@@ 2@@ )@@ .
This represents a 35@@ % reduction in the risk of fra@@ cture in patients receiving A@@ cla@@ sta@@ .
In Pa@@ get@@ ’ s dise@@ as@@ e@@ , A@@ cla@@ sta was more effective than ri@@ se@@ dr@@ on@@ ate@@ .
After six mon@@ th@@ s@@ , the proportion of patients who had responded to treatment was 9@@ 5@@ % in one study and 9@@ 7@@ % in the o@@ ther@@ , compared with 75@@ % and 7@@ 3@@ % of the patients who received ri@@ se@@ dr@@ on@@ ate@@ .
What is the risk associated with A@@ cla@@ sta@@ ?
Most side effects with A@@ cla@@ sta tend to occur within the first three days after in@@ fu@@ sion@@ , becoming less common with repeated in@@ fu@@ sion@@ s.
The most common side effect with A@@ cla@@ sta (@@ seen in more than 1 patient in 10@@ ) is fe@@ ver@@ .
For the full list of all side effects reported with A@@ cla@@ sta@@ , see the Pack@@ age Le@@ af@@ let@@ .
A@@ cla@@ sta should not be used in people who may be hyper@@ sensitive (@@ aller@@ gi@@ c@@ ) to z@@ ole@@ dr@@ onic aci@@ d@@ , to other bi@@ sph@@ osph@@ on@@ ates or to any of the other ingredi@@ ent@@ s.
A@@ cla@@ sta should not be used in patients with hypo@@ cal@@ ca@@ emi@@ a (@@ low blood cal@@ ci@@ um level@@ s@@ ) or in pregnant or bre@@ ast@@ -@@ feeding wom@@ en@@ .
As with all bi@@ sph@@ osph@@ on@@ at@@ es@@ , patients taking A@@ cla@@ sta may also be at risk of ki@@ dney proble@@ ms@@ , re@@ actions at the site of in@@ fusion and o@@ ste@@ on@@ ec@@ ro@@ sis (@@ death of bone tis@@ su@@ e@@ ) in the j@@ aw@@ .
Why has A@@ cla@@ sta been appro@@ v@@ ed@@ ?
The Committee recommended that A@@ cla@@ sta be given marketing author@@ is@@ ation@@ .
Which measures are being taken to ensure the safe use of A@@ cla@@ sta@@ ?
The company that makes A@@ cla@@ sta will provide educational p@@ acks for doctors who prescri@@ be A@@ cla@@ sta for o@@ ste@@ op@@ or@@ o@@ si@@ s@@ , remin@@ ding them how the medicine should be use@@ d@@ , and similar p@@ acks for pati@@ ent@@ s@@ , which explain the medic@@ ine@@ ’ s side effects and when they should contact their do@@ ct@@ or@@ .
Other information about A@@ cla@@ sta@@ :
The European Commission granted a marketing author@@ isation val@@ id throughout the European Union for A@@ cla@@ sta to Nov@@ arti@@ s Euro@@ ph@@ arm Limited on 15 April 200@@ 5.
2@@ / 3 The full EP@@ AR for A@@ cla@@ sta is available her@@ e@@ .
This sum@@ mary was last updated in 09@@ -@@ 200@@ 8.
3@@ / 3
EU Number
Inv@@ ented name
St@@ ren@@ g@@ th
P@@ harm@@ ac@@ eu@@ tical Form
Route of Administration
Pack@@ aging
Cont@@ ent
Pack@@ age size
EU@@ / 1@@ / 05@@ / 30@@ 8@@ / 00@@ 1
A@@ cla@@ sta
5 m@@ g@@ / 100 ml
Sol@@ ution for in@@ fusion
In@@ tra@@ ven@@ ous use
bottle (@@ pla@@ st@@ ic@@ )
100 ml
1 bottle
EU@@ / 1@@ / 05@@ / 30@@ 8@@ / 00@@ 2
A@@ cla@@ sta
5 m@@ g@@ / 100 ml
Sol@@ ution for in@@ fusion
In@@ tra@@ ven@@ ous use
bottle (@@ pla@@ st@@ ic@@ )
100 ml
1@@ / 1
AN@@ NE@@ X
CON@@ D@@ IT@@ I@@ ON@@ S O@@ R RE@@ ST@@ R@@ IC@@ TI@@ ON@@ S W@@ IT@@ H RE@@ G@@ ARD TO THE S@@ AF@@ E AND E@@ FF@@ EC@@ T@@ IV@@ E US@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T TO BE I@@ MP@@ LE@@ M@@ EN@@ T@@ ED B@@ Y THE ME@@ M@@ BER ST@@ AT@@ ES • CON@@ D@@ IT@@ I@@ ON@@ S O@@ R RE@@ ST@@ R@@ IC@@ TI@@ ON@@ S W@@ IT@@ H RE@@ G@@ ARD TO THE S@@ AF@@ E AND E@@ FF@@ EC@@ T@@ IV@@ E US@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T TO BE I@@ MP@@ LE@@ M@@ EN@@ T@@ ED B@@ Y THE ME@@ M@@ BER ST@@ AT@@ ES
The Member States shall ensure that the educational programme implemented for the author@@ ised indication of treatment of post@@ -@@ men@@ op@@ aus@@ al o@@ ste@@ op@@ or@@ o@@ si@@ s@@ , is extended to the potential prescri@@ bers concerned by the new indic@@ ation@@ : treatment of o@@ ste@@ op@@ or@@ o@@ sis in post@@ -@@ men@@ op@@ aus@@ al women and men at increased risk of frac@@ ture@@ , including those with a recent low@@ -@@ trauma hip frac@@ ture@@ .
The educational programme contains the follo@@ w@@ ing@@ :
• Physi@@ cian educational material • Patient information pack
The physi@@ cian educational material should contain the following key elem@@ ent@@ s@@ : • The Sum@@ mary of Product Char@@ ac@@ ter@@ ist@@ ics • Rem@@ inder card with the following key mes@@ sa@@ ges@@ : o Ne@@ ed to measure ser@@ um cre@@ at@@ in@@ ine before treatment with A@@ cla@@ sta o Re@@ commen@@ dation not to use A@@ cla@@ sta in patients with cre@@ at@@ in@@ ine clear@@ ance < 35 m@@ l@@ / min o Con@@ tra@@ indication in pregnancy and in bre@@ ast@@ -@@ feeding women due to potential ter@@ at@@ o@@ gen@@ ic@@ ity o Ne@@ ed to ensure appropriate hy@@ dra@@ tion of the patient o Ne@@ ed to inf@@ use A@@ cla@@ sta slowly over a period of no less than 15 minutes o O@@ ne@@ -@@ ye@@ arly d@@ osing regime o A@@ de@@ qu@@ ate cal@@ ci@@ um and vit@@ amin D in@@ take are recommended in association with A@@ cla@@ sta administ@@ ration@@ . o Ne@@ ed for appropriate physical activ@@ it@@ y@@ , non@@ -@@ smoking and healthy diet • Patient information pack
The patient information pack should be provided and contain the following key mes@@ sa@@ ges@@ : • Pack@@ age le@@ af@@ let • Con@@ tra@@ indication in pregnancy and in bre@@ ast@@ -@@ feeding women • Ne@@ ed for adequate cal@@ ci@@ um and vit@@ amin D supp@@ lement@@ ation@@ , appropriate physical activ@@ it@@ y@@ , non@@ - smoking and healthy diet • Key signs and symptoms of serious ad@@ verse events • When to seek attention from the health care provider
AN@@ NE@@ X I
SU@@ M@@ MAR@@ Y O@@ F P@@ RO@@ D@@ UC@@ T CH@@ AR@@ AC@@ TER@@ IS@@ T@@ IC@@ S
1 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
A@@ cla@@ sta 5 mg solution for in@@ fusion
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each bottle with 100 ml of solution contains 5 mg z@@ ole@@ dr@@ onic acid an@@ hydro@@ us@@ , correspon@@ ding to 5.@@ 330 mg z@@ ole@@ dr@@ onic acid mon@@ oh@@ y@@ dr@@ ate@@ .
One ml solution contains 0.0@@ 5 mg z@@ ole@@ dr@@ onic acid an@@ hydro@@ us@@ , correspon@@ ding to 0.0@@ 5@@ 33 mg z@@ ole@@ dr@@ onic acid mon@@ oh@@ y@@ dr@@ ate@@ .
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Sol@@ ution for in@@ fusion
Cle@@ ar and colo@@ ur@@ less sol@@ u@@ tion@@ .
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
Tre@@ at@@ ment of o@@ ste@@ op@@ or@@ o@@ sis • in post@@ -@@ men@@ op@@ aus@@ al women • in men at increased risk of frac@@ ture@@ , including those with a recent low@@ -@@ trauma hip frac@@ ture@@ .
Tre@@ at@@ ment of Pa@@ get@@ ’ s disease of the bon@@ e@@ .
4.@@ 2 Pos@@ ology and method of administration
For the treatment of post@@ -@@ men@@ op@@ aus@@ al o@@ ste@@ op@@ or@@ o@@ sis and o@@ ste@@ op@@ or@@ o@@ sis in men@@ , the recommended dose is a single in@@ tra@@ ven@@ ous in@@ fusion of 5 mg A@@ cla@@ sta administ@@ ered once a ye@@ ar@@ .
In patients with a recent low@@ -@@ trauma hip frac@@ ture@@ , it is recommended to give the A@@ cla@@ sta in@@ fusion two or more weeks after hip fra@@ cture repair (@@ see section 5.@@ 1@@ )@@ .
For the treatment of Pa@@ get@@ ’ s dise@@ as@@ e@@ , A@@ cla@@ sta should be prescri@@ bed only by physi@@ cians with experience in treatment of Pa@@ get@@ ’ s disease of the bon@@ e@@ .
The recommended dose is a single in@@ tra@@ ven@@ ous in@@ fusion of 5 mg A@@ cla@@ sta@@ .
Ret@@ re@@ at@@ ment of Pa@@ get@@ ’ s dise@@ as@@ e@@ : specific re@@ treatment data are not avail@@ ab@@ le@@ .
After a single treatment with A@@ cla@@ sta in Pa@@ get@@ ’ s dise@@ as@@ e@@ , an extended re@@ mission period is observed in responding patients (@@ see section 5.@@ 1@@ )@@ .
A@@ cla@@ sta (@@ 5 mg in 100 ml read@@ y@@ -@@ to@@ -@@ inf@@ use sol@@ u@@ tion@@ ) is administ@@ ered via a v@@ ented in@@ fusion line and given at a constant in@@ fusion rat@@ e@@ .
The in@@ fusion time must not be less than 15 min@@ ut@@ es@@ .
For information on the in@@ fusion of A@@ cla@@ sta@@ , see section 6.@@ 6.
Pati@@ ents must be appropri@@ ately hydr@@ ated prior to administration of A@@ cla@@ sta@@ .
This is especially important for the elderly and for patients receiving di@@ ure@@ tic therap@@ y@@ .
2 A@@ de@@ qu@@ ate cal@@ ci@@ um and vit@@ amin D in@@ take are recommended in association with A@@ cla@@ sta administ@@ ration@@ .
In addi@@ tion@@ , in patients with Pa@@ get@@ ’ s dise@@ as@@ e@@ , it is strongly advised that adequate supp@@ le@@ mental cal@@ ci@@ um correspon@@ ding to at least 500 mg elem@@ ental cal@@ ci@@ um twice daily is ensured for at least 10 days following A@@ cla@@ sta administration (@@ see section 4.@@ 4@@ )@@ .
In patients with a recent low@@ -@@ trauma hip frac@@ ture@@ , a lo@@ ading dose of 50,000 to 12@@ 5,000 I@@ U of vit@@ amin D given or@@ ally or via the in@@ tra@@ mus@@ cular route is recommended prior to the first A@@ cla@@ sta in@@ fu@@ sion@@ .
The inci@@ dence of post@@ -@@ dose symptoms occ@@ urring within the first three days after administration of A@@ cla@@ sta can be reduced with the administration of par@@ ac@@ et@@ am@@ ol or i@@ bu@@ pro@@ fen shortly following A@@ cla@@ sta administ@@ ration@@ .
Pati@@ ents with ren@@ al im@@ pa@@ ir@@ ment (@@ see section 4.@@ 4@@ ) Use of A@@ cla@@ sta in patients with cre@@ at@@ in@@ ine clear@@ ance < 35 m@@ l@@ / min is not recommended due to limited clinical experience in this pop@@ ula@@ tion@@ .
No dose adju@@ st@@ ment is necessary in patients with cre@@ at@@ in@@ ine clear@@ ance ≥ 35 m@@ l@@ / min@@ .
Pati@@ ents with he@@ pati@@ c im@@ pa@@ ir@@ ment No dose adju@@ st@@ ment is required (@@ see section 5.@@ 2@@ )@@ .
El@@ derly patients (@@ ≥ 65 ye@@ ar@@ s@@ ) No dose adju@@ st@@ ment is necessary since bio@@ avail@@ abili@@ ty@@ , distribution and elim@@ ination were similar in elderly patients and younger sub@@ jec@@ ts@@ .
Children and adol@@ es@@ cents A@@ cla@@ sta is not recommended for use in children and adol@@ es@@ cents below 18 years of age due to lack of data on safety and eff@@ ic@@ ac@@ y@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ents or to any bi@@ sph@@ osph@@ on@@ at@@ es@@ .
A@@ cla@@ sta is contra@@ indicated for patients with hypo@@ cal@@ ca@@ emi@@ a (@@ see section 4.@@ 4@@ )@@ .
A@@ cla@@ sta is contra@@ indicated during pregnancy and in bre@@ ast@@ -@@ feeding women (@@ see section 4.@@ 6@@ )@@ .
4.@@ 4 Special warnings and prec@@ au@@ tions for use
The dose of 5 mg z@@ ole@@ dr@@ onic acid must be administ@@ ered over at least 15 min@@ ut@@ es@@ .
A@@ cla@@ sta is not recommended in patients with severe ren@@ al im@@ pa@@ ir@@ ment (@@ cre@@ at@@ in@@ ine clear@@ ance < 35 m@@ l@@ / min@@ ) due to limited clinical experience in this pop@@ ula@@ tion@@ .
Pati@@ ents should have their ser@@ um cre@@ at@@ in@@ ine level measured before receiving A@@ cla@@ sta@@ .
Pati@@ ents must be appropri@@ ately hydr@@ ated prior to administration of A@@ cla@@ sta@@ .
This is especially important in the elderly and for patients receiving di@@ ure@@ tic therap@@ y@@ .
Cau@@ tion is indicated when A@@ cla@@ sta is administ@@ ered in con@@ junction with medic@@ inal products that can significantly impact ren@@ al function (@@ e@@ . g. am@@ in@@ o@@ g@@ ly@@ co@@ sides or di@@ ure@@ tics that may cause de@@ hy@@ dra@@ tion@@ )@@ , see section 4.@@ 5.
Pre@@ -@@ existing hypo@@ cal@@ ca@@ emi@@ a must be treated by adequate in@@ take of cal@@ ci@@ um and vit@@ amin D before initi@@ ating therapy with A@@ cla@@ sta (@@ see section 4.@@ 3@@ )@@ .
Other distur@@ ban@@ ces of min@@ eral met@@ aboli@@ sm must also be effectively treated (@@ e@@ . g. di@@ mini@@ shed par@@ ath@@ y@@ ro@@ id reser@@ ve@@ , inte@@ st@@ inal cal@@ ci@@ um mal@@ absor@@ p@@ tion@@ )@@ .
Physi@@ cians should consider clinical monitoring for these pati@@ ent@@ s.
3 Ele@@ v@@ ated bone turno@@ ver is a characterist@@ ic of Pa@@ get@@ ’ s disease of the bon@@ e@@ .
D@@ ue to the rapid on@@ set of effect of z@@ ole@@ dr@@ onic acid on bone turno@@ ver@@ , tran@@ si@@ ent hypo@@ cal@@ ca@@ emi@@ a@@ , sometimes symp@@ tom@@ ati@@ c@@ , may develop and is usually maximal within the first 10 days after in@@ fusion of A@@ cla@@ sta (@@ see section 4.@@ 8@@ )@@ .
A@@ de@@ qu@@ ate cal@@ ci@@ um and vit@@ amin D in@@ take are recommended in association with A@@ cla@@ sta administ@@ ration@@ .
In addi@@ tion@@ , in patients with Pa@@ get@@ '@@ s dise@@ as@@ e@@ , it is strongly advised that adequate supp@@ le@@ mental cal@@ ci@@ um correspon@@ ding to at least 500 mg elem@@ ental cal@@ ci@@ um twice daily is ensured for at least 10 days following A@@ cla@@ sta administration (@@ see section 4.@@ 2@@ )@@ .
Pati@@ ents should be informed about symptoms of hypo@@ cal@@ ca@@ emi@@ a and receive adequate clinical monitoring during the period of risk@@ .
Me@@ as@@ u@@ rement of ser@@ um cal@@ ci@@ um before in@@ fusion of A@@ cla@@ sta is recommended for patients with Pa@@ get@@ ´@@ s dise@@ as@@ e@@ .
Sever@@ e and occasionally inc@@ ap@@ ac@@ it@@ ating bon@@ e@@ , joint and@@ / or muscle pain have been in@@ frequently reported in patients taking bi@@ sph@@ osph@@ on@@ at@@ es@@ , including A@@ cla@@ sta@@ .
A@@ cla@@ sta contains the same active substance found in Z@@ omet@@ a (@@ z@@ ole@@ dr@@ onic aci@@ d@@ )@@ , used for onc@@ ology indic@@ ations@@ , and a patient being treated with Z@@ omet@@ a should not be treated with A@@ cla@@ sta@@ .
O@@ ste@@ on@@ ec@@ ro@@ sis of the ja@@ w (@@ ON@@ J@@ )@@ :
O@@ ste@@ on@@ ec@@ ro@@ sis of the ja@@ w has been reported pre@@ domin@@ antly in patients with cancer receiving treatment regim@@ ens including bi@@ sph@@ osph@@ on@@ at@@ es@@ , including z@@ ole@@ dr@@ onic aci@@ d.
Many of these patients were also receiving ch@@ emo@@ therapy and cor@@ ti@@ co@@ ster@@ o@@ i@@ ds@@ .
The majority of reported cases have been associated with dental procedures such as to@@ oth extra@@ c@@ tion@@ .
Many had signs of local infection including o@@ ste@@ om@@ y@@ eli@@ ti@@ s.
A dental examination with appropriate pre@@ ven@@ tive denti@@ stry should be considered prior to treatment with bi@@ sph@@ osph@@ on@@ ates in patients with con@@ co@@ mit@@ ant risk factors (@@ e@@ . g. canc@@ er@@ , ch@@ emo@@ therap@@ y@@ , cor@@ ti@@ co@@ ster@@ o@@ i@@ ds@@ , poor oral hy@@ gi@@ ene@@ )@@ .
While on treat@@ ment@@ , these patients should avoid inv@@ a@@ sive dental procedures if possi@@ ble@@ .
For patients who develop o@@ ste@@ on@@ ec@@ ro@@ sis of the ja@@ w while on bi@@ sph@@ osph@@ onate therap@@ y@@ , dental surgery may exac@@ erb@@ ate the condi@@ tion@@ .
For patients requiring dental proce@@ du@@ res@@ , there are no data available to suggest whether dis@@ continu@@ ation of bi@@ sph@@ osph@@ onate treatment redu@@ ces the risk of o@@ ste@@ on@@ ec@@ ro@@ sis of the j@@ aw@@ .
The clinical jud@@ gement of the treating physi@@ cian should guide the management plan of each patient based on individual benef@@ it@@ / risk asse@@ ss@@ ment@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
Speci@@ fic dru@@ g@@ -@@ drug inter@@ action studies have not been conducted with z@@ ole@@ dr@@ onic aci@@ d.
Z@@ ole@@ dr@@ onic acid is not sy@@ ste@@ mi@@ cally met@@ aboli@@ sed and does not affect human cy@@ to@@ ch@@ rome P@@ 450 enz@@ ym@@ es in vit@@ ro (@@ see section 5.@@ 2@@ )@@ .
Z@@ ole@@ dr@@ onic acid is not highly bound to p@@ las@@ ma prot@@ eins (@@ approximately 43@@ -@@ 55@@ % bo@@ und@@ ) and inter@@ actions resulting from displa@@ cement of highly prot@@ ein@@ -@@ bound drugs are therefore un@@ lik@@ el@@ y@@ .
Z@@ ole@@ dr@@ onic acid is elim@@ inated by ren@@ al ex@@ cre@@ tion@@ .
Cau@@ tion is indicated when A@@ cla@@ sta is administ@@ ered in con@@ junction with medic@@ inal products that can significantly impact ren@@ al function (@@ e@@ . g. am@@ in@@ o@@ g@@ ly@@ co@@ sides or di@@ ure@@ tics that may cause de@@ hy@@ dra@@ tion@@ )@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
There are no adequate data on the use of z@@ ole@@ dr@@ onic acid in pregnant wom@@ en@@ .
Studies in animals with z@@ ole@@ dr@@ onic acid have shown re@@ productive tox@@ ic@@ ological effects including mal@@ form@@ ations (@@ see section 5.@@ 3@@ )@@ .
The potential risk for humans is unk@@ no@@ wn@@ .
It is not known whether z@@ ole@@ dr@@ onic acid is ex@@ cre@@ ted into human breast mil@@ k@@ .
A@@ cla@@ sta is contra@@ indicated during pregnancy and in bre@@ ast@@ -@@ feeding women (@@ see section 4.@@ 3@@ )@@ .
4.@@ 7 Eff@@ ects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been per@@ for@@ med@@ .
4 4.@@ 8 Un@@ desi@@ rable effects
The overall percentage of patients who experienced post@@ -@@ dose symptoms were 4@@ 4.@@ 7@@ %@@ , 16.@@ 7@@ % and 10.@@ 2@@ % after the fir@@ st@@ , second and third in@@ fu@@ sion@@ , respec@@ ti@@ vel@@ y@@ .
In@@ ci@@ dence of individual symptoms following the first in@@ fusion was@@ : fe@@ ver (@@ 17.@@ 1@@ %@@ )@@ , my@@ al@@ gia (@@ 7.@@ 8@@ %@@ )@@ , flu@@ -@@ like symptoms (@@ 6.@@ 7@@ %@@ )@@ , ar@@ th@@ r@@ al@@ gia (@@ 4.@@ 8@@ %@@ ) and hea@@ da@@ che (@@ 5.@@ 1@@ %@@ )@@ .
The inci@@ dence of these symptoms decre@@ ased mar@@ ke@@ dly with subsequent d@@ oses of A@@ cla@@ sta@@ .
The majority of these symptoms occur within the first three days following A@@ cla@@ sta administ@@ ration@@ .
The majority of these symptoms were mild to moderate and resolved within three days of the event on@@ se@@ t.
The percentage of patients who experienced post@@ -@@ dose symptoms was lower in a smaller study (@@ 19.@@ 5@@ %@@ , 10.@@ 4@@ %@@ , 10.@@ 7@@ % after the fir@@ st@@ , second and third in@@ fu@@ sion@@ , respec@@ ti@@ vel@@ y@@ )@@ , where pro@@ ph@@ y@@ la@@ xis against post@@ -@@ dose symptoms was used as described bel@@ ow@@ .
The inci@@ dence of post@@ -@@ dose symptoms occ@@ urring within the first three days after administration of A@@ cla@@ sta can be reduced with the administration of par@@ ac@@ et@@ am@@ ol or i@@ bu@@ pro@@ fen shortly following A@@ cla@@ sta administration (@@ see section 4.@@ 2@@ )@@ .
In the H@@ OR@@ I@@ Z@@ ON – Pi@@ vot@@ al Fra@@ cture Tri@@ al [@@ P@@ FT@@ ] (@@ see section 5.@@ 1@@ )@@ , the overall inci@@ dence of atri@@ al fi@@ bri@@ l@@ lation was 2.@@ 5@@ % (@@ 96 out of 3,@@ 8@@ 6@@ 2@@ ) and 1.@@ 9@@ % (@@ 75 out of 3,@@ 8@@ 5@@ 2@@ ) in patients receiving A@@ cla@@ sta and pla@@ c@@ ebo@@ , respec@@ ti@@ vel@@ y@@ .
The rate of atri@@ al fi@@ bri@@ l@@ lation serious ad@@ verse events was increased in patients receiving A@@ cla@@ sta (@@ 1.@@ 3@@ %@@ ) (@@ 51 out of 3,@@ 8@@ 6@@ 2@@ ) compared with patients receiving pla@@ c@@ eb@@ o (@@ 0.@@ 6@@ %@@ ) (@@ 22 out of 3,@@ 8@@ 5@@ 2@@ )@@ .
The mechan@@ ism behind the increased inci@@ dence of atri@@ al fi@@ bri@@ l@@ lation is unk@@ no@@ wn@@ .
In the o@@ ste@@ op@@ or@@ o@@ sis trials (@@ P@@ FT@@ , H@@ OR@@ I@@ Z@@ ON - Rec@@ ur@@ rent Fra@@ cture Tri@@ al [@@ R@@ FT@@ ]@@ ) the po@@ ol@@ ed atri@@ al fi@@ bri@@ l@@ lation inci@@ den@@ ces were compar@@ able between A@@ cla@@ sta (@@ 2.@@ 6@@ %@@ ) and pla@@ c@@ eb@@ o (@@ 2.@@ 1@@ %@@ )@@ .
For atri@@ al fi@@ bri@@ l@@ lation serious ad@@ verse events the po@@ ol@@ ed inci@@ den@@ ces were 1.@@ 3@@ % for A@@ cla@@ sta and 0.@@ 8@@ % for pla@@ c@@ ebo@@ .
Very common (@@ ≥ 1@@ / 10@@ )@@ , common (@@ ≥ 1@@ / 100@@ , < 1@@ / 10@@ )@@ , un@@ common (@@ ≥ 1@@ / 1,@@ 00@@ 0@@ , < 1@@ / 100@@ )@@ , rare (@@ ≥ 1@@ / 10,@@ 00@@ 0@@ , < 1@@ / 1,@@ 00@@ 0@@ ) ad@@ verse drug re@@ actions are shown in Table 1.
Within each frequ@@ ency gro@@ up@@ ing@@ , un@@ desi@@ rable effects are presented in order of decre@@ asing seri@@ ous@@ ness@@ .
Table 1@@ *
Investig@@ ations Cardi@@ ac disor@@ ders Ner@@ v@@ ous system disor@@ ders
Un@@ common Comm@@ on Comm@@ on Un@@ common
Bloo@@ d pressure increased A@@ trial fi@@ bri@@ l@@ lation He@@ a@@ da@@ che@@ , di@@ zz@@ iness Le@@ th@@ ar@@ gy@@ , para@@ es@@ the@@ si@@ a@@ , som@@ n@@ ol@@ en@@ ce@@ , tre@@ mor@@ , syn@@ cope
E@@ ye disor@@ ders
Un@@ common R@@ are
Con@@ jun@@ cti@@ vi@@ tis@@ , eye pain U@@ vei@@ tis@@ , epis@@ cl@@ eri@@ tis@@ , i@@ ri@@ tis
E@@ ar and lab@@ y@@ r@@ inth disor@@ ders Res@@ pir@@ ator@@ y@@ , thor@@ ac@@ ic and medi@@ ast@@ inal disor@@ ders
Un@@ common Un@@ common
Ver@@ ti@@ go Dy@@ sp@@ no@@ ea
Gast@@ ro@@ inte@@ st@@ inal disor@@ ders
Comm@@ on Un@@ common
Nau@@ se@@ a@@ , vo@@ mi@@ ting Di@@ arr@@ ho@@ e@@ a@@ , dy@@ sp@@ ep@@ si@@ a@@ , ab@@ dom@@ inal pain@@ , dry mouth
Ren@@ al and ur@@ inary disor@@ ders Sk@@ in and sub@@ cut@@ an@@ e@@ ous tissue disor@@ ders
Un@@ common Un@@ common
Bloo@@ d cre@@ at@@ in@@ ine increas@@ ed@@ , pol@@ la@@ ki@@ uri@@ a Rash@@ , night swe@@ ats@@ , hyper@@ hydro@@ si@@ s@@ , p@@ ru@@ rit@@ us@@ , er@@ y@@ thema
Mus@@ cul@@ os@@ kel@@ et@@ al and connec@@ tive tissue disor@@ ders
Comm@@ on Un@@ common
My@@ al@@ gi@@ a@@ , ar@@ th@@ r@@ al@@ gi@@ a@@ , bone pain@@ , back pain@@ , pain in extremi@@ ty N@@ eck pain@@ , mus@@ cul@@ os@@ kel@@ et@@ al sti@@ ff@@ ness@@ , joint sw@@ ell@@ ing@@ , shoulder pain@@ , muscle sp@@ as@@ ms@@ , mus@@ cul@@ os@@ kel@@ et@@ al pain@@ , non@@ -@@ cardi@@ ac chest pain@@ , ar@@ thri@@ tis@@ , mus@@ cular weak@@ ness@@ , joint sti@@ ff@@ ness
Met@@ aboli@@ sm and nutri@@ tion disor@@ ders
Comm@@ on Un@@ common
Hy@@ po@@ cal@@ ca@@ emi@@ a@@ † An@@ or@@ ex@@ i@@ a@@ , decre@@ ased appeti@@ te
5
Inf@@ ections and in@@ fest@@ ations V@@ as@@ cular disor@@ ders General disor@@ ders and administration site conditions
Un@@ common Un@@ common Very common Comm@@ on
In@@ flu@@ enz@@ a Hy@@ per@@ ten@@ sion@@ , fl@@ ushing F@@ ever Flu@@ -@@ like symp@@ tom@@ s@@ , ch@@ ill@@ s@@ , f@@ ati@@ gu@@ e@@ , as@@ th@@ eni@@ a@@ , pain@@ , mal@@ ai@@ se@@ , rig@@ or@@ s@@ †
Un@@ common
Peri@@ pher@@ al oe@@ de@@ ma@@ , thir@@ st
Immun@@ e system disor@@ ders
Not kno@@ wn@@ *@@ *
Hy@@ per@@ sensi@@ tivity re@@ actions including rare cases of bron@@ cho@@ con@@ stri@@ c@@ tion@@ , ur@@ tic@@ aria and an@@ gi@@ oe@@ de@@ ma@@ , and very rare cases of an@@ ap@@ hy@@ la@@ ctic re@@ ac@@ tion@@ / shock
P@@ sychiatri@@ c disor@@ ders
Un@@ common
Ins@@ om@@ nia
* Additional ad@@ verse events which were reported in the individual studies but were not included due to the po@@ ol@@ ed presentation are@@ :
Un@@ common@@ : dys@@ ge@@ usi@@ a@@ , o@@ es@@ oph@@ ag@@ i@@ tis@@ , t@@ ooth@@ ach@@ e@@ . † Comm@@ on in Pa@@ get@@ ’ s disease on@@ ly@@ .
For hypo@@ cal@@ ca@@ emi@@ a@@ , see also text bel@@ ow@@ . *@@ * Based on post@@ -@@ marketing repor@@ ts@@ .
Since these reports are from a population of uncertain size and are subject to con@@ fo@@ unding fac@@ tor@@ s@@ , it is not possible to reli@@ ably estimate their frequ@@ ency or establish a caus@@ al relationship to exposure to the medic@@ inal produc@@ t.
Class effec@@ ts@@ :
Ren@@ al dys@@ function Z@@ ole@@ dr@@ onic acid has been associated with ren@@ al dys@@ function manifest@@ ed as deterior@@ ation in ren@@ al function (@@ i@@ . e@@ . increased ser@@ um cre@@ at@@ in@@ ine@@ ) and in rare cases ac@@ ute ren@@ al fail@@ ure@@ .
Ren@@ al dys@@ function has been observed following the administration of z@@ ole@@ dr@@ onic aci@@ d@@ , especially in patients with pre@@ -@@ existing ren@@ al compromise or additional risk factors (@@ e@@ . g onc@@ ology patients with ch@@ emo@@ therap@@ y@@ , con@@ co@@ mit@@ ant ne@@ p@@ hr@@ oto@@ x@@ ic medic@@ ations@@ , severe de@@ hy@@ dra@@ tion@@ )@@ , the majority of whom received a 4 mg dose every 3@@ – 4 wee@@ ks@@ , but it has been observed in patients after a single administ@@ ration@@ .
In clinical trials in o@@ ste@@ op@@ or@@ o@@ si@@ s@@ , the change in cre@@ at@@ in@@ ine clear@@ ance (@@ measured annually prior to d@@ os@@ ing@@ ) and the inci@@ dence of ren@@ al failure and im@@ pa@@ ir@@ ment was compar@@ able for both the A@@ cla@@ sta and pla@@ c@@ eb@@ o treatment groups over three ye@@ ar@@ s.
There was a tran@@ si@@ ent increase in ser@@ um cre@@ at@@ in@@ ine observed within 10 days in 1.@@ 8@@ % of A@@ cla@@ sta@@ -@@ treated patients versus 0.@@ 8@@ % of pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
Hy@@ po@@ cal@@ ca@@ emi@@ a In clinical trials in o@@ ste@@ op@@ or@@ o@@ si@@ s@@ , approximately 0.@@ 2@@ % of patients had not@@ able dec@@ lines of ser@@ um cal@@ ci@@ um levels (@@ less than 1.@@ 87 mm@@ ol@@ / l@@ ) following A@@ cla@@ sta administ@@ ration@@ .
No symp@@ tom@@ atic cases of hypo@@ cal@@ ca@@ emi@@ a were observ@@ ed@@ .
In the Pa@@ get@@ ’ s disease tri@@ al@@ s@@ , symp@@ tom@@ atic hypo@@ cal@@ ca@@ emi@@ a was observed in approximately 1@@ % of pati@@ ent@@ s@@ , in all of whom it resol@@ v@@ ed@@ .
Based on lab@@ oratory asse@@ ss@@ ment@@ , tran@@ si@@ ent as@@ ymp@@ tom@@ atic cal@@ ci@@ um levels below the normal reference range (@@ less than 2.@@ 10 mm@@ ol@@ / l@@ ) occurred in 2.@@ 3@@ % of A@@ cla@@ sta@@ -@@ treated patients in a large clinical trial compared to 21@@ % of A@@ cla@@ sta@@ -@@ treated patients in the Pa@@ get@@ ’ s disease tri@@ al@@ s.
The frequ@@ ency of hypo@@ cal@@ ca@@ emi@@ a was much lower following subsequent in@@ fu@@ sion@@ s.
All patients received adequate supp@@ lement@@ ation with vit@@ amin D and cal@@ ci@@ um in the post@@ -@@ men@@ op@@ aus@@ al o@@ ste@@ op@@ or@@ o@@ sis tri@@ al@@ , the pre@@ vention of clinical frac@@ tures after hip fra@@ cture tri@@ al@@ , and the Pa@@ get@@ ’ s disease trials (@@ see also section 4.@@ 2@@ )@@ .
In the trial for the pre@@ vention of clinical frac@@ tures following a recent hip frac@@ ture@@ , vit@@ amin D levels were not rout@@ inely measured but the majority of patients received a lo@@ ading dose of vit@@ amin D prior to A@@ cla@@ sta administration (@@ see section 4.@@ 2@@ )@@ .
Local re@@ actions In a large clinical tri@@ al@@ , local re@@ actions at the in@@ fusion si@@ te@@ , such as re@@ dn@@ ess@@ , sw@@ elling and@@ / or pain@@ , were reported (@@ 0.@@ 7@@ %@@ ) following the administration of z@@ ole@@ dr@@ onic aci@@ d.
6 O@@ ste@@ on@@ ec@@ ro@@ sis of the ja@@ w Un@@ common@@ ly@@ , cases of o@@ ste@@ on@@ ec@@ ro@@ sis (@@ primarily of the j@@ aw@@ ) have been repor@@ te@@ d@@ , pre@@ domin@@ antly in cancer patients treated with bi@@ sph@@ osph@@ on@@ at@@ es@@ , including z@@ ole@@ dr@@ onic aci@@ d.
Many of these patients had signs of local infection including o@@ ste@@ om@@ y@@ eli@@ tis@@ , and the majority of the reports refer to cancer patients following to@@ oth extra@@ ctions or other dental sur@@ ger@@ i@@ es@@ .
O@@ ste@@ on@@ ec@@ ro@@ sis of the ja@@ w has multiple well documented risk factors including a diagnosis of canc@@ er@@ , con@@ co@@ mit@@ ant therap@@ ies (@@ e@@ . g. ch@@ emo@@ therap@@ y@@ , radio@@ therap@@ y@@ , cor@@ ti@@ co@@ ster@@ o@@ i@@ ds@@ ) and co@@ -@@ mor@@ bid conditions (@@ e@@ . g. an@@ a@@ emi@@ a@@ , co@@ agu@@ lo@@ pa@@ thi@@ es@@ , inf@@ ec@@ tion@@ , pre@@ - existing dental dise@@ as@@ e@@ )@@ .
Although caus@@ ality has not been determin@@ ed@@ , it is p@@ ru@@ dent to avoid dental surgery as recovery may be pro@@ lon@@ ged (@@ see section 4.@@ 4@@ )@@ .
In a large clinical trial in 7,@@ 7@@ 36 pati@@ ent@@ s@@ , o@@ ste@@ on@@ ec@@ ro@@ sis of the ja@@ w has been reported in one patient treated with A@@ cla@@ sta and one patient treated with pla@@ c@@ ebo@@ .
Both cases resol@@ v@@ ed@@ .
4.@@ 9 Over@@ dose
There is no experience of ac@@ ute in@@ tox@@ ic@@ ation with A@@ cla@@ sta@@ .
Pati@@ ents who have received d@@ oses higher than those recommended should be carefully monit@@ or@@ ed@@ .
In the event of over@@ dose leading to clin@@ ically significant hypo@@ cal@@ ca@@ emi@@ a@@ , re@@ versal may be achieved with supp@@ le@@ mental oral cal@@ ci@@ um and@@ / or an in@@ tra@@ ven@@ ous in@@ fusion of cal@@ ci@@ um glu@@ con@@ ate@@ .
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ :
Bi@@ sph@@ osph@@ on@@ ate@@ , AT@@ C co@@ de@@ :
M@@ 05@@ BA@@ 08
Mechan@@ ism of action Z@@ ole@@ dr@@ onic acid belon@@ gs to the class of nit@@ ro@@ gen@@ -@@ containing bi@@ sph@@ osph@@ on@@ ates and acts primarily on bon@@ e@@ .
It is an in@@ hi@@ bit@@ or of o@@ ste@@ o@@ cla@@ st@@ -@@ medi@@ ated bone res@@ or@@ p@@ tion@@ .
P@@ harm@@ ac@@ o@@ dynamic effects A@@ cla@@ sta treatment rapidly reduced the rate of bone turno@@ ver from elev@@ ated post@@ -@@ men@@ op@@ aus@@ al levels with the na@@ dir for res@@ or@@ ption mark@@ ers observed at 7 da@@ ys@@ , and for formation mark@@ ers at 12 wee@@ ks@@ .
Ther@@ e@@ after bone mark@@ ers stabili@@ sed within the pre@@ -@@ men@@ op@@ aus@@ al ran@@ ge@@ .
There was no progressive reduction of bone turno@@ ver mark@@ ers with repeated annual d@@ os@@ ing@@ .
Clin@@ ical eff@@ ic@@ acy in the treatment of post@@ -@@ men@@ op@@ aus@@ al o@@ ste@@ op@@ or@@ o@@ sis (@@ P@@ FT@@ ) The eff@@ ic@@ acy and safety of A@@ cla@@ sta 5 mg once a year for 3 consecutive years were demonstrated in post@@ -@@ men@@ op@@ aus@@ al women (@@ 7,@@ 7@@ 36 women aged 65@@ – 89 ye@@ ar@@ s@@ ) with ei@@ ther@@ : a fem@@ oral neck bone min@@ eral den@@ sity (@@ BM@@ D@@ ) with a T@@ -@@ score ≤ – 1.5 and at least two mild or one moderate existing ver@@ te@@ bra@@ l frac@@ ture@@ (@@ s@@ )@@ ; or a fem@@ oral neck BM@@ D T@@ -@@ score ≤ – 2.5 with or without evidence of existing ver@@ te@@ bra@@ l frac@@ ture@@ (@@ s@@ )@@ .
8@@ 5@@ % of patients were bi@@ sph@@ osph@@ on@@ ate@@ -@@ na@@ ï@@ ve@@ .
Women who were evalu@@ ated for the inci@@ dence of ver@@ te@@ bra@@ l frac@@ tures did not receive con@@ co@@ mit@@ ant o@@ ste@@ op@@ or@@ o@@ sis therap@@ y@@ , which was allowed for women contribut@@ ing to the hip and all clinical fra@@ cture evalu@@ ations@@ .
Con@@ co@@ mit@@ ant o@@ ste@@ op@@ or@@ o@@ sis therapy inclu@@ de@@ d@@ : cal@@ cit@@ on@@ in@@ , r@@ alo@@ xi@@ fen@@ e@@ , t@@ amo@@ xi@@ fen@@ , hor@@ mone replacement therap@@ y@@ , ti@@ bol@@ one@@ ; but exclu@@ ded other bi@@ sph@@ osph@@ on@@ at@@ es@@ .
All women received 1,000 to 1,500 mg elem@@ ental cal@@ ci@@ um and 400 to 1,@@ 200 I@@ U of vit@@ amin D supp@@ lements da@@ ily@@ .
Eff@@ ect on mor@@ ph@@ omet@@ ric ver@@ te@@ bra@@ l frac@@ tures A@@ cla@@ sta significantly decre@@ ased the inci@@ dence of one or more new ver@@ te@@ bra@@ l frac@@ tures over three years and as early as the one year ti@@ me@@ point (@@ see Table 2@@ )@@ .
7 Table 2
Sum@@ mary of ver@@ te@@ bra@@ l fra@@ cture eff@@ ic@@ acy at 12@@ , 24 and 36 months
Out@@ come
A@@ cla@@ sta Pla@@ c@@ eb@@ o Absol@@ ute reduction in (@@ %@@ ) (@@ %@@ ) fra@@ cture inci@@ den@@ ce@@ % (@@ C@@ I@@ )
reduction in inci@@ den@@ ce@@ % (@@ C@@ I@@ )
At least one new ver@@ te@@ bra@@ l fra@@ cture (@@ 0@@ – 1 ye@@ ar@@ )
1.5
3.@@ 7
2.@@ 2 (@@ 1.@@ 4@@ , 3.@@ 1@@ )
60 (@@ 43@@ , 7@@ 2@@ )@@ *@@ *
At least one new ver@@ te@@ bra@@ l fra@@ cture (@@ 0@@ – 2 ye@@ ar@@ )
2.@@ 2
7.@@ 7
5.5 (@@ 4.@@ 4@@ , 6.@@ 6@@ )
71 (@@ 6@@ 2@@ , 78@@ )@@ *@@ *
At least one new ver@@ te@@ bra@@ l fra@@ cture (@@ 0@@ – 3 ye@@ ar@@ ) *@@ * p < 0.0@@ 00@@ 1
3.@@ 3
10.@@ 9
7.@@ 6 (@@ 6.@@ 3@@ , 9@@ .0@@ )
70 (@@ 6@@ 2@@ , 76@@ )@@ *@@ *
A@@ cla@@ sta@@ -@@ treated patients aged 75 years and older exhi@@ bited a 60@@ % reduction in the risk of ver@@ te@@ bra@@ l frac@@ tures compared to pla@@ c@@ eb@@ o patients (@@ p < 0.0@@ 00@@ 1@@ )@@ .
Eff@@ ect on hip frac@@ tures A@@ cla@@ sta demonstrated a consistent effect over 3 ye@@ ar@@ s@@ , resulting in a 4@@ 1@@ % reduction in the risk of hip frac@@ tures (@@ 9@@ 5@@ % C@@ I@@ , 17@@ % to 58@@ %@@ )@@ .
The hip fra@@ cture event rate was 1.@@ 44@@ % for A@@ cla@@ sta@@ -@@ treated patients compared to 2.@@ 49@@ % for pla@@ c@@ ebo@@ -@@ treated pati@@ ent@@ s.
The risk reduction was 5@@ 1@@ % in bi@@ sph@@ osph@@ on@@ ate@@ -@@ na@@ ï@@ ve patients and 4@@ 2@@ % in patients allowed to take con@@ co@@ mit@@ ant o@@ ste@@ op@@ or@@ o@@ sis therap@@ y@@ .
A sum@@ mary of results is presented in Table 3.
Table 3
Between treatment compar@@ is@@ ons of the inci@@ dence over 3 years
of key clinical fra@@ cture vari@@ ables
Out@@ come
Pla@@ c@@ eb@@ o Absol@@ ute reduction (@@ N@@ =@@ 3,@@ 8@@ 6@@ 1@@ ) in fra@@ cture event
Rel@@ ative risk reduction in
event rate (@@ %@@ )
event rate (@@ %@@ )
rat@@ e@@ % (@@ C@@ I@@ )
fra@@ cture inci@@ den@@ ce@@ % (@@ C@@ I@@ )
Any clinical fra@@ cture (@@ 1@@ ) Clin@@ ical ver@@ te@@ bra@@ l fra@@ cture (@@ 2@@ ) Non@@ -@@ ver@@ te@@ bra@@ l fra@@ cture (@@ 1@@ ) *@@ p@@ -@@ value < 0.0@@ 0@@ 1@@ , *@@ *@@ p@@ -@@ value < 0.0@@ 00@@ 1
8.@@ 4 0.5 8.@@ 0
12.@@ 8 2.@@ 6 10.@@ 7
4.@@ 4 2.@@ 1 2.@@ 7
(@@ 3@@ .0@@ , 5.@@ 8@@ ) (@@ 1.@@ 5@@ , 2.@@ 7@@ ) (@@ 1.@@ 4@@ , 4@@ .0@@ )
33 (@@ 23@@ , 4@@ 2@@ )@@ *@@ * 77 (@@ 6@@ 3@@ , 8@@ 6@@ )@@ *@@ * 25 (@@ 13@@ , 36@@ )@@ *
(@@ 1@@ ) Ex@@ clu@@ ding f@@ inger@@ , toe and facial frac@@ tures (@@ 2@@ ) In@@ clu@@ ding clinical thor@@ ac@@ ic and clinical l@@ um@@ bar ver@@ te@@ bra@@ l frac@@ tures
Eff@@ ect on bone min@@ eral den@@ sity (@@ BM@@ D@@ ) A@@ cla@@ sta significantly increased BM@@ D at the l@@ um@@ bar sp@@ ine@@ , hi@@ p@@ , and dist@@ al radi@@ us relative to treatment with pla@@ c@@ eb@@ o at all ti@@ me@@ points (@@ 6@@ , 12@@ , 24 and 36 mon@@ th@@ s@@ )@@ .
Tre@@ at@@ ment with A@@ cla@@ sta resulted in a 6.@@ 7@@ % increase in BM@@ D at the l@@ um@@ bar sp@@ ine@@ , 6@@ .0@@ % at the total hi@@ p@@ , 5.@@ 1@@ % at the fem@@ oral neck@@ , and 3.@@ 2@@ % at the dist@@ al radi@@ us over 3 years as compared to pla@@ c@@ ebo@@ .
B@@ one hist@@ ology B@@ one bi@@ op@@ sies were obtained from the ili@@ ac cre@@ st 1 year after the third annual dose in 15@@ 2 post@@ - men@@ op@@ aus@@ al patients with o@@ ste@@ op@@ or@@ o@@ sis treated with A@@ cla@@ sta (@@ N@@ =@@ 8@@ 2@@ ) or pla@@ c@@ eb@@ o (@@ N@@ =@@ 70@@ )@@ .
Hist@@ om@@ or@@ ph@@ omet@@ ric analysis showed a 6@@ 3@@ % reduction in bone turno@@ ver@@ .
In patients treated with A@@ cla@@ sta@@ , no o@@ ste@@ om@@ al@@ aci@@ a@@ , mar@@ row fi@@ bro@@ sis or wo@@ ven bone formation was dete@@ c@@ te@@ d.
Mic@@ ro@@ comp@@ uted
8 tom@@ o@@ graphy (@@ μ C@@ T@@ ) analysis demonstrated increased tra@@ bec@@ ular bone volume and preser@@ vation of tra@@ bec@@ ular bone architecture in patients treated with A@@ cla@@ sta compared to pla@@ c@@ ebo@@ .
B@@ one turno@@ ver mark@@ ers B@@ one specific al@@ kal@@ ine ph@@ osp@@ hat@@ ase (@@ BS@@ AP@@ )@@ , ser@@ um N@@ -@@ terminal pro@@ pe@@ p@@ tide of type I col@@ lagen (@@ P@@ 1@@ N@@ P@@ ) and ser@@ um be@@ ta@@ -@@ C@@ -@@ tel@@ op@@ ep@@ ti@@ des (@@ b@@ -@@ C@@ T@@ x@@ ) were evalu@@ ated in sub@@ sets ranging from 5@@ 17 to 1,@@ 24@@ 6 patients at perio@@ dic inter@@ vals throughout the stu@@ dy@@ .
Tre@@ at@@ ment with a 5 mg annual dose of A@@ cla@@ sta significantly reduced BS@@ AP by 30@@ % relative to bas@@ eline at 12 months which was sustained at 28@@ % below bas@@ eline levels at 36 mon@@ th@@ s.
P@@ 1@@ NP was significantly reduced by 6@@ 1@@ % below bas@@ eline levels at 12 months and was sustained at 5@@ 2@@ % below bas@@ eline levels at 36 mon@@ th@@ s.
B@@ -@@ C@@ T@@ x was significantly reduced by 6@@ 1@@ % below bas@@ eline levels at 12 months and was sustained at 55@@ % below bas@@ eline levels at 36 mon@@ th@@ s.
During this entire time period bone turno@@ ver mark@@ ers were within the pre@@ -@@ men@@ op@@ aus@@ al range at the end of each ye@@ ar@@ .
Re@@ pe@@ at d@@ osing did not lead to further reduction of bone turno@@ ver mark@@ er@@ s.
Eff@@ ect on height In the thre@@ e@@ -@@ year o@@ ste@@ op@@ or@@ o@@ sis study standing height was measured annually using a sta@@ di@@ ome@@ ter@@ .
The A@@ cla@@ sta group revealed approximately 2.5 mm less height loss compared to pla@@ c@@ eb@@ o (@@ 9@@ 5@@ % C@@ I@@ :
1.6 mm@@ , 3.5 mm@@ ) [@@ p < 0.0@@ 00@@ 1@@ ]@@ .
Days of disability A@@ cla@@ sta significantly reduced the mean days of limited activity and the days of bed rest due to back pain by 17.@@ 9 days and 11.@@ 3 days respectively compared to pla@@ c@@ eb@@ o and significantly reduced the mean days of limited activity and the days of bed rest due to frac@@ tures by 2.@@ 9 days and 0.5 days respectively compared to pla@@ c@@ eb@@ o (@@ all p < 0.0@@ 1@@ )@@ .
Clin@@ ical eff@@ ic@@ acy in the treatment of o@@ ste@@ op@@ or@@ o@@ sis in patients at increased risk of fra@@ cture after a recent hip fra@@ cture (@@ R@@ FT@@ ) The inci@@ dence of clinical frac@@ tu@@ res@@ , including ver@@ te@@ br@@ al@@ , non@@ -@@ ver@@ te@@ bra@@ l and hip frac@@ tu@@ res@@ , was evalu@@ ated in 2,@@ 12@@ 7 men and women aged 50@@ -@@ 95 years (@@ mean age 7@@ 4.@@ 5 ye@@ ar@@ s@@ ) with a recent (@@ within 90 da@@ ys@@ ) low@@ - trauma hip fra@@ cture who were followed for an average of 2 years on study medic@@ ation@@ .
Ap@@ pro@@ xim@@ ately 4@@ 2@@ % of patients had a fem@@ oral neck BM@@ D T@@ -@@ score below -@@ 2.5 and approximately 45@@ % of the patients had a fem@@ oral neck BM@@ D T@@ -@@ score above -@@ 2.@@ 5.
A@@ cla@@ sta was administ@@ ered once a ye@@ ar@@ , until at least 2@@ 11 patients in the study population had confirmed clinical frac@@ tu@@ res@@ .
Vit@@ amin D levels were not rout@@ inely measured but a lo@@ ading dose of vit@@ amin D (@@ 50,000 to 12@@ 5,000 I@@ U or@@ ally or via the in@@ tra@@ mus@@ cular rou@@ te@@ ) was given to the majority of patients 2 weeks prior to in@@ fu@@ sion@@ .
All participants received 1,000 to 1,500 mg of elem@@ ental cal@@ ci@@ um plus 800 to 1,@@ 200 I@@ U of vit@@ amin D supp@@ lement@@ ation per day@@ .
N@@ in@@ et@@ y@@ -@@ five percent of the patients received their in@@ fusion two or more weeks after the hip fra@@ cture repair and the medi@@ an timing of in@@ fusion was approximately six weeks after the hip fra@@ cture re@@ pa@@ ir@@ .
The primary eff@@ ic@@ acy vari@@ able was the inci@@ dence of clinical frac@@ tures over the dur@@ ation of the stu@@ dy@@ .
Eff@@ ect on all clinical frac@@ tures The inci@@ dence rates of key clinical fra@@ cture vari@@ ables are presented in Table 4.
9 Table 4
Between treatment compar@@ is@@ ons of the inci@@ dence of key clinical fra@@ cture vari@@ ables
Out@@ come
A@@ cla@@ sta Pla@@ c@@ eb@@ o Absol@@ ute reduction (@@ N@@ =@@ 1,@@ 06@@ 5@@ ) (@@ N@@ =@@ 1,@@ 06@@ 2@@ ) in fra@@ cture event
Rel@@ ative risk reduction in
event rate event rate (@@ %@@ ) (@@ %@@ )
rat@@ e@@ % (@@ C@@ I@@ )
fra@@ cture inci@@ den@@ ce@@ % (@@ C@@ I@@ )
Any clinical fra@@ cture (@@ 1@@ ) Clin@@ ical ver@@ te@@ bra@@ l fra@@ cture (@@ 2@@ ) Non@@ -@@ ver@@ te@@ bra@@ l fra@@ cture (@@ 1@@ ) *@@ p@@ -@@ value < 0.0@@ 5@@ , *@@ *@@ p@@ -@@ value < 0.0@@ 1
8.@@ 6 13.@@ 9 1.@@ 7 3.@@ 8 7.@@ 6 10.@@ 7
5.@@ 3 2.@@ 1 3.@@ 1
(@@ 2.@@ 3@@ , 8.@@ 3@@ ) (@@ 0.@@ 5@@ , 3.@@ 7@@ ) (@@ 0.@@ 3@@ , 5.@@ 9@@ )
35 (@@ 16@@ , 50@@ )@@ *@@ * 46 (@@ 8@@ , 68@@ )@@ * 27 (@@ 2@@ , 45@@ )@@ *
(@@ 1@@ ) Ex@@ clu@@ ding f@@ inger@@ , toe and facial frac@@ tures (@@ 2@@ ) In@@ clu@@ ding clinical thor@@ ac@@ ic and clinical l@@ um@@ bar ver@@ te@@ bra@@ l frac@@ tures
The study was not designed to measure significant differences in hip frac@@ ture@@ , but a trend was seen towards reduction in new hip frac@@ tu@@ res@@ .
All cause mort@@ ality was 10@@ % (@@ 101 pati@@ ent@@ s@@ ) in the A@@ cla@@ sta@@ -@@ treated group compared to 13@@ % (@@ 14@@ 1 pati@@ ent@@ s@@ ) in the pla@@ c@@ eb@@ o gro@@ up@@ .
This correspon@@ ds to a 28@@ % reduction in the risk of all cause mort@@ ality (@@ p@@ =@@ 0.0@@ 1@@ )@@ .
The inci@@ dence of delayed hip fra@@ cture he@@ aling was compar@@ able between A@@ cla@@ sta (@@ 34 [@@ 3.@@ 2@@ %@@ ]@@ ) and pla@@ c@@ eb@@ o (@@ 29 [@@ 2.@@ 7@@ %@@ ]@@ )@@ .
Eff@@ ect on bone min@@ eral den@@ sity (@@ BM@@ D@@ ) In the H@@ OR@@ I@@ Z@@ ON@@ -@@ R@@ FT study A@@ cla@@ sta treatment significantly increased BM@@ D at the total hip and fem@@ oral neck relative to treatment with pla@@ c@@ eb@@ o at all ti@@ me@@ poin@@ ts@@ .
Tre@@ at@@ ment with A@@ cla@@ sta resulted in an increase in BM@@ D of 5.@@ 4@@ % at the total hip and 4.@@ 3@@ % at the fem@@ oral neck over 24 months as compared to pla@@ c@@ ebo@@ .
Clin@@ ical eff@@ ic@@ acy in men In the H@@ OR@@ I@@ Z@@ ON@@ -@@ R@@ FT study 50@@ 8 men were rand@@ o@@ mis@@ ed into the study and 185 patients had BM@@ D asse@@ ssed at 24 mon@@ th@@ s.
At 24 months a similar significant increase of 3.@@ 6@@ % in total hip BM@@ D was observed for patients treated with A@@ cla@@ sta as compared to the effects observed in post@@ -@@ men@@ op@@ aus@@ al women in the H@@ OR@@ I@@ Z@@ ON@@ -@@ P@@ FT stu@@ dy@@ .
The study was not powered to show a reduction in clinical frac@@ tures in men@@ ; the inci@@ dence of clinical frac@@ tures was 7.@@ 5@@ % in men treated with A@@ cla@@ sta versus 8.@@ 7@@ % for pla@@ c@@ ebo@@ .
In another study in men (@@ study C@@ Z@@ OL@@ 4@@ 46@@ M@@ 2@@ 30@@ 8@@ ) an annual in@@ fusion of A@@ cla@@ sta was non@@ -@@ inf@@ eri@@ or to weekly al@@ en@@ dr@@ onate for the percentage change in l@@ um@@ bar sp@@ ine BM@@ D at month 24 relative to bas@@ el@@ ine@@ .
Clin@@ ical eff@@ ic@@ acy in the treatment of Pa@@ get@@ ’ s disease of the bone A@@ cla@@ sta was studied in male and female patients aged above 30 years with primarily mild to moderate Pa@@ get@@ ’ s disease of the bone (@@ medi@@ an ser@@ um al@@ kal@@ ine ph@@ osp@@ hat@@ ase level 2.@@ 6@@ – 3.@@ 0 times the upper limit of the age@@ -@@ specific normal reference range at the time of study entr@@ y@@ ) confirmed by radio@@ graphic evi@@ den@@ ce@@ .
The eff@@ ic@@ acy of one in@@ fusion of 5 mg z@@ ole@@ dr@@ onic acid versus daily d@@ oses of 30 mg ri@@ se@@ dr@@ onate for 2 months was demonstrated in two 6@@ -@@ month compar@@ ative tri@@ al@@ s.
After 6 mon@@ th@@ s@@ , A@@ cla@@ sta showed 9@@ 6@@ % (@@ 16@@ 9@@ / 17@@ 6@@ ) and 89@@ % (@@ 15@@ 6@@ / 17@@ 6@@ ) response and ser@@ um al@@ kal@@ ine ph@@ osp@@ hat@@ ase (@@ S@@ AP@@ ) normal@@ isation rates compared to 7@@ 4@@ % (@@ 12@@ 7@@ / 17@@ 1@@ ) and 58@@ % (@@ 99@@ / 17@@ 1@@ ) for ri@@ se@@ dr@@ onate (@@ all p < 0.0@@ 0@@ 1@@ )@@ .
In the po@@ ol@@ ed resul@@ ts@@ , a similar decre@@ ase in pain sever@@ ity and pain inter@@ ference scores relative to bas@@ eline were observed over 6 months for A@@ cla@@ sta and ri@@ se@@ dr@@ on@@ ate@@ .
10 Pati@@ ents who were classified as respon@@ ders at the end of the 6 month core study were eligible to enter an extended follo@@ w@@ -@@ up peri@@ od@@ .
Of the 14@@ 3 A@@ cla@@ sta@@ -@@ treated patients and 10@@ 7 ri@@ se@@ dr@@ on@@ ate@@ -@@ treated patients who entered an extended ob@@ servation stu@@ dy@@ , after a medi@@ an dur@@ ation of follo@@ w@@ -@@ up of 18 months from time of d@@ os@@ ing@@ , 14@@ 1 A@@ cla@@ sta@@ -@@ treated patients maintained their therapeu@@ tic response compared to 71 ri@@ se@@ dr@@ on@@ ate@@ -@@ treated pati@@ ent@@ s.
This correspon@@ ds to a 9@@ 6@@ % reduction of risk of re@@ lap@@ se in A@@ cla@@ sta versus ri@@ se@@ dr@@ on@@ ate@@ -@@ treated pati@@ ent@@ s.
B@@ one hist@@ ology was evalu@@ ated in 7 patients with Pa@@ get@@ ’ s disease 6 months after treatment with 5 mg z@@ ole@@ dr@@ onic aci@@ d.
B@@ one bi@@ op@@ sy results showed bone of normal quality with no evidence of im@@ paired bone re@@ mod@@ elling and no evidence of min@@ er@@ alisation def@@ ec@@ ts@@ .
These results were consistent with bio@@ chemical mar@@ ker evidence of normal@@ isation of bone turno@@ ver@@ .
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
Single and multiple 5 and 15@@ -@@ minute in@@ fu@@ sions of 2@@ , 4@@ , 8 and 16 mg z@@ ole@@ dr@@ onic acid in 64 patients y@@ iel@@ ded the following pharmac@@ ok@@ ine@@ tic dat@@ a@@ , which were found to be dose inde@@ pend@@ ent@@ .
After initi@@ ation of the z@@ ole@@ dr@@ onic acid in@@ fu@@ sion@@ , p@@ las@@ ma conc@@ ent@@ rations of the active substance increased rap@@ id@@ ly@@ , achieving their peak at the end of the in@@ fusion peri@@ od@@ , followed by a rapid decline to < 10@@ % of peak after 4 hours and < 1@@ % of peak after 24 ho@@ urs@@ , with a subsequent pro@@ lon@@ ged period of very low conc@@ ent@@ rations not exce@@ eding 0.@@ 1@@ % of peak level@@ s.
In@@ tra@@ ven@@ ously administ@@ ered z@@ ole@@ dr@@ onic acid is elim@@ inated by a tri@@ p@@ ha@@ sic proc@@ ess@@ : rapid bi@@ p@@ ha@@ sic dis@@ appearance from the sy@@ ste@@ mic circu@@ la@@ tion@@ , with half@@ -@@ lives of t@@ ½@@ α 0.@@ 24 and t@@ ½@@ β 1.@@ 87 ho@@ urs@@ , followed by a long elim@@ ination phase with a terminal elim@@ ination half@@ -@@ life of t@@ ½@@ γ 14@@ 6 ho@@ urs@@ .
There was no accum@@ ulation of the active substance in p@@ las@@ ma after multiple d@@ oses given every 28 day@@ s.
The early di@@ sposition ph@@ ases (@@ α and β@@ , with t@@ ½ values abo@@ ve@@ ) presum@@ ably represent rapid up@@ take into bone and ex@@ cre@@ tion via the ki@@ d@@ ne@@ y@@ s.
Z@@ ole@@ dr@@ onic acid is not met@@ aboli@@ sed and is ex@@ cre@@ ted un@@ changed via the ki@@ d@@ ne@@ y@@ .
Over the first 24 ho@@ urs@@ , 39 ± 16@@ % of the administ@@ ered dose is recovered in the ur@@ ine@@ , while the rema@@ inder is princip@@ ally bound to bone tis@@ su@@ e@@ .
From the bone tissue it is released very slowly back into the sy@@ ste@@ mic circu@@ lation and elim@@ inated via the ki@@ d@@ ne@@ y@@ .
The total body clear@@ ance is 5@@ .0@@ 4 ± 2.5 l@@ / h@@ , independent of d@@ os@@ e@@ , and un@@ affected by gen@@ der@@ , age@@ , race or body wei@@ ght@@ .
The inter@@ - and in@@ tra@@ -@@ subject vari@@ ation for p@@ las@@ ma clear@@ ance of z@@ ole@@ dr@@ onic acid was shown to be 36@@ % and 34@@ %@@ , respec@@ ti@@ vel@@ y@@ .
In@@ cre@@ asing the in@@ fusion time from 5 to 15 minutes caused a 30@@ % decre@@ ase in z@@ ole@@ dr@@ onic acid concentration at the end of the in@@ fu@@ sion@@ , but had no effect on the area under the p@@ las@@ ma concentration versus time cur@@ ve@@ .
No specific dru@@ g@@ -@@ drug inter@@ action studies have been conducted with z@@ ole@@ dr@@ onic aci@@ d.
Since z@@ ole@@ dr@@ onic acid is not met@@ aboli@@ sed in humans and the substance was found to have little or no capacity as a direc@@ t@@ - acting and@@ / or ir@@ re@@ versi@@ ble met@@ aboli@@ sm@@ -@@ dependent in@@ hi@@ bit@@ or of P@@ 450 enz@@ ym@@ es@@ , z@@ ole@@ dr@@ onic acid is unlikely to reduce the met@@ aboli@@ c clear@@ ance of sub@@ stances which are met@@ aboli@@ sed via the cy@@ to@@ ch@@ rome P@@ 450 enz@@ y@@ me system@@ s.
Z@@ ole@@ dr@@ onic acid is not highly bound to p@@ las@@ ma prot@@ eins (@@ approximately 43@@ -@@ 55@@ % bo@@ und@@ ) and bin@@ ding is concentration inde@@ pend@@ ent@@ .
Ther@@ e@@ fore@@ , inter@@ actions resulting from displa@@ cement of highly prot@@ ein@@ -@@ bound drugs are un@@ lik@@ el@@ y@@ .
Special pop@@ ulations (@@ see section 4.@@ 2@@ ) The ren@@ al clear@@ ance of z@@ ole@@ dr@@ onic acid was cor@@ related with cre@@ at@@ in@@ ine clear@@ anc@@ e@@ , ren@@ al clear@@ ance representing 75 ± 33@@ % of the cre@@ at@@ in@@ ine clear@@ anc@@ e@@ , which showed a mean of 84 ± 29 m@@ l@@ / min (@@ range 22 to 14@@ 3 m@@ l@@ / min@@ ) in the 64 patients studi@@ ed@@ .
Small observed increases in AU@@ C@@ (@@ 0@@ -@@ 24@@ hr@@ )@@ , by about 30@@ % to 40@@ % in mild to moderate ren@@ al im@@ pa@@ ir@@ ment@@ , compared to a patient with normal ren@@ al func@@ tion@@ , and lack of accum@@ ulation of drug with multiple d@@ oses ir@@ respective of ren@@ al func@@ tion@@ , suggest that dose adju@@ st@@ ments of z@@ ole@@ dr@@ onic acid in mild (@@ Cl@@ c@@ r = 50@@ – 80 m@@ l@@ / min@@ ) and moderate ren@@ al im@@ pa@@ ir@@ ment down to a cre@@ at@@ in@@ ine clear@@ ance of 35 m@@ l@@ / min are not necess@@ ar@@ y@@ .
As only limited data are available in severe ren@@ al im@@ pa@@ ir@@ ment (@@ cre@@ at@@ in@@ ine clear@@ ance < 30 m@@ l@@ / min@@ )@@ , no d@@ osing recommendations are possible for this pop@@ ula@@ tion@@ .
11 5.@@ 3 P@@ rec@@ lin@@ ical safety data
A@@ cute tox@@ ic@@ ity The highest non@@ -@@ le@@ thal single in@@ tra@@ ven@@ ous dose was 10 m@@ g@@ / kg body weight in mi@@ ce and 0.@@ 6 m@@ g@@ / kg in rats@@ .
In the sing@@ le@@ -@@ dose dog in@@ fusion stu@@ dies@@ , 1.@@ 0 m@@ g@@ / kg (@@ 6 fold the recommended human therapeu@@ tic exposure based on AU@@ C@@ ) administ@@ ered over 15 minutes was well toler@@ ated with no ren@@ al effec@@ ts@@ .
Sub@@ chronic and chronic tox@@ ic@@ ity In the in@@ tra@@ ven@@ ous in@@ fusion stu@@ dies@@ , ren@@ al toler@@ ability of z@@ ole@@ dr@@ onic acid was established in rats when given 0.@@ 6 m@@ g@@ / kg as 15@@ -@@ minute in@@ fu@@ sions at 3@@ -@@ day inter@@ val@@ s@@ , six times in total (@@ for a cum@@ ula@@ tive dose that cor@@ responded to AU@@ C levels about 6 times the human therapeu@@ tic exp@@ os@@ ure@@ ) while five 15@@ -@@ minute in@@ fu@@ sions of 0.@@ 25 m@@ g@@ / kg administ@@ ered at 2@@ – 3@@ -@@ week inter@@ vals (@@ a cum@@ ula@@ tive dose that cor@@ responded to 7 times the human therapeu@@ tic exp@@ os@@ ure@@ ) were well toler@@ ated in do@@ gs@@ .
In the in@@ tra@@ ven@@ ous bol@@ us stu@@ dies@@ , the d@@ oses that were well@@ -@@ toler@@ ated decre@@ ased with increasing study dur@@ ation@@ :
0.@@ 2 and 0.0@@ 2 m@@ g@@ / kg daily was well toler@@ ated for 4 weeks in rats and do@@ gs@@ , respectively but only 0.0@@ 1 m@@ g@@ / kg and 0.0@@ 05 m@@ g@@ / kg in rats and do@@ gs@@ , respec@@ ti@@ vel@@ y@@ , when given for 52 wee@@ ks@@ .
Lon@@ ger@@ -@@ term repeat administration at cum@@ ula@@ tive exp@@ os@@ ures suff@@ ici@@ ently exce@@ eding the maximum intended human exposure produced tox@@ ic@@ ological effects in other organ@@ s@@ , including the ga@@ stro@@ inte@@ st@@ inal tra@@ ct and li@@ ver@@ , and at the site of in@@ tra@@ ven@@ ous administ@@ ration@@ .
The clinical relev@@ ance of these findings is unk@@ no@@ wn@@ .
The most frequent finding in the repe@@ at@@ -@@ dose studies consi@@ sted of increased primary spon@@ gi@@ osa in the met@@ ap@@ hy@@ ses of long bones in growing animals at nearly all d@@ os@@ es@@ , a finding that reflected the com@@ po@@ und@@ ’ s pharmac@@ ological anti@@ res@@ or@@ p@@ tive activ@@ it@@ y@@ .
Re@@ production tox@@ ic@@ ity Ter@@ at@@ ology studies were performed in two speci@@ es@@ , both via sub@@ cut@@ an@@ e@@ ous administ@@ ration@@ .
Ter@@ at@@ o@@ gen@@ ic@@ ity was observed in rats at d@@ oses ≥ 0.@@ 2 m@@ g@@ / kg and was manifest@@ ed by ex@@ tern@@ al@@ , vi@@ sc@@ eral and sk@@ el@@ et@@ al mal@@ form@@ ations@@ .
Dy@@ sto@@ cia was observed at the lowest dose (@@ 0.0@@ 1 m@@ g@@ / kg body wei@@ ght@@ ) tested in rats@@ .
No ter@@ at@@ ological or em@@ br@@ yo@@ / fo@@ et@@ al effects were observed in rab@@ bit@@ s@@ , although mat@@ ern@@ al tox@@ ic@@ ity was marked at 0.@@ 1 m@@ g@@ / kg due to decre@@ ased ser@@ um cal@@ ci@@ um level@@ s.
Mut@@ agen@@ ic@@ ity and car@@ cin@@ o@@ gen@@ ic potential Z@@ ole@@ dr@@ onic acid was not mut@@ agen@@ ic in the mut@@ agen@@ ic@@ ity tests performed and car@@ cin@@ o@@ gen@@ ic@@ ity testing did not provide any evidence of car@@ cin@@ o@@ gen@@ ic potenti@@ al@@ .
6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
Mann@@ it@@ ol So@@ dium cit@@ rate Water for in@@ jections
6.@@ 2 In@@ comp@@ ati@@ bilities
A@@ cla@@ sta must not be allowed to come into contact with any cal@@ ci@@ um@@ -@@ containing sol@@ u@@ tions@@ .
A@@ cla@@ sta must not be mixed or given in@@ tra@@ ven@@ ously with any other medic@@ inal produc@@ ts@@ .
6.@@ 3 Shel@@ f life
U@@ no@@ pen@@ ed bot@@ t@@ le@@ :
3 years
After op@@ en@@ ing@@ :
24 hours at 2@@ °@@ C - 8@@ °@@ C
12 From a micro@@ bi@@ ological point of vie@@ w@@ , the product should be used immedi@@ at@@ el@@ y@@ .
If not used immedi@@ at@@ el@@ y@@ , in@@ -@@ use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2@@ °@@ C - 8@@ °@@ C.
6.@@ 4 Special prec@@ au@@ tions for storage
The un@@ opened bottle does not require any special storage condi@@ tions@@ .
6.5 Nature and cont@@ ents of container
100 ml transparent plastic (@@ cy@@ clo@@ ole@@ fin@@ ic poly@@ mer@@ ) bottle closed with a flu@@ or@@ o@@ -@@ poly@@ mer co@@ ated bro@@ mo@@ but@@ yl rubber stop@@ per and an al@@ umini@@ um@@ / poly@@ prop@@ yl@@ ene cap with a fli@@ p compon@@ ent@@ .
A@@ cla@@ sta is supp@@ lied in p@@ acks containing one bottle as unit pack or in multi@@ -@@ p@@ acks com@@ prising 5 pack@@ s@@ , each containing 1 bot@@ t@@ le@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al and other handling
For single use on@@ ly@@ .
Any un@@ used solution should be disc@@ ar@@ de@@ d.
Only clear solution free from partic@@ les and disc@@ ol@@ or@@ ation should be use@@ d.
If re@@ fri@@ ger@@ at@@ ed@@ , allow the re@@ fri@@ ger@@ ated solution to reach room temperature before administ@@ ration@@ .
A@@ se@@ p@@ tic techniques must be followed during the preparation of the in@@ fu@@ sion@@ .
7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Nov@@ arti@@ s Euro@@ ph@@ arm Limited Wimble@@ hur@@ st Road Hor@@ s@@ ham West Sus@@ sex@@ , R@@ H@@ 12 5@@ AB United Kingdom
8.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 05@@ / 30@@ 8@@ / 00@@ 1 EU@@ / 1@@ / 05@@ / 30@@ 8@@ / 00@@ 2
9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
15@@ .04.@@ 2005
10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
13 AN@@ NE@@ X II
A.
M@@ AN@@ U@@ F@@ AC@@ T@@ UR@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER RE@@ SP@@ ON@@ S@@ IB@@ LE FO@@ R B@@ AT@@ CH RE@@ LE@@ AS@@ E
B.
CON@@ D@@ IT@@ I@@ ON@@ S O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION
14 A.
M@@ AN@@ U@@ F@@ AC@@ T@@ UR@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER RE@@ SP@@ ON@@ S@@ IB@@ LE FO@@ R B@@ AT@@ CH RE@@ LE@@ AS@@ E
Name and address of the manufacturer responsible for bat@@ ch rele@@ as@@ e@@ :
Nov@@ arti@@ s Phar@@ ma GmbH Ro@@ on@@ straße 25 D@@ -@@ 90@@ 4@@ 29 Nu@@ re@@ mberg Germany
B.
CON@@ D@@ IT@@ I@@ ON@@ S O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION
• CON@@ D@@ IT@@ I@@ ON@@ S O@@ R RE@@ ST@@ R@@ IC@@ TI@@ ON@@ S RE@@ G@@ AR@@ D@@ ING SU@@ P@@ PL@@ Y AND US@@ E I@@ MP@@ O@@ SED ON THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
(@@ See Anne@@ x I@@ :
Sum@@ mary of Product Char@@ ac@@ ter@@ ist@@ ic@@ s@@ , section 4.@@ 2@@ )
• CON@@ D@@ IT@@ I@@ ON@@ S O@@ R RE@@ ST@@ R@@ IC@@ TI@@ ON@@ S W@@ IT@@ H RE@@ G@@ ARD TO THE S@@ AF@@ E AND E@@ FF@@ EC@@ T@@ IV@@ E US@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
The Marketing Auth@@ or@@ isation Hol@@ der (@@ MA@@ H@@ ) shall ensure that the educational programme implemented for the author@@ ised indication of treatment of post@@ -@@ men@@ op@@ aus@@ al o@@ ste@@ op@@ or@@ o@@ si@@ s@@ , is extended to the potential prescri@@ bers concerned by the new indic@@ ation@@ : treatment of o@@ ste@@ op@@ or@@ o@@ sis in post@@ - men@@ op@@ aus@@ al women and men at increased risk of frac@@ ture@@ , including those with a recent low@@ -@@ trauma hip frac@@ ture@@ .
The educational programme contains the follo@@ w@@ ing@@ : • Physi@@ cian educational material • Patient information pack
The physi@@ cian educational material should contain the following key elem@@ ent@@ s@@ : • The Sum@@ mary of Product Char@@ ac@@ ter@@ ist@@ ics • Rem@@ inder card with the following key mes@@ sa@@ ges@@ : o Ne@@ ed to measure ser@@ um cre@@ at@@ in@@ ine before treatment with A@@ cla@@ sta o Re@@ commen@@ dation not to use A@@ cla@@ sta in patients with cre@@ at@@ in@@ ine clear@@ ance < 35 m@@ l@@ / min o Con@@ tra@@ indication in pregnancy and in bre@@ ast@@ -@@ feeding women due to potential ter@@ at@@ o@@ gen@@ ic@@ ity o Ne@@ ed to ensure appropriate hy@@ dra@@ tion of the patient o Ne@@ ed to inf@@ use A@@ cla@@ sta slowly over a period of no less than 15 minutes o O@@ ne@@ -@@ ye@@ arly d@@ osing regime o A@@ de@@ qu@@ ate cal@@ ci@@ um and vit@@ amin D in@@ take are recommended in association with A@@ cla@@ sta administration o Ne@@ ed for appropriate physical activ@@ it@@ y@@ , non@@ -@@ smoking and healthy diet • Patient information pack
The patient information pack should be provided and contain the following key mes@@ sa@@ ges@@ : • Pack@@ age le@@ af@@ let • Con@@ tra@@ indication in pregnancy and in bre@@ ast@@ -@@ feeding women • Ne@@ ed for adequate cal@@ ci@@ um and vit@@ amin D supp@@ lement@@ ation@@ , appropriate physical activ@@ it@@ y@@ , non@@ - smoking and healthy diet • Key signs and symptoms of serious ad@@ verse events • When to seek attention from the health care provider
15 • O@@ TH@@ ER CON@@ D@@ IT@@ I@@ ON@@ S
P@@ harm@@ ac@@ o@@ vig@@ il@@ ance system The MA@@ H must ensure that the system of pharmac@@ o@@ vig@@ il@@ anc@@ e@@ , as described in the version 3.@@ 0 dated 13 July 2007 presented in Mo@@ dule 1.@@ 8.@@ 1. of the Marketing Auth@@ or@@ isation App@@ lic@@ ation@@ , is in place and func@@ tioning before and whilst the product is on the market@@ .
Ris@@ k Management Plan The MA@@ H com@@ mits to performing the studies and additional pharmac@@ o@@ vig@@ il@@ ance activities detailed in the P@@ harm@@ ac@@ o@@ vig@@ il@@ ance Plan@@ , as agreed in version 00@@ 4 of the Ris@@ k Management Plan (@@ R@@ MP@@ ) presented in Mo@@ dule 1.@@ 8.@@ 2. of the Marketing Auth@@ or@@ isation App@@ lic@@ ation and any subsequent updates of the R@@ MP agreed by the CH@@ MP@@ .
As per the CH@@ MP Gui@@ del@@ ine on Ris@@ k Management Systems for medic@@ inal products for human use@@ , the updated R@@ MP should be submitted at the same time as the next Peri@@ o@@ dic Safety Update Report (@@ P@@ S@@ UR@@ )@@ .
In addi@@ tion@@ , an updated R@@ MP should be submitted • When new information is received that may impact on the current Safety Speci@@ fic@@ ation@@ , P@@ harm@@ ac@@ o@@ vig@@ il@@ ance Plan or risk mini@@ mis@@ ation activities • Within 60 days of an important (@@ pharmac@@ o@@ vig@@ il@@ ance or risk mini@@ mis@@ ation@@ ) mi@@ lestone being reached • At the request of the E@@ ME@@ A
16 AN@@ NE@@ X III
LA@@ B@@ EL@@ LIN@@ G AND P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T
17 A.
LA@@ B@@ EL@@ LIN@@ G
18 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING AND ON THE IM@@ ME@@ DI@@ AT@@ E P@@ AC@@ K@@ AG@@ ING
F@@ OL@@ D@@ ING BO@@ X (@@ W@@ IT@@ H BL@@ U@@ E BO@@ X@@ ) AND B@@ OT@@ T@@ LE LA@@ B@@ EL FO@@ R UN@@ IT P@@ AC@@ K
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
A@@ cla@@ sta 5 mg solution for in@@ fusion Z@@ ole@@ dr@@ onic acid
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE@@ (@@ S@@ )
1 bottle contains 5 mg z@@ ole@@ dr@@ onic acid (@@ an@@ hydro@@ us@@ )@@ .
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
Mann@@ it@@ ol@@ , so@@ dium cit@@ rate and water for in@@ jec@@ tions@@ .
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
1 bottle – 100 ml
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
In@@ tra@@ ven@@ ous use@@ .
For single use on@@ ly@@ .
Read the package le@@ af@@ let before use@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P After op@@ en@@ ing@@ :
24 hours at 2@@ °@@ C - 8@@ °@@ C.
9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
19 10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Nov@@ arti@@ s Euro@@ ph@@ arm Limited Wimble@@ hur@@ st Road Hor@@ s@@ ham West Sus@@ sex@@ , R@@ H@@ 12 5@@ AB United Kingdom
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 05@@ / 30@@ 8@@ / 00@@ 1
13.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
Justi@@ fication for not including bra@@ ille accep@@ te@@ d.
20 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE IN@@ TER@@ ME@@ DI@@ AT@@ E P@@ AC@@ K@@ AG@@ ING
F@@ OL@@ D@@ ING BO@@ X (@@ W@@ IT@@ H BL@@ U@@ E BO@@ X@@ ) AND B@@ OT@@ T@@ LE LA@@ B@@ EL FO@@ R IN@@ TER@@ ME@@ DI@@ AT@@ E P@@ AC@@ K
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
A@@ cla@@ sta 5 mg solution for in@@ fusion Z@@ ole@@ dr@@ onic acid
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE@@ (@@ S@@ )
1 bottle contains 5 mg z@@ ole@@ dr@@ onic acid (@@ an@@ hydro@@ us@@ )@@ .
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
Mann@@ it@@ ol@@ , so@@ dium cit@@ rate and water for in@@ jec@@ tions@@ .
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
1 bottle - 100 ml Comp@@ on@@ ent of a multi@@ -@@ pack com@@ prising 5 bot@@ t@@ les@@ , each bottle of 100 m@@ l.
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
In@@ tra@@ ven@@ ous use@@ .
For single use on@@ ly@@ .
Read the package le@@ af@@ let before use@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P After op@@ en@@ ing@@ :
24 hours at 2@@ °@@ C - 8@@ °@@ C.
9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
21 10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Nov@@ arti@@ s Euro@@ ph@@ arm Limited Wimble@@ hur@@ st Road Hor@@ s@@ ham West Sus@@ sex@@ , R@@ H@@ 12 5@@ AB United Kingdom
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 05@@ / 30@@ 8@@ / 00@@ 2
13.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
Justi@@ fication for not including bra@@ ille accep@@ te@@ d.
22 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER C@@ AR@@ T@@ ON O@@ F M@@ UL@@ TI@@ -@@ P@@ AC@@ K (@@ IN@@ CL@@ U@@ D@@ ING BL@@ U@@ E BO@@ X@@ )
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
A@@ cla@@ sta 5 mg solution for in@@ fusion Z@@ ole@@ dr@@ onic acid
2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE@@ (@@ S@@ )
1 bottle contains 5 mg z@@ ole@@ dr@@ onic acid (@@ an@@ hydro@@ us@@ )@@ .
3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
Mann@@ it@@ ol@@ , so@@ dium cit@@ rate and water for in@@ jec@@ tions@@ .
4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
Multi@@ -@@ pack com@@ prising 5 bot@@ t@@ les@@ , each bottle of 100 m@@ l.
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION
In@@ tra@@ ven@@ ous use@@ .
For single use on@@ ly@@ .
Read the package le@@ af@@ let before use@@ .
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ .
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P After op@@ en@@ ing@@ :
24 hours at 2@@ °@@ C - 8@@ °@@ C.
9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
23 10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Nov@@ arti@@ s Euro@@ ph@@ arm Limited Wimble@@ hur@@ st Road Hor@@ s@@ ham West Sus@@ sex@@ , R@@ H@@ 12 5@@ AB United Kingdom
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
EU@@ / 1@@ / 05@@ / 30@@ 8@@ / 00@@ 2
13.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
Justi@@ fication for not including bra@@ ille accep@@ te@@ d.
24 B.
P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T
25 P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T@@ :
IN@@ F@@ OR@@ M@@ AT@@ ION FO@@ R THE US@@ ER
A@@ cla@@ sta 5 mg solution for in@@ fusion Z@@ ole@@ dr@@ onic acid
Read all of this le@@ af@@ let carefully before you are given this medic@@ ine@@ .
- Keep this le@@ af@@ let@@ .
You may need to read it aga@@ in@@ .
- If you have any further questi@@ ons@@ , ask your do@@ ct@@ or@@ , pharmac@@ ist or nur@@ se@@ .
- If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ ,
please tell your do@@ ct@@ or@@ , pharmac@@ ist or nur@@ se@@ .
In this le@@ af@@ let@@ :
1.
What A@@ cla@@ sta is and what it is used for 2.
Before you are given A@@ cla@@ sta 3.
How A@@ cla@@ sta is given 4.
Pos@@ sible side effects 5.
How to store A@@ cla@@ sta 6.
Further information
1.
WH@@ AT AC@@ LA@@ ST@@ A IS AND WH@@ AT IT IS US@@ ED FO@@ R
A@@ cla@@ sta is given as a single in@@ fusion into a v@@ ein by a doctor or nur@@ se@@ .
It belon@@ gs to a group of medic@@ ines called bi@@ sph@@ osph@@ on@@ ates and is used to treat o@@ ste@@ op@@ or@@ o@@ sis in post@@ -@@ men@@ op@@ aus@@ al wom@@ en@@ , o@@ ste@@ op@@ or@@ o@@ sis in men and Pa@@ get@@ ’ s disease of the bon@@ e@@ .
O@@ ste@@ op@@ or@@ o@@ sis O@@ ste@@ op@@ or@@ o@@ sis is a disease that involves the th@@ inning and weak@@ ening of the bones and is common in women after the men@@ op@@ au@@ se@@ , but can also occur in men@@ .
At the men@@ op@@ au@@ se@@ , a wom@@ an@@ ’ s o@@ vari@@ es stop producing the female hor@@ mone o@@ est@@ ro@@ gen@@ , which helps keep bones health@@ y@@ .
Following the men@@ op@@ ause bone loss occ@@ urs@@ , bones become we@@ aker and break more easi@@ ly@@ .
Many patients with o@@ ste@@ op@@ or@@ o@@ sis have no symptoms but they are still at risk of breaking bones because o@@ ste@@ op@@ or@@ o@@ sis has made their bones weak@@ er@@ .
Dec@@ re@@ ased cir@@ cul@@ ating levels of sex hor@@ mon@@ es@@ , mainly o@@ est@@ ro@@ gens converted from and@@ ro@@ gen@@ s@@ , also play a role in the more gradu@@ al bone loss observed in men@@ .
In both women and men@@ , A@@ cla@@ sta strength@@ ens the bone and therefore makes it less likely to break@@ .
Because A@@ cla@@ sta works for a long ti@@ me@@ , you will not need another dose of A@@ cla@@ sta for a ye@@ ar@@ .
Pa@@ get@@ ’ s disease of the bone It is normal that old bone is removed and is replaced with new bone materi@@ al@@ .
This process is called re@@ mod@@ ell@@ ing@@ .
In Pa@@ get@@ ’ s dise@@ as@@ e@@ , bone re@@ mod@@ elling is too rapid and new bone is formed in a disor@@ dered fashi@@ on@@ , which makes it we@@ aker than normal@@ .
If the disease is not treat@@ ed@@ , bones may become de@@ formed and pain@@ ful@@ , and may break@@ .
A@@ cla@@ sta works by returning the bone re@@ mod@@ elling process to normal@@ , securing formation of normal bon@@ e@@ , thus restor@@ ing strength to the bon@@ e@@ .
2.
BE@@ F@@ ORE Y@@ O@@ U AR@@ E G@@ IV@@ EN AC@@ LA@@ ST@@ A
Follow all instructions given to you by your doctor carefully before you are given A@@ cla@@ sta@@ .
You should not be given A@@ cla@@ sta
- if you are aller@@ gic (@@ hyper@@ sensi@@ ti@@ ve@@ ) to z@@ ole@@ dr@@ onic aci@@ d@@ , other bi@@ sph@@ osph@@ on@@ ates or any of the other
ingredients of A@@ cla@@ sta@@ .
- if you have hypo@@ cal@@ ca@@ emi@@ a (@@ this means that the levels of cal@@ ci@@ um in your blood are too low@@ )@@ .
- if you are pregnant or plan to become pregn@@ ant@@ .
- if you are bre@@ ast@@ -@@ fe@@ ed@@ ing@@ .
26 Take special care with A@@ cla@@ sta T@@ ell your doctor before you are given A@@ cla@@ sta@@ :
- if you are being treated with Z@@ omet@@ a@@ , which contains the same active substance as A@@ cla@@ sta@@ .
- if you have a ki@@ dney problem@@ , or used to have one@@ .
- if you are unable to take daily cal@@ ci@@ um supp@@ lement@@ s.
- if you have had some or all of the par@@ ath@@ y@@ ro@@ id gl@@ ands in your neck sur@@ gi@@ cally re@@ mov@@ ed@@ .
- if you have had sections of your inte@@ stine re@@ mov@@ ed@@ .
- if you had or have pain@@ , sw@@ elling or num@@ b@@ ness of the ja@@ w or a lo@@ os@@ ening of the t@@ ooth@@ .
If you are under dental treatment or will under@@ go dental sur@@ ger@@ y@@ , tell your denti@@ st that you are being treated with A@@ cla@@ sta@@ .
A@@ cla@@ sta is not recommended for anyone under 18 years of age@@ .
The use of A@@ cla@@ sta in children and adol@@ es@@ cents has not been studi@@ ed@@ .
Taking other medic@@ ines Please tell your do@@ ct@@ or@@ , pharmac@@ ist or nurse if you are taking or have recently taken any other medi@@ cin@@ es@@ , including medic@@ ines obtained without a prescri@@ p@@ tion@@ .
It is especially important for your doctor to know if you are taking any medic@@ ines known to be harm@@ ful to your ki@@ d@@ ne@@ y@@ s.
Using A@@ cla@@ sta with food and drink Make sure you drink enough flu@@ ids (@@ at least one or two g@@ las@@ ses@@ ) before and after the treatment with A@@ cla@@ sta@@ , as directed by your do@@ ct@@ or@@ .
This will help to prevent de@@ hy@@ dra@@ tion@@ .
You may eat normally on the day you are treated with A@@ cla@@ sta@@ .
El@@ derly patients (@@ age 65 years and over@@ ) A@@ cla@@ sta can be given to older pati@@ ent@@ s.
Pre@@ gn@@ ancy and bre@@ ast@@ -@@ feeding You should not be given A@@ cla@@ sta if you are pregnant or plan to become pregn@@ ant@@ .
You should not be given A@@ cla@@ sta if you are bre@@ ast@@ -@@ fe@@ ed@@ ing@@ .
As@@ k your do@@ ct@@ or@@ , pharmac@@ ist or nurse for advice before taking any medic@@ ine@@ .
Dri@@ ving and using machines A@@ cla@@ sta has no known effects on the ability to drive or use mach@@ in@@ es@@ .
3.
HO@@ W AC@@ LA@@ ST@@ A IS G@@ IV@@ EN
O@@ ste@@ op@@ or@@ o@@ sis The usual dose is 5 mg given as one in@@ fusion per year into a v@@ ein by your doctor or nur@@ se@@ .
The in@@ fusion will take at least 15 min@@ ut@@ es@@ .
In case you recently broke your hi@@ p@@ , it is recommended that A@@ cla@@ sta is administ@@ ered two or more weeks after your hip repair sur@@ ger@@ y@@ .
Follow carefully all instructions given to you by your doctor or nur@@ se@@ .
It is important to take cal@@ ci@@ um and vit@@ amin D supp@@ lements (@@ for example tab@@ le@@ ts@@ ) as directed by your do@@ ct@@ or@@ .
For o@@ ste@@ op@@ or@@ o@@ si@@ s@@ , A@@ cla@@ sta works for one year and you will need the next dose after one ye@@ ar@@ .
27 Pa@@ get@@ ’ s disease The usual dose is 5 m@@ g@@ , given to you as one single in@@ fusion into a v@@ ein by your doctor or nur@@ se@@ .
The in@@ fusion will take at least 15 min@@ ut@@ es@@ .
As A@@ cla@@ sta works for a long ti@@ me@@ , you may not need another dose of A@@ cla@@ sta for a year or lon@@ ger@@ .
Follow carefully all instructions given to you by your doctor or nur@@ se@@ .
Your doctor may advi@@ se you to take cal@@ ci@@ um and vit@@ amin D supp@@ lements (@@ e@@ . g. tab@@ le@@ ts@@ ) for at least the first ten days after being given A@@ cla@@ sta@@ .
It is important that you follow this advice carefully so that the level of cal@@ ci@@ um in your blood does not become too low in the period after the in@@ fu@@ sion@@ .
Your doctor will in@@ form you regarding the symptoms associated with hypo@@ cal@@ ca@@ emi@@ a.
For Pa@@ get@@ ’ s disease A@@ cla@@ sta may work for longer than one ye@@ ar@@ , and your doctor will let you know if you need to be treated aga@@ in@@ .
If a dose of A@@ cla@@ sta is missed Contact your doctor or hospital as soon as possible to re@@ -@@ schedule your appoin@@ t@@ ment@@ .
Before stopping A@@ cla@@ sta therapy If you are considering stopping A@@ cla@@ sta treat@@ ment@@ , please go to your next appointment and discuss this with your do@@ ct@@ or@@ .
Your doctor will advi@@ se you and decide how long you should be treated with A@@ cla@@ sta@@ .
If you have any questions on the use of this produc@@ t@@ , ask your do@@ ct@@ or@@ , pharmac@@ ist or nur@@ se@@ .
4.
P@@ OS@@ S@@ IB@@ LE SI@@ DE E@@ FF@@ EC@@ TS
Like all medi@@ cin@@ es@@ , A@@ cla@@ sta can cause side effec@@ ts@@ , although not everybody gets them@@ .
In most cas@@ es@@ , no specific treatment is requi@@ re@@ d.
Side effects related to the first in@@ fusion are very common (@@ occ@@ urring in more than 30@@ % of pati@@ ent@@ s@@ ) but are less common following subsequent in@@ fu@@ sion@@ s.
The majority of the side effec@@ ts@@ , such as fe@@ ver and ch@@ ill@@ s@@ , pain in the muscles or jo@@ in@@ ts@@ , and hea@@ da@@ che@@ , occur within the first three days following the dose of A@@ cla@@ sta@@ .
The symptoms are usually mild to moderate and go away within three day@@ s.
Your doctor can recommend a mild pain relie@@ ver such as i@@ bu@@ pro@@ fen or par@@ ac@@ et@@ am@@ ol to reduce these side effec@@ ts@@ .
The chance of experiencing these side effects decre@@ ases with subsequent d@@ oses of A@@ cla@@ sta@@ .
Ir@@ regular heart rhyth@@ m (@@ atri@@ al fi@@ bri@@ l@@ la@@ tion@@ ) has been seen in patients receiving A@@ cla@@ sta for post@@ - men@@ op@@ aus@@ al o@@ ste@@ op@@ or@@ o@@ si@@ s.
It is currently unclear whether A@@ cla@@ sta causes this ir@@ regular heart rhyth@@ m but you should report it to your doctor if you experience such symptoms after you have received A@@ cla@@ sta@@ .
Very common side effects (@@ affecting 10 or more in every 100 pati@@ ent@@ s@@ )@@ :
F@@ ever
Comm@@ on side effects (@@ affecting less than 10 in every 100 pati@@ ent@@ s@@ )@@ :
F@@ ever and ch@@ ill@@ s@@ , hea@@ da@@ che@@ , feeling sick@@ , pain in your mus@@ cle@@ s@@ , pain in your bones and@@ / or jo@@ in@@ ts@@ , ti@@ re@@ dn@@ ess@@ , weak@@ ness@@ , di@@ zz@@ in@@ ess@@ , vo@@ mit@@ ing@@ , pain in your back@@ , arms or leg@@ s.
In patients with Pa@@ get@@ ’ s dise@@ as@@ e@@ : symptoms due to low blood cal@@ ci@@ um@@ , such as muscle sp@@ as@@ ms@@ , or num@@ bn@@ ess@@ , or a t@@ ing@@ ling sens@@ ation especially in the area around the mou@@ th@@ .
Un@@ common side effects (@@ affecting less than 1 in every 100 pati@@ ent@@ s@@ )@@ :
Flu@@ , sle@@ ep@@ less@@ ness@@ , ti@@ re@@ dn@@ ess@@ , feeling of p@@ ins and need@@ les or t@@ ing@@ ling sensation@@ , dro@@ w@@ sin@@ ess@@ , tre@@ mor@@ , temporary loss of consci@@ ous@@ ness@@ , taste distur@@ b@@ anc@@ e@@ , di@@ arr@@ ho@@ e@@ a@@ , indi@@ gesti@@ on@@ , ab@@ dom@@ inal pain@@ , dry mou@@ th@@ , infl@@ amm@@ ation of o@@ es@@ oph@@ ag@@ us@@ , t@@ ooth@@ ach@@ e@@ , joint pain@@ , joint sw@@ ell@@ ing@@ , sti@@ ff@@ ness@@ , eating disor@@ der@@ , re@@ dn@@ ess@@ , it@@ ching and pain in the ey@@ es@@ , chest pain@@ , increased blood pressu@@ re@@ , fl@@ ush@@ ing@@ , short@@ ness of breath@@ , ra@@ sh@@ ,
R@@ are side effects (@@ affecting less than 1 in every 1,000 pati@@ ent@@ s@@ )@@ :
Pa@@ in@@ ful red e@@ ye@@ .
Sk@@ in re@@ actions such as re@@ dn@@ ess@@ , sw@@ elling and@@ / or pain at the in@@ fusion site may occ@@ ur@@ .
Bi@@ sph@@ osph@@ on@@ ates (@@ the group of sub@@ stances A@@ cla@@ sta belon@@ gs to@@ ) may cause sw@@ ell@@ ing@@ , re@@ dn@@ ess@@ , pain and it@@ ching of the eyes or eye sensi@@ tivity to light@@ .
Per@@ si@@ stent pain and@@ / or non@@ -@@ he@@ aling sor@@ es of the mouth or ja@@ w have been reported primarily in patients treated with bi@@ sph@@ osph@@ on@@ ates for other ill@@ nes@@ ses@@ .
If you experience these symp@@ tom@@ s@@ , tell your doctor or denti@@ st@@ .
Aller@@ gic re@@ actions have been reported including rare cases of difficulty breath@@ ing@@ , hi@@ ves and an@@ gi@@ oe@@ de@@ ma (@@ such as s@@ wollen fac@@ e@@ , ton@@ gue or thro@@ at@@ )@@ .
There have been isolated reports of very serious aller@@ gic re@@ ac@@ tions@@ .
If you notice any of these side effec@@ ts@@ , tell your do@@ ct@@ or@@ .
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your do@@ ct@@ or@@ , pharmac@@ ist or nur@@ se@@ .
5.
HO@@ W TO ST@@ ORE AC@@ LA@@ ST@@ A
Your do@@ ct@@ or@@ , pharmac@@ ist or nurse knows how to store A@@ cla@@ sta proper@@ ly@@ .
- Keep A@@ cla@@ sta out of the reach and sight of chil@@ dr@@ en@@ .
- Do not use A@@ cla@@ sta after the exp@@ iry date which is stated on the car@@ ton and bot@@ t@@ le@@ .
- The un@@ opened bottle does not require any special storage condi@@ tions@@ .
- After opening the bot@@ t@@ le@@ , the product should be used immediately in order to avoid micro@@ bi@@ al
contam@@ in@@ ation@@ .
If not used immedi@@ at@@ el@@ y@@ , in@@ -@@ use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2@@ °@@ C – 8@@ °@@ C.
Al@@ low the re@@ fri@@ ger@@ ated solution to reach room temperature before administ@@ ration@@ .
6.
F@@ UR@@ TH@@ ER IN@@ F@@ OR@@ M@@ AT@@ ION
What A@@ cla@@ sta contains
- The active substance is z@@ ole@@ dr@@ onic aci@@ d.
Each bottle with 100 ml of solution contains 5 mg
z@@ ole@@ dr@@ onic acid an@@ hydro@@ us@@ , correspon@@ ding to 5.@@ 330 mg z@@ ole@@ dr@@ onic acid mon@@ oh@@ y@@ dr@@ ate@@ .
One ml solution contains 0.0@@ 5 mg z@@ ole@@ dr@@ onic acid an@@ hydro@@ us correspon@@ ding to 0.0@@ 5@@ 330 mg z@@ ole@@ dr@@ onic acid mon@@ oh@@ y@@ dr@@ ate@@ .
- The other ingredients are mann@@ it@@ ol@@ , so@@ dium cit@@ rate and water for in@@ jec@@ tions@@ .
What A@@ cla@@ sta looks like and cont@@ ents of the pack A@@ cla@@ sta is a clear and colo@@ ur@@ less sol@@ u@@ tion@@ .
It comes in 100 ml plastic bottles as a read@@ y@@ -@@ to@@ -@@ use solution for in@@ fu@@ sion@@ .
It is supp@@ lied in p@@ acks containing one bottle as unit pack or in multi@@ -@@ p@@ acks com@@ prising 5 pack@@ s@@ , each containing 1 bot@@ t@@ le@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
29 Marketing Auth@@ or@@ isation Hol@@ der Nov@@ arti@@ s Euro@@ ph@@ arm Limited Wimble@@ hur@@ st Road Hor@@ s@@ ham West Sus@@ sex@@ , R@@ H@@ 12 5@@ AB United Kingdom
Manu@@ fac@@ tur@@ er Nov@@ arti@@ s Phar@@ ma GmbH Ro@@ on@@ straße 25 D@@ -@@ 90@@ 4@@ 29 Nu@@ re@@ mberg Germany
For any information about this medic@@ ine@@ , please contact the local representative of the Marketing Auth@@ or@@ isation Hol@@ der@@ .
Belgi@@ ë@@ / Belgi@@ qu@@ e@@ / Belgien Nov@@ arti@@ s Phar@@ ma N. V.
T@@ é@@ l@@ / Tel@@ : +@@ 32 2 24@@ 6 16 11
Luxem@@ bour@@ g@@ / Luxemburg Nov@@ arti@@ s Phar@@ ma GmbH T@@ é@@ l@@ / Tel@@ : +@@ 49 9@@ 11 27@@ 3 0
Б@@ ъ@@ л@@ г@@ а@@ р@@ и@@ я Nov@@ arti@@ s Phar@@ ma Services Inc.
Т@@ е@@ л@@ : +@@ 3@@ 59 2 4@@ 89 98 28
Mag@@ y@@ ar@@ or@@ sz@@ á@@ g Nov@@ arti@@ s Hung@@ á@@ ria K@@ ft@@ .
Phar@@ ma Tel@@ .@@ : +@@ 36 1 4@@ 57 65 00
Č es@@ k@@ á republi@@ ka Nov@@ arti@@ s s. r. o.
Tel@@ : +@@ 4@@ 20 2@@ 25 7@@ 75 111
Malta Nov@@ arti@@ s Phar@@ ma Services Inc.
Tel@@ : +@@ 3@@ 56 2@@ 29@@ 8 32@@ 17
Dan@@ mark Nov@@ arti@@ s Heal@@ th@@ care A@@ / S T@@ l@@ f@@ : +@@ 45 39 16 84 00
Ne@@ der@@ land Nov@@ arti@@ s Phar@@ ma B. V.
Tel@@ : +@@ 31 26 37 82 111
Deutschland Nov@@ arti@@ s Phar@@ ma GmbH Tel@@ : +@@ 49 9@@ 11 27@@ 3 0
Nor@@ ge Nov@@ arti@@ s Nor@@ ge AS T@@ l@@ f@@ : +@@ 47 23 05 20 00
E@@ est@@ i Nov@@ arti@@ s Phar@@ ma Services Inc.
Tel@@ : +@@ 3@@ 72 60 62 400
Österreich Nov@@ arti@@ s Phar@@ ma GmbH Tel@@ : +@@ 43 1 86 65@@ 70
Ε@@ λ@@ λ@@ ά@@ δ@@ α Nov@@ arti@@ s (@@ Hell@@ as@@ ) A. E. B. E.
Τ@@ η@@ λ@@ : +@@ 30 210 28@@ 1 17 12
Pol@@ ska Nov@@ arti@@ s Poland Sp@@ . z o. o.
Tel@@ .@@ : +@@ 48 22 550 88@@ 88
E@@ spa@@ ñ@@ a Nov@@ arti@@ s Far@@ mac@@ é@@ u@@ tic@@ a@@ , S. A.
Tel@@ : +@@ 34 93 30@@ 6 42 00
Portugal Nov@@ arti@@ s Far@@ ma - Pro@@ d@@ ut@@ os Far@@ mac@@ ê@@ u@@ tic@@ os@@ , S. A.
Tel@@ : +@@ 3@@ 51 21 000 8@@ 600
France Nov@@ arti@@ s Phar@@ ma S. A. S.
T@@ é@@ l@@ : +@@ 33 1 55 47 66 00
Rom@@ â@@ nia Nov@@ arti@@ s Phar@@ ma Services Inc.
Tel@@ : +@@ 40 21 3@@ 12@@ 99 01
Ireland Nov@@ arti@@ s Ireland Limited Tel@@ : +@@ 3@@ 53 1 260 12 55
Slo@@ ven@@ i@@ ja Nov@@ arti@@ s Phar@@ ma Services Inc.
Tel@@ : +@@ 38@@ 6 1 300 75 77
30 Í@@ s@@ land V@@ ist@@ or hf@@ .
S@@ í@@ mi@@ : +@@ 3@@ 54 5@@ 35 7000
Slo@@ ven@@ sk@@ á republi@@ ka Nov@@ arti@@ s Slovakia s. r. o.
Tel@@ : +@@ 4@@ 21 2 55@@ 42 54@@ 39
Itali@@ a Nov@@ arti@@ s Far@@ ma S. p. A.
Tel@@ : +@@ 39 02 96 54 1
Su@@ omi@@ / Fin@@ land Nov@@ arti@@ s Fin@@ land O@@ y Pu@@ h@@ / Tel@@ : +@@ 3@@ 58 9 61 33 22 11
Κ@@ ύ@@ π@@ ρ@@ ο@@ ς Δ@@ η@@ μ@@ η@@ τ@@ ρ@@ ι@@ ά@@ δ@@ η@@ ς κ@@ α@@ ι Π@@ α@@ π@@ α@@ έ@@ λ@@ λ@@ η@@ ν@@ α@@ ς Λ@@ τ@@ δ Τ@@ η@@ λ@@ : +@@ 3@@ 57 22 6@@ 90 6@@ 90
S@@ ver@@ ige Nov@@ arti@@ s S@@ ver@@ ige AB Tel@@ : +@@ 46 8 7@@ 32 32 00
Lat@@ vi@@ ja Nov@@ arti@@ s Phar@@ ma Services Inc.
Tel@@ : +@@ 3@@ 71 7 8@@ 87 0@@ 70
United Kingdom Nov@@ arti@@ s P@@ harm@@ ac@@ eu@@ tic@@ als UK L@@ t@@ d.
Tel@@ : +@@ 44 12@@ 76 6@@ 98@@ 370
Lie@@ tu@@ va Nov@@ arti@@ s Phar@@ ma Services Inc.
Tel@@ : +@@ 370 5 26@@ 9 16 50
This le@@ af@@ let was last approved in {@@ dat@@ e@@ }
31 IN@@ F@@ OR@@ M@@ AT@@ ION FO@@ R THE HE@@ AL@@ TH@@ C@@ AR@@ E P@@ RO@@ F@@ ES@@ SI@@ ON@@ AL
The following information is intended for medical or healthcare professionals on@@ ly@@ :
The dose of 5 mg of z@@ ole@@ dr@@ onic acid must be administ@@ ered over at least 15 min@@ ut@@ es@@ .
A@@ cla@@ sta is not recommended for patients with severe ren@@ al im@@ pa@@ ir@@ ment (@@ cre@@ at@@ in@@ ine clear@@ ance < 35 m@@ l@@ / min@@ ) due to lack of adequate clinical experience in this pop@@ ula@@ tion@@ .
Pati@@ ents should have their ser@@ um cre@@ at@@ in@@ ine level measured before receiving A@@ cla@@ sta@@ .
In patients with a recent low@@ -@@ trauma hip frac@@ ture@@ , it is recommended to give the A@@ cla@@ sta in@@ fusion two or more weeks after hip fra@@ cture re@@ pa@@ ir@@ .
Pati@@ ents must be appropri@@ ately hydr@@ ated prior to and following administration of A@@ cla@@ sta@@ ; this is especially important for patients receiving di@@ ure@@ tic therap@@ y@@ .
Cau@@ tion is indicated when A@@ cla@@ sta is administ@@ ered in con@@ junction with medic@@ inal products that can significantly impact ren@@ al function (@@ e@@ . g. am@@ in@@ o@@ g@@ ly@@ co@@ sides or di@@ ure@@ tics that may cause de@@ hy@@ dra@@ tion@@ )@@ .
Pre@@ -@@ existing hypo@@ cal@@ ca@@ emi@@ a must be treated by adequate in@@ take of cal@@ ci@@ um and vit@@ amin D before initi@@ ating therapy with A@@ cla@@ sta@@ .
Other distur@@ ban@@ ces of min@@ eral met@@ aboli@@ sm must also be effectively treated (@@ e@@ . g. di@@ mini@@ shed par@@ ath@@ y@@ ro@@ id reser@@ ve@@ , inte@@ st@@ inal cal@@ ci@@ um mal@@ absor@@ p@@ tion@@ )@@ .
Physi@@ cians should consider clinical monitoring for these pati@@ ent@@ s.
Ele@@ v@@ ated bone turno@@ ver is a characterist@@ ic of Pa@@ get@@ ’ s disease of the bon@@ e@@ .
D@@ ue to the rapid on@@ set of effect of z@@ ole@@ dr@@ onic acid on bone turno@@ ver@@ , tran@@ si@@ ent hypo@@ cal@@ ca@@ emi@@ a@@ , sometimes symp@@ tom@@ ati@@ c@@ , may develop and is usually maximal within the first 10 days after in@@ fusion of A@@ cla@@ sta@@ .
A@@ de@@ qu@@ ate cal@@ ci@@ um and vit@@ amin D in@@ take are recommended in association with A@@ cla@@ sta administ@@ ration@@ .
In addi@@ tion@@ , in patients with Pa@@ get@@ '@@ s dise@@ as@@ e@@ , it is strongly advised that adequate supp@@ le@@ mental cal@@ ci@@ um correspon@@ ding to at least 500 mg elem@@ ental cal@@ ci@@ um twice daily is ensured for at least 10 days following A@@ cla@@ sta administ@@ ration@@ .
Pati@@ ents should be informed about symptoms of hypo@@ cal@@ ca@@ emi@@ a and receive adequate clinical monitoring during the period of risk@@ .
Me@@ as@@ u@@ rement of ser@@ um cal@@ ci@@ um before in@@ fusion of A@@ cla@@ sta is recommended for patients with Pa@@ get@@ ´@@ s dise@@ as@@ e@@ .
In patients with a recent low@@ -@@ trauma hip frac@@ ture@@ , a lo@@ ading dose of 50,000 to 12@@ 5,000 I@@ U of vit@@ amin D given or@@ ally or via the in@@ tra@@ mus@@ cular route is recommended prior to the first A@@ cla@@ sta in@@ fu@@ sion@@ .
How to prepare and ad@@ minister A@@ cla@@ sta
- A@@ cla@@ sta 5 mg solution for in@@ fusion is ready for use@@ .
For single use on@@ ly@@ .
Any un@@ used solution should be disc@@ ar@@ de@@ d.
Only clear solution free from partic@@ les and disc@@ ol@@ or@@ ation should be use@@ d.
A@@ cla@@ sta must not be mixed or given in@@ tra@@ ven@@ ously with any other medication and must be given through a separate v@@ ented in@@ fusion line at a constant in@@ fusion rat@@ e@@ .
The in@@ fusion time must not be less than 15 min@@ ut@@ es@@ .
A@@ cla@@ sta must not be allowed to come into contact with any cal@@ ci@@ um@@ -@@ containing sol@@ u@@ tions@@ .
If re@@ fri@@ ger@@ at@@ ed@@ , allow the re@@ fri@@ ger@@ ated solution to reach room temperature before administ@@ ration@@ .
A@@ se@@ p@@ tic techniques must be followed during preparation of the in@@ fu@@ sion@@ .
The in@@ fusion must be conducted according to standard medical prac@@ tic@@ e@@ .
How to store A@@ cla@@ sta
- Keep A@@ cla@@ sta out of the reach and sight of chil@@ dr@@ en@@ .
- Do not use A@@ cla@@ sta after the exp@@ iry date which is stated on the car@@ ton and bot@@ t@@ le@@ .
- The un@@ opened bottle does not require any special storage condi@@ tions@@ .
- After opening the bot@@ t@@ le@@ , the product should be used immediately in order to avoid micro@@ bi@@ al
contam@@ in@@ ation@@ .
If not used immedi@@ at@@ el@@ y@@ , in@@ -@@ use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2@@ °@@ C - 8@@ °@@ C.
Al@@ low the re@@ fri@@ ger@@ ated solution to reach room temperature before administ@@ ration@@ .
32
d European Medic@@ ines Agency
ise E@@ ME@@ A@@ / H@@ / C@@ / 6@@ 66
or EU@@ RO@@ P@@ E@@ AN P@@ U@@ BL@@ IC AS@@ S@@ ES@@ SM@@ EN@@ T RE@@ P@@ OR@@ T (@@ EP@@ AR@@ )
AC@@ O@@ MP@@ L@@ IA
u@@ th EP@@ AR sum@@ mary for the public
ra This document is a sum@@ mary of the European Public As@@ se@@ ssment Report (@@ EP@@ AR@@ )@@ .
It explains how the Committee for Medic@@ inal Produc@@ ts for Human Use (@@ CH@@ MP@@ ) asse@@ ssed the studies per@@ for@@ med@@ , to reach their recommendations on how to use the medic@@ ine@@ .
If you need more information about your medical condition or your treat@@ ment@@ , read the Pack@@ age
What is AC@@ O@@ MP@@ LI@@ A@@ ?
AC@@ O@@ MP@@ L@@ IA is a medicine containing the active substance ri@@ mon@@ ab@@ ant@@ .
It is available as wh@@ it@@ e@@ , te@@ ard@@ rop@@ - shaped tab@@ le@@ ts@@ . no
What is AC@@ O@@ MP@@ L@@ IA used for@@ ?
AC@@ O@@ MP@@ L@@ IA is used together with diet and exercise to treat adult pati@@ ent@@ s@@ : • who are obe@@ se (@@ very over@@ wei@@ ght@@ ) with a body mass index (@@ BM@@ I@@ ) greater than or equal to 30 k@@ g@@ / m@@ ²@@ , • who are over@@ weight (@@ with a BM@@ I greater than or equal to 27 k@@ g@@ / m@@ ²@@ ) and also have other risk fac@@ tor@@ s@@ , ct
such as type 2 diabetes or dy@@ sli@@ pi@@ da@@ emi@@ a (@@ ab@@ normal levels of fat in their bloo@@ d@@ )@@ .
The medicine can only be obtained with a prescri@@ p@@ tion@@ . du
How is AC@@ O@@ MP@@ L@@ IA use@@ d@@ ?
AC@@ O@@ MP@@ L@@ IA is taken as one tab@@ let once a day@@ , before break@@ fa@@ st@@ .
The medicine should not be used in patients who ro
have severe problems with their liver or their ki@@ d@@ ne@@ y@@ s. l@@ p
How does AC@@ O@@ MP@@ L@@ IA work@@ ?
The active substance in AC@@ O@@ MP@@ LI@@ A@@ , ri@@ mon@@ ab@@ ant@@ , is a cann@@ abin@@ oid rec@@ ep@@ tor ant@@ agon@@ ist@@ .
It acts by blocking a specific type of rec@@ ep@@ tor@@ , the cann@@ abin@@ oid type 1 (@@ C@@ B@@ 1@@ ) rec@@ ep@@ tor@@ s.
The rec@@ ep@@ tors are ina
also found in adi@@ po@@ cy@@ tes (@@ fat tis@@ su@@ e@@ )@@ .
How has AC@@ O@@ MP@@ L@@ IA been studi@@ ed@@ ?
The effects of AC@@ O@@ MP@@ L@@ IA were first tested in experim@@ ental models before being studied in hum@@ ans@@ . dic
Four studies of AC@@ O@@ MP@@ L@@ IA in over@@ weight and obe@@ se patients were carried out@@ , involving almost 7,000 pati@@ ent@@ s@@ , whose weight at the start of the studies was on average 94 to 104 k@@ g.
7 West@@ fer@@ ry Cir@@ cus@@ , Can@@ ary W@@ har@@ f@@ , London E@@ 14 4@@ HB@@ , UK Tel@@ .
(@@ 44@@ -@@ 20@@ ) 74 18 84 00 Fax (@@ 44@@ -@@ 20@@ ) 74 18 84 16 E@@ -@@ mail@@ : mail@@ @@@ eme@@ a. europa@@ . e@@ u htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . e@@ u ©@@ E@@ ME@@ A 2007 Re@@ production and@@ / or distribution of this document is author@@ ised for non commercial purposes only provided the E@@ ME@@ A is acknowledged studies compared the effect of AC@@ O@@ MP@@ L@@ IA with that of a pla@@ c@@ eb@@ o (@@ a dum@@ my treat@@ ment@@ ) on weight loss
d over one to two ye@@ ar@@ s.
One study also looked at how this loss could be maintained during the second ye@@ ar@@ .
ise Four studies of AC@@ O@@ MP@@ L@@ IA as a help to stop smoking were also carried out in over 7,000 pati@@ ent@@ s@@ , compar@@ ing it with pla@@ c@@ ebo@@ , and meas@@ uring the effect of the medicine given for 10 weeks (@@ one year in one of the stu@@ dies@@ ) on smoking c@@ ess@@ ation@@ , and on re@@ lap@@ ses in the following ye@@ ar@@ .
or What benefit has AC@@ O@@ MP@@ L@@ IA shown during the stu@@ dies@@ ?
After one ye@@ ar@@ , all patients who received AC@@ O@@ MP@@ L@@ IA lost more weight than those who received pla@@ c@@ ebo@@ : they lost on average 4.@@ 9 kg more than pla@@ c@@ ebo@@ , except in the study in di@@ abe@@ tic pati@@ ent@@ s@@ , where the
u@@ th difference in the weight loss was 3.@@ 9 k@@ g.
The medicine also reduced the risk of re@@ gaining wei@@ ght@@ .
The studies in smoking c@@ ess@@ ation did not show consistent resul@@ ts@@ , and the effect of AC@@ O@@ MP@@ L@@ IA in this area was difficult to estim@@ ate@@ .
The company decided to withdraw its application for smoking c@@ ess@@ ation@@ .
Ther@@ e@@ fore@@ , AC@@ O@@ MP@@ L@@ IA is not recommended as an aid for smoking c@@ ess@@ ation
During the stu@@ dies@@ , the most common side effects with AC@@ O@@ MP@@ L@@ IA (@@ seen in more than 1 patient in 10@@ ) were nau@@ sea (@@ feeling sick@@ ) and inf@@ ections of the upper resp@@ ir@@ atory tra@@ ct@@ .
For the full list of all side effects
ge reported with AC@@ O@@ MP@@ LI@@ A@@ , see the Pack@@ age Le@@ af@@ let@@ .
AC@@ O@@ MP@@ L@@ IA should not be used in patients who may be hyper@@ sensitive (@@ aller@@ gi@@ c@@ ) to ri@@ mon@@ ab@@ ant or any of the other ingredi@@ ent@@ s@@ , or in women who are breast fe@@ ed@@ ing@@ .
It must also not be used in patients with ongoing major depression or who are being treated with anti@@ depres@@ san@@ ts@@ , since it can increase the risk of lon depres@@ sion@@ , including thoughts about suicide in a small minority of pati@@ ent@@ s.
Pati@@ ents who experience symptoms of depression should speak to their doctor and may need to stop treat@@ ment@@ .
Cau@@ tion should be used when taking AC@@ O@@ MP@@ L@@ IA with some medi@@ cin@@ es@@ , such as ket@@ o@@ con@@ az@@ ole or it@@ ra@@ con@@ az@@ ole (@@ anti@@ -@@ f@@ ung@@ al medi@@ cin@@ es@@ )@@ , rit@@ on@@ avi@@ r (@@ used in HIV inf@@ ec@@ tion@@ )@@ , or tel@@ i@@ thro@@ my@@ c@@ in or clari@@ thro@@ my@@ c@@ in (@@ anti@@ bio@@ tic@@ s@@ )@@ . no
Why has AC@@ O@@ MP@@ L@@ IA been appro@@ v@@ ed@@ ?
The Committee for Medic@@ inal products for Human Use (@@ CH@@ MP@@ ) concluded that AC@@ O@@ MP@@ L@@ IA had shown its effec@@ tiveness in weight reduction in obe@@ se or over@@ weight patients with associated risk fac@@ tor@@ s.
The Committee decided that AC@@ O@@ MP@@ LI@@ A@@ ’ s benefits are greater than its risks when use@@ d@@ , in addition to diet and ct
exer@@ ci@@ se@@ , to treat obe@@ se patients and over@@ weight patients with risk factors such as type 2 diabetes or dy@@ sli@@ pi@@ da@@ emi@@ a.
The Committee recommended that AC@@ O@@ MP@@ L@@ IA be given marketing author@@ is@@ ation@@ . du
The company that makes AC@@ O@@ MP@@ L@@ IA will put in place a programme to ensure that the medicine is used in patients who need it for health@@ , rather than for cos@@ me@@ tic reas@@ ons@@ , by providing educational p@@ acks for ro
patients and do@@ ct@@ or@@ s@@ , and to monitor how the medicine is use@@ d.
The company will use specific datab@@ ases to monitor AC@@ O@@ MP@@ LI@@ A@@ ’ s side effec@@ ts@@ , especially those linked to the nervous system@@ . l@@ p
Other information about AC@@ O@@ MP@@ LI@@ A@@ :
The European Commission granted a marketing author@@ isation val@@ id throughout the European Union for AC@@ O@@ MP@@ L@@ IA to san@@ o@@ fi@@ -@@ av@@ enti@@ s on 19 June 200@@ 6. ina
The full EP@@ AR for AC@@ O@@ MP@@ L@@ IA can be found her@@ e@@ .
This sum@@ mary was last updated in 10@@ -@@ 200@@ 7. dic Me
©@@ E@@ ME@@ A 2007
2@@ / 2
or administration EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 1 EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 2
AC@@ O@@ MP@@ L@@ IA AC@@ O@@ MP@@ L@@ IA
20 mg 20 mg
Film@@ -@@ co@@ ated tab@@ let Film@@ -@@ co@@ ated tab@@ let
O@@ ral use O@@ ral use
Bli@@ ster (@@ P@@ V@@ C@@ / al@@ umini@@ um@@ ) Bli@@ ster (@@ P@@ V@@ C@@ / al@@ umini@@ um@@ )
14 tab@@ lets 28 tab@@ lets
th EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 3 EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 4
AC@@ O@@ MP@@ L@@ IA AC@@ O@@ MP@@ L@@ IA
20 mg 20 mg
Film@@ -@@ co@@ ated tab@@ let Film@@ -@@ co@@ ated tab@@ let
O@@ ral use O@@ ral use
Bli@@ ster (@@ P@@ V@@ C@@ / al@@ umini@@ um@@ ) Bli@@ ster (@@ P@@ V@@ C@@ / al@@ umini@@ um@@ )
56 tab@@ lets 70@@ x@@ 1 tab@@ lets
u EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 5
AC@@ O@@ MP@@ L@@ IA
20 mg
Film@@ -@@ co@@ ated tab@@ let
O@@ ral use
Bli@@ ster (@@ P@@ V@@ C@@ / al@@ umini@@ um@@ )
84 tab@@ lets
a EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 6 EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 7
AC@@ O@@ MP@@ L@@ IA AC@@ O@@ MP@@ L@@ IA
20 mg 20 mg
Film@@ -@@ co@@ ated tab@@ let Film@@ -@@ co@@ ated tab@@ let
O@@ ral use O@@ ral use
Bli@@ ster (@@ P@@ V@@ C@@ / al@@ umini@@ um@@ ) B@@ ott@@ le (@@ HD@@ P@@ E@@ )
98 tab@@ lets 28 tab@@ lets
r EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 8
AC@@ O@@ MP@@ L@@ IA
20 mg
Film@@ -@@ co@@ ated tab@@ let
O@@ ral use
B@@ ott@@ le (@@ HD@@ P@@ E@@ )
98 tab@@ lets
e EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 9
AC@@ O@@ MP@@ L@@ IA
20 mg
Film@@ -@@ co@@ ated tab@@ let
O@@ ral use
B@@ ott@@ le (@@ HD@@ P@@ E@@ )
500 tab@@ lets
g EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 0@@ 10 EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 0@@ 11
AC@@ O@@ MP@@ L@@ IA AC@@ O@@ MP@@ L@@ IA
20 mg 20 mg
Film@@ -@@ co@@ ated tab@@ let Film@@ -@@ co@@ ated tab@@ let
O@@ ral use O@@ ral use
Bli@@ ster (@@ P@@ V@@ C@@ / al@@ umini@@ um@@ ) Bli@@ ster (@@ P@@ V@@ C@@ / al@@ umini@@ um@@ )
30 tab@@ lets 90 tab@@ lets
d
u
c
t
n
o
lo
n
pro l i na d ic M e 1@@ / 1
d ise or u@@ th ra ge lon AN@@ NE@@ X I
1 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
d AC@@ O@@ MP@@ L@@ IA 20 mg film@@ -@@ co@@ ated tab@@ lets
ise 2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each tab@@ let contains 20 mg ri@@ mon@@ ab@@ ant@@ .
115 mg la@@ ct@@ os@@ e@@ .
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see section 6.@@ 1.
u@@ th 3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
ra Film@@ -@@ co@@ ated tab@@ let Bi@@ conv@@ ex@@ , te@@ ard@@ rop@@ -@@ shap@@ ed@@ , white tab@@ lets deb@@ os@@ sed with “ 20 ” on one si@@ de.
ge 4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations lon As an ad@@ jun@@ ct to diet and exercise for the treatment of obe@@ se patients (@@ BM@@ I ≥ 30 k@@ g@@ / m@@ 2@@ )@@ , or over@@ weight patients (@@ BM@@ I > 27 k@@ g@@ / m@@ 2@@ ) with associated risk fac@@ tor@@ (@@ s@@ )@@ , such as type 2 diabetes or dy@@ sli@@ pi@@ da@@ emi@@ a (@@ see section 5.@@ 1@@ )@@ . no
4.@@ 2 Pos@@ ology and method of administration
In ad@@ ul@@ ts@@ , the recommended d@@ os@@ age is one 20 mg tab@@ let daily to be taken in the morning before break@@ fa@@ st@@ . ct
The treatment should be introduced with a mi@@ ld@@ ly reduced cal@@ orie di@@ et@@ . du
The safety and eff@@ ic@@ acy of ri@@ mon@@ ab@@ ant have not been evalu@@ ated beyond 2 ye@@ ar@@ s.
• Special Pop@@ ulations ro
El@@ der@@ ly@@ :
AC@@ O@@ MP@@ L@@ IA should be used with l@@ p
caution in patients over 75 years of age (@@ see section 4.@@ 4@@ )@@ .
Pati@@ ents with he@@ pati@@ c in@@ suff@@ ici@@ en@@ cy@@ : ina
No d@@ os@@ age adju@@ st@@ ment is required for patients with mild or moderate he@@ pati@@ c im@@ pa@@ ir@@ ment@@ .
AC@@ O@@ MP@@ L@@ IA should be used with caution in patients with moderate he@@ pati@@ c im@@ pa@@ ir@@ ment@@ .
AC@@ O@@ MP@@ L@@ IA should not be used in patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment (@@ see section 4.@@ 4 and 5.@@ 2@@ )@@ . dic
Pati@@ ents with ren@@ al im@@ pa@@ ir@@ ment@@ :
No d@@ os@@ age adju@@ st@@ ment is required for patients with mild and moderate ren@@ al im@@ pa@@ ir@@ ment (@@ see section 5.@@ 2@@ )@@ .
Me
Pa@@ edi@@ atri@@ c@@ s@@ :
AC@@ O@@ MP@@ L@@ IA is not recommended for use in children below age 18 due to a lack of data on eff@@ ic@@ acy and safet@@ y@@ .
2 4.@@ 3 Con@@ tra@@ indic@@ ations
Hy@@ per@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ents
d L@@ act@@ ation@@ .
On@@ going major depres@@ sive illness and@@ / or ongoing anti@@ depres@@ sive treatment (@@ see section 4.@@ 4@@ )
ise 4.@@ 4 Special warnings and prec@@ au@@ tions for use
• Depres@@ sive disor@@ ders
or Depres@@ sive disor@@ ders or mood alter@@ ations with depres@@ sive symptoms have been reported in up to 10@@ %@@ , and suici@@ dal ide@@ ation in up to 1@@ %@@ , of patients receiving ri@@ mon@@ ab@@ ant (@@ see section 4.@@ 8@@ )@@ .
In patients with current suici@@ dal ide@@ ations and@@ / or with a history of suici@@ dal ide@@ ation and depres@@ sive disorder ri@@ mon@@ ab@@ ant
u@@ th should not be used unless the benefits of treatment are considered to out@@ weigh these risks in an individual pati@@ ent@@ .
(@@ See section 4.@@ 3 and 4.@@ 8@@ )@@ .
O@@ be@@ sity is a condition that can be associated with depres@@ sive disor@@ der@@ s.
Depres@@ sive disor@@ ders can be associated with an increased risk of suici@@ dal thou@@ gh@@ ts@@ , self harm and suici@@ de.
ra The prescri@@ ber should carefully investigate if the patient has had a depres@@ sive disorder in the past in order to evalu@@ ate the potential risks with ri@@ mon@@ ab@@ ant treat@@ ment@@ .
ge Depres@@ sive re@@ actions may occur in patients who have no obvious risk fac@@ tor@@ s@@ , apart from obesity it@@ sel@@ f@@ .
In post@@ marketing experi@@ en@@ ce@@ , more than half of the patients who develop such re@@ actions appear to do so within 1 month of starting treat@@ ment@@ , approximately 80@@ % appear to do so within 3 mon@@ th@@ s. lon Pati@@ ents should be actively monit@@ ored for signs and symptoms of psychiatri@@ c disor@@ der@@ s@@ , particularly depression following the start of treat@@ ment@@ .
The patient should be monit@@ ored and treated appropri@@ at@@ el@@ y@@ .
Pati@@ ent@@ s@@ , especially those with a history of depres@@ sive disor@@ der@@ s@@ / mood alter@@ ations@@ , (@@ and relatives or no
other relevant person@@ s@@ ) should be al@@ er@@ ted about the need to monitor for the emer@@ gence of such symptoms and to seek medical advice immediately if these occ@@ ur@@ .
• Other psychiatri@@ c conditions ct
Therap@@ y with ri@@ mon@@ ab@@ ant is not recommended in patients with un@@ controlled psychiatri@@ c ill@@ ness@@ .
If psychiatri@@ c illness is diagnosed during ri@@ mon@@ ab@@ ant therap@@ y@@ , treatment must be stop@@ pe@@ d. du
• Sei@@ zu@@ res R@@ im@@ on@@ ab@@ ant has not been studied in patients being treated for ep@@ ile@@ p@@ sy@@ .
R@@ im@@ on@@ ab@@ ant@@ , ro
ho@@ we@@ ver@@ , should be used with caution in these pati@@ ent@@ s@@ , see also section 5.@@ 3.
• H@@ ep@@ atic im@@ pa@@ ir@@ ment l@@ p
R@@ im@@ on@@ ab@@ ant is met@@ aboli@@ sed by the li@@ ver@@ , thus caution is advised in patients with moderate he@@ pati@@ c im@@ pa@@ ir@@ ment@@ .
The pharmac@@ ok@@ ine@@ tics and safety of ri@@ mon@@ ab@@ ant have not been studied in patients with severe he@@ pati@@ c im@@ pa@@ ir@@ ment@@ ; its use in these patients is not recommen@@ de@@ d. ina
• Ren@@ al im@@ pa@@ ir@@ ment There are limited data in patients with moderate ren@@ al im@@ pa@@ ir@@ ment and no data in patients with severe ren@@ al im@@ pa@@ ir@@ ment@@ .
R@@ im@@ on@@ ab@@ ant should not be used in patients with severe ren@@ al im@@ pa@@ ir@@ ment (@@ see section dic
4.@@ 2 and 5.@@ 2@@ )@@ .
• El@@ derly The eff@@ ic@@ acy and safety of ri@@ mon@@ ab@@ ant treatment in patients over 75 years of age has not suff@@ ici@@ ently Me
R@@ im@@ on@@ ab@@ ant should be used with caution in this population (@@ see section 5.@@ 2@@ )@@ .
d (@@ see section 5.@@ 2@@ )@@ .
ise • Di@@ abe@@ tic patients
D@@ ue to the effect of ri@@ mon@@ ab@@ ant on the blood glu@@ c@@ ose level@@ , when ri@@ mon@@ ab@@ ant is administ@@ ered in di@@ abe@@ tic pati@@ ent@@ s@@ , hypo@@ g@@ ly@@ ce@@ ami@@ a can occur (@@ see section 4.@@ 8@@ )@@ .
Mon@@ it@@ oring of blood glu@@ c@@ ose level is
or recommended in these pati@@ ent@@ s.
• Dru@@ g Inter@@ action
u@@ th R@@ im@@ on@@ ab@@ ant should be used with caution in combination with pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ ors (@@ e@@ . g. ket@@ o@@ con@@ az@@ ole@@ , it@@ ra@@ con@@ az@@ ole@@ , rit@@ on@@ a@@ vir@@ , tel@@ i@@ thro@@ my@@ cin@@ , clari@@ thro@@ my@@ cin@@ , ne@@ fa@@ zo@@ don@@ e@@ )@@ (@@ see section 4.@@ 5@@ )@@ .
• L@@ act@@ ose
ra Since AC@@ O@@ MP@@ L@@ IA tab@@ lets contain la@@ ct@@ os@@ e@@ , patients with rare her@@ edi@@ tary problems of gal@@ act@@ ose int@@ oler@@ anc@@ e@@ , the L@@ app la@@ ct@@ ase def@@ ici@@ ency or glu@@ cos@@ e@@ -@@ gal@@ act@@ ose mal@@ absor@@ p@@ tion@@ , should not take this medic@@ ine@@ .
ge Pati@@ ents should be instru@@ cted not to increase their dose of AC@@ O@@ MP@@ LI@@ A.
Pati@@ ents who had a cardi@@ ov@@ as@@ cular event (@@ m@@ yo@@ cardi@@ al inf@@ ar@@ c@@ tion@@ , stro@@ ke@@ , et@@ c@@ .@@ ) less than 6 months ago lon were exclu@@ ded in the studies for ri@@ mon@@ ab@@ ant@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
R@@ im@@ on@@ ab@@ ant is met@@ aboli@@ zed by both C@@ Y@@ P@@ 3@@ A and ami@@ do@@ hydro@@ las@@ e (@@ pre@@ domin@@ antly he@@ pati@@ c@@ ) path@@ ways in no
Con@@ co@@ mit@@ ant administration of C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ ors will lead to increased exposure of ri@@ mon@@ ab@@ ant@@ .
Con@@ co@@ mit@@ ant administration of C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers is expected to reduce the exposure of ri@@ mon@@ ab@@ ant@@ . ct
Pot@@ ential for other medic@@ inal products to affect ri@@ mon@@ ab@@ ant@@ :
Con@@ co@@ mit@@ ant administration of ket@@ o@@ con@@ az@@ ole (@@ a pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ or@@ ) increased ri@@ mon@@ ab@@ ant AU@@ C du
by 10@@ 4@@ % (@@ 9@@ 5@@ % predi@@ ction inter@@ val@@ :
40@@ % - 197@@ %@@ )@@ .
A similar increase in exposure is expected with other pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ or@@ s.
Cau@@ tion is advised during con@@ co@@ mit@@ ant use of AC@@ O@@ MP@@ L@@ IA and pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ ors (@@ e@@ . g. ket@@ o@@ con@@ az@@ ole@@ , it@@ ra@@ con@@ az@@ ole@@ , rit@@ on@@ a@@ vir@@ , tel@@ i@@ thro@@ my@@ cin@@ , clari@@ thro@@ my@@ cin@@ , ne@@ fa@@ zo@@ don@@ e@@ )@@ . ro
Although con@@ co@@ mit@@ ant administration of C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers (@@ e@@ . g. ri@@ f@@ amp@@ ic@@ in@@ , phen@@ y@@ to@@ in@@ , phen@@ ob@@ ar@@ bit@@ al@@ , car@@ b@@ amaz@@ ep@@ ine@@ , St John@@ ’ s wor@@ t@@ ) has not been studi@@ ed@@ , it is expected that con@@ co@@ mit@@ ant administration of pot@@ ent C@@ Y@@ P@@ 3@@ A4 in@@ duc@@ ers may reduce the p@@ las@@ ma concentration of ri@@ mon@@ ab@@ ant and may result in loss of l@@ p
eff@@ ic@@ ac@@ y@@ .
Con@@ co@@ mit@@ ant administration of or@@ li@@ stat@@ , eth@@ an@@ ol or lor@@ az@@ ep@@ am had no significant effect on the p@@ las@@ ma ina
levels of ri@@ mon@@ ab@@ ant@@ .
Pot@@ ential for ri@@ mon@@ ab@@ ant to affect other medic@@ inal produc@@ ts@@ :
The in vi@@ vo in@@ hi@@ bit@@ ory effect on C@@ Y@@ P@@ 2@@ C@@ 8 has not been studi@@ ed@@ .
Ho@@ we@@ ver@@ , in vit@@ ro@@ , ri@@ mon@@ ab@@ ant had a dic
mild in@@ hi@@ bit@@ ory effect on C@@ Y@@ P@@ 2@@ C@@ 8.
The potential for in@@ hibition of C@@ Y@@ P@@ 2@@ C@@ 8 in vi@@ vo appears to be low@@ .
R@@ im@@ on@@ ab@@ ant does not in@@ hi@@ bit or indu@@ ce other C@@ Y@@ P enz@@ ym@@ es or P@@ -@@ g@@ ly@@ cop@@ rot@@ ein (@@ P@@ -@@ g@@ p@@ ) in vit@@ ro@@ .
Me
4 4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
Ani@@ mal data are in@@ conclu@@ sive but
d suggest possible del@@ e@@ teri@@ ous effects on em@@ br@@ y@@ onal@@ / fo@@ et@@ al development (@@ see section 5.@@ 3@@ )@@ .
The potential risk for humans is unk@@ no@@ wn@@ .
Use in pregnancy is@@ , ther@@ e@@ fore@@ , not recommen@@ de@@ d.
Pati@@ ents should noti@@ fy
ise their physi@@ cian if they become pregnant during treatment with AC@@ O@@ MP@@ LI@@ A.
R@@ im@@ on@@ ab@@ ant has been dete@@ cted in the milk of la@@ ct@@ ating rats and ri@@ mon@@ ab@@ ant may in@@ hi@@ bit the su@@ ck@@ ling refle@@ x@@ .
It is not known if ri@@ mon@@ ab@@ ant is ex@@ cre@@ ted in human mil@@ k@@ .
AC@@ O@@ MP@@ L@@ IA is contra@@ indicated during
or bre@@ ast@@ -@@ feeding (@@ see section 4.@@ 3@@ )@@ .
4.@@ 7 Eff@@ ects on ability to drive and use machines
u@@ th No studies on the effects on the ability to drive and use machines have been per@@ for@@ med@@ .
Co@@ gni@@ tive investigations in clinical pharmac@@ ology studies demonstrated that ri@@ mon@@ ab@@ ant is de@@ vo@@ id of any significant co@@ gni@@ tive or se@@ d@@ ative effec@@ t.
ra 4.@@ 8 Un@@ desi@@ rable effects
AC@@ O@@ MP@@ L@@ IA 20 mg has been evalu@@ ated for safety in approximately 2500 patients en@@ rolled in studies
ge that examined the met@@ aboli@@ c and weight loss effects in over@@ weight and obe@@ se patients and in approximately 3@@ 800 patients in other indic@@ ations@@ .
In pla@@ c@@ ebo@@ -@@ controlled stu@@ dies@@ , the dis@@ continu@@ ation rate due to ad@@ verse re@@ actions was 15.@@ 7@@ % for patients receiving ri@@ mon@@ ab@@ ant@@ .
The most common ad@@ verse lon re@@ actions resulting in dis@@ continu@@ ation wer@@ e@@ : nau@@ se@@ a@@ , mood alter@@ ation with depres@@ sive symp@@ tom@@ s@@ , depres@@ sive disor@@ der@@ s@@ , anxiety and di@@ zz@@ in@@ ess@@ .
Depres@@ sive disor@@ ders were reported in 3.@@ 2@@ % of obe@@ se pati@@ ent@@ s@@ , or over@@ weight patients with associated risk fac@@ tor@@ (@@ s@@ ) treated with ri@@ mon@@ ab@@ ant 20 m@@ g.
These were usually mild or moderate in sever@@ ity and no
resulted in recovery in all cases either after correc@@ tive treatment or dis@@ continu@@ ation of ri@@ mon@@ ab@@ ant and did not exhi@@ bit any differ@@ enti@@ ating characterist@@ ics compared to cases reported in the control gro@@ up@@ s.
The following table (@@ table 1@@ ) shows all treat@@ ment@@ -@@ emerg@@ ent ad@@ verse re@@ actions from pla@@ c@@ ebo@@ -@@ controlled ct
studies in patients treated for weight loss and related met@@ aboli@@ c disor@@ ders when these inci@@ den@@ ces were stati@@ st@@ ically significantly greater than the correspon@@ ding pla@@ c@@ eb@@ o rate (@@ for events ≥ 1@@ %@@ ) or considered clin@@ ically relevant (@@ for events < 1@@ %@@ )@@ . du
Very common (@@ ≥ 10@@ %@@ )@@ ; Comm@@ on (@@ ≥ 1@@ , < 10@@ %@@ )@@ ; Un@@ common (@@ ≥ 0.@@ 1@@ , < 1@@ %@@ )@@ ; R@@ are (@@ ≥ 0.0@@ 1@@ , < 0.@@ 1@@ %@@ )@@ ; Very ro
rare (@@ < 0.0@@ 1@@ %@@ )@@ , Not known (@@ cannot be estimated from the available dat@@ a@@ )@@ . l@@ p ina dic Me
5 Within each frequ@@ ency gro@@ up@@ ing@@ , un@@ desi@@ rable effects are presented in order of decre@@ asing seri@@ ous@@ ness@@ .
Table 1@@ :
d
System Or@@ gan Class
Very common
Comm@@ on
Un@@ common
ise
Inf@@ ections in@@ fest@@ ations Met@@ aboli@@ sm and
and U@@ pper resp@@ ir@@ atory Gast@@ ro@@ enter@@ i@@ tis tra@@ ct infection
Hy@@ po@@ g@@ ly@@ ca@@ emi@@ a@@ *
or nutri@@ tion disor@@ ders
P@@ sychiatri@@ c disor@@ ders
Depres@@ sive disor@@ ders
P@@ anic symptoms An@@ ger
Hall@@ u@@ cin@@ ations
u@@ th M@@ ood alter@@ ations Dy@@ sph@@ oria
with depres@@ sive symptoms An@@ x@@ iety
Emo@@ tional disorder Su@@ ici@@ dal ide@@ ation
Ir@@ rit@@ ability Ner@@ v@@ ousness S@@ leep disor@@ ders Ins@@ om@@ nia
Aggres@@ si@@ veness Aggres@@ sive behaviour
ge Par@@ as@@ om@@ ni@@ as
Ner@@ v@@ ous system disor@@ ders
Mem@@ ory loss Di@@ zz@@ iness lon Hy@@ po@@ aes@@ the@@ sia Sci@@ ati@@ ca Par@@ es@@ the@@ sia
Le@@ th@@ ar@@ gy Tre@@ m@@ or
V@@ as@@ cular disor@@ ders Res@@ pir@@ ator@@ y@@ ,
no
Hot fl@@ ush
thor@@ ac@@ ic and medi@@ ast@@ inal disor@@ ders
Nau@@ sea ct
Di@@ arr@@ ho@@ ea
disor@@ ders
Pru@@ rit@@ us
Night swe@@ ats
sub@@ cut@@ an@@ e@@ ous tissue disor@@ ders
Hy@@ per@@ hi@@ dro@@ sis
Mus@@ cul@@ os@@ kel@@ et@@ al and ro
T@@ end@@ oni@@ tis Mus@@ cle cra@@ mp
connec@@ tive tissue disor@@ ders l@@ p
Mus@@ cle sp@@ as@@ ms
General disor@@ ders
As@@ th@@ eni@@ a@@ / f@@ ati@@ gue In@@ flu@@ enz@@ a
In@@ j@@ ur@@ y@@ , Po@@ is@@ oning and proce@@ dur@@ al ina
complic@@ ations
*@@ frequ@@ ency is based only on reports in obe@@ se or over@@ weight di@@ abe@@ tic pati@@ ent@@ s.
In clinical studies for other indic@@ ations@@ , the following additional ad@@ verse re@@ actions were commonly dic
repor@@ te@@ d@@ : − inf@@ ections and in@@ fest@@ ations@@ : sin@@ usi@@ tis − met@@ aboli@@ sm and nutri@@ tion disor@@ der@@ s@@ : an@@ or@@ ex@@ i@@ a@@ , decre@@ ased appeti@@ te@@ , Me
− ga@@ stro@@ inte@@ st@@ inal disor@@ der@@ s@@ : stomach dis@@ comfort@@ , dry mou@@ th@@ .
6 Post@@ -@@ Marketing In addition the following ad@@ verse re@@ actions were reported during post@@ marketing (@@ frequ@@ ency not kno@@ wn@@ )@@ :
d − P@@ sychiatri@@ c disor@@ der@@ : p@@ sycho@@ tic disor@@ ders including hall@@ u@@ cin@@ ations@@ , del@@ u@@ sion and par@@ ano@@ i@@ a. − Sk@@ in and sub@@ cut@@ an@@ e@@ ous tissue disor@@ der@@ s@@ : ra@@ sh@@ .
ise − Ner@@ v@@ ous disor@@ der@@ s@@ : con@@ vul@@ sions@@ , distur@@ b@@ ance in atten@@ tion@@ , hea@@ da@@ che@@ . − ga@@ stro@@ inte@@ st@@ inal disor@@ der@@ s@@ : ab@@ dom@@ inal pain@@ .
Lab@@ oratory ad@@ verse events
or AC@@ O@@ MP@@ L@@ IA has not been shown to alter lab@@ oratory test valu@@ es@@ .
4.@@ 9 Over@@ dose
u@@ th Ex@@ peri@@ ence with ri@@ mon@@ ab@@ ant in over@@ d@@ os@@ age is limi@@ te@@ d.
In a sing@@ le@@ -@@ dose toler@@ ability stu@@ dy@@ , d@@ oses up to 300 mg were administ@@ ered to a limited number of subjects with only minor symptoms repor@@ te@@ d.
The pharmac@@ ok@@ ine@@ tic profile demonstr@@ ates that a
ra plat@@ e@@ au in exp@@ os@@ ures is reached at 180 m@@ g.
There is no specific anti@@ d@@ ote for ri@@ mon@@ ab@@ ant@@ ; ther@@ e@@ fore@@ , appropriate supportive measures should be initi@@ ated in case of over@@ d@@ os@@ e@@ .
Tre@@ at@@ ment should consi@@ st of the general measures employed in the management of over@@ d@@ os@@ es@@ , such as keeping air@@ ways
ge un@@ ob@@ struc@@ te@@ d@@ , monitoring cardi@@ ov@@ as@@ cular function and general symp@@ tom@@ atic and supportive meas@@ u@@ res@@ .
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S lon 5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ -@@ therapeu@@ tic gro@@ up@@ :
Anti obesity agent AT@@ C co@@ de@@ :
A@@ 08@@ A@@ X@@ 01 no
The en@@ do@@ cann@@ abin@@ oid system is a physi@@ ological system present in brain and peri@@ pher@@ al tis@@ su@@ es ct
(@@ including adi@@ po@@ cy@@ tes@@ ) that affects energy bal@@ anc@@ e@@ , glu@@ c@@ ose and lip@@ id met@@ aboli@@ sm and body wei@@ ght@@ , and in neur@@ ons of the mes@@ oli@@ m@@ bic system mod@@ ul@@ ates the in@@ take of highly pal@@ at@@ ab@@ le@@ , sweet or fat@@ ty foo@@ ds@@ . du
Clin@@ ical study results
Wei@@ ght Management ro
In total more than 6@@ 800 patients were included in the Phase 2 and Phase 3 clinical stu@@ dies@@ .
The patients included in the phase 3 trials followed a restri@@ ctive diet during the trial prescri@@ bed by a die@@ ti@@ cian and l@@ p
they were advised to increase their physical activ@@ it@@ y@@ .
Pati@@ ents had a BM@@ I ≥@@  30 k@@ g@@ / m@@ ² or BM@@ I > 27 k@@ g@@ / m@@ ² with hyper@@ tension and@@ / or dy@@ sli@@ p@@ ide@@ mia at inclu@@ sion@@ .
Ap@@ pro@@ xim@@ ately 80@@ % of the population were wom@@ en@@ , 8@@ 7@@ % Cau@@ c@@ asi@@ an and 9@@ % Black@@ .
Ex@@ peri@@ ence in patients over 75 years and ina
Ori@@ ent@@ al@@ s@@ / Asi@@ ans was limi@@ te@@ d.
A mean weight loss of 6.5 kg dic
from bas@@ eline to one year was shown for AC@@ O@@ MP@@ L@@ IA 20 mg versus a mean weight loss of 1.6 kg for pla@@ c@@ eb@@ o (@@ Differ@@ ence -@@ 4.@@ 9 kg C@@ I@@ 9@@ 5@@ % -@@ 5.@@ 3@@ ; -@@ 4.@@ 4@@ , p < 0.0@@ 0@@ 1@@ )@@ .
Me
7 Table 2@@ :
Non@@ -@@ di@@ abe@@ tic studies
Di@@ abe@@ tic study
Pla@@ c@@ eb@@ o AC@@ O@@ MP@@ L@@ IA
Pla@@ c@@ eb@@ o
20 mg
20 mg
n@@ IT@@ T
12@@ 54
2@@ 16@@ 4
3@@ 48
3@@ 39
Wei@@ ght at bas@@ eline (@@ k@@ g@@ )
101
101
96
95
Sub@@ jects with a 5@@ %
19.@@ 7@@ %
50@@ .@@ 8@@ %
14.@@ 5@@ %
4@@ 9.@@ 4@@ %
Differ@@ ence (@@ C@@ I 9@@ 5@@ %@@ )
31.@@ 1@@ % (@@ 28@@ %@@ ; 34@@ %@@ )
3@@ 4.@@ 9@@ % (@@ 28@@ %@@ ; 4@@ 1@@ %@@ )
Sub@@ jects with a 10@@ % 7.@@ 8@@ % weight reduction
27@@ .0@@ %
2@@ .0@@ %
16.@@ 2@@ %
Differ@@ ence (@@ C@@ I 9@@ 5@@ %@@ ) 19.@@ 2@@ % (@@ 17@@ %@@ ; 22@@ %@@ )
14.@@ 2@@ % (@@ 10@@ %@@ ; 19@@ %@@ )
ra Most of the observed weight reduction was obtained within the first nine months of treat@@ ment@@ .
AC@@ O@@ MP@@ L@@ IA 20 mg was effective in maintaining weight loss up to two ye@@ ar@@ s.
Wei@@ ght loss at two years
ge was 5.@@ 1 kg for patients who received AC@@ O@@ MP@@ L@@ IA 20 mg and 1.2 kg for pla@@ c@@ eb@@ o (@@ Differ@@ ence -@@ 3.@@ 8 k@@ g@@ ; C@@ I@@ 9@@ 5@@ % -@@ 4.@@ 4@@ , -@@ 3.@@ 3@@ ; p < 0.0@@ 0@@ 1@@ )@@ .
R@@ im@@ on@@ ab@@ ant 20 mg reduced the risk of weight re@@ ga@@ in@@ .
Pati@@ ents who received AC@@ O@@ MP@@ L@@ IA 20 mg for one year were re@@ -@@ rand@@ omi@@ zed to AC@@ O@@ MP@@ L@@ IA 20 mg or pla@@ c@@ ebo@@ .
At two ye@@ ar@@ s@@ , patients continuing on ri@@ mon@@ ab@@ ant had a mean total weight loss of 7.5 kg over 2 years whereas patients re@@ -@@ rand@@ omi@@ zed to pla@@ c@@ eb@@ o group during the second year had a mean total weight loss of 3.@@ 1 kg over 2 ye@@ ar@@ s.
At two ye@@ ar@@ s@@ , the difference in total weight loss between AC@@ O@@ MP@@ L@@ IA and pla@@ c@@ eb@@ o was -@@ 4.@@ 2 kg (@@ C@@ I@@ 9@@ 5@@ % -@@ 5@@ .0@@ ; - no
Tre@@ at@@ ment with ri@@ mon@@ ab@@ ant was associated with significant re@@ ductions in waist circum@@ fer@@ en@@ ce@@ , a known mar@@ ker of in@@ tra@@ -@@ ab@@ dom@@ inal fat@@ . ct
The effects on body weight appeared to be consistent among men and wom@@ en@@ .
In the limited number of Black patients weight loss was less pron@@ ounced (@@ mean difference to pla@@ c@@ eb@@ o -@@ 2.@@ 9 k@@ g@@ )@@ .
No du
conclu@@ sions can be drawn with regard to effects in patients over 75 years or in Asi@@ an@@ / Ori@@ ental patients due to the low number of pati@@ ent@@ s. ro
For l@@ p
H@@ DL@@ -@@ C an average increase of 16.@@ 4@@ % was seen under ri@@ mon@@ ab@@ ant 20 mg (@@ bas@@ eline H@@ DL@@ -@@ C 1.@@ 24 mm@@ ol@@ / l@@ ) compared to an increase of 8.@@ 9@@ % for pla@@ c@@ eb@@ o (@@ bas@@ eline H@@ DL@@ -@@ C 1.@@ 21 mm@@ ol@@ / l@@ )@@ .
For the ina
trig@@ ly@@ c@@ eri@@ des an average decre@@ ase of 6.@@ 9@@ % was seen under ri@@ mon@@ ab@@ ant 20 mg (@@ bas@@ eline TG 1.@@ 62 mm@@ ol@@ / l@@ ) compared to an increase of 5.@@ 8@@ % for pla@@ c@@ eb@@ o (@@ bas@@ eline TG 1.@@ 65 mm@@ ol@@ / l@@ )@@ .
The difference was stati@@ st@@ ically significant (@@ Differ@@ ence -@@ 13.@@ 3@@ % C@@ I@@ 9@@ 5@@ % -@@ 16.@@ 5@@ ; -@@ 10.@@ 2@@ % p < 0.0@@ 0@@ 1@@ )@@ .
It is estimated that approximately half of the observed improvement in H@@ DL@@ -@@ C and trig@@ ly@@ c@@ eri@@ des in patients who received dic
ri@@ mon@@ ab@@ ant 20 mg was beyond that expected from weight loss al@@ one@@ .
Gener@@ ally AC@@ O@@ MP@@ L@@ IA 20 mg had no significant effect on Tot@@ al@@ -@@ C or L@@ DL@@ -@@ C level@@ s.
In the trial in type 2 di@@ abe@@ tic patients (@@ R@@ IO@@ -@@ Di@@ abet@@ es@@ ) who were over@@ weight or obe@@ se treated with Me
The absolute change in H@@ b@@ A@@ 1@@ c at one year was -@@ 0.@@ 6 for ri@@ mon@@ ab@@ ant 20 mg (@@ bas@@ eline 7.@@ 3@@ %@@ ) and +@@ 0.@@ 1 on pla@@ c@@ eb@@ o (@@ bas@@ eline 7.@@ 2@@ %@@ )@@ .
Differ@@ ences were stati@@ st@@ ically significant (@@ Differ@@ ence -@@ 0.@@ 7@@ %@@ , C@@ I@@ 9@@ 5@@ % -@@ 0.@@ 80@@ ; -@@ 0.@@ 5@@ , p < 0.0@@ 0@@ 1@@ )@@ .
8 At one year a mean weight loss of 5.@@ 3 kg was shown for AC@@ O@@ MP@@ L@@ IA 20 mg versus a loss on pla@@ c@@ eb@@ o of 1.4 kg (@@ Differ@@ ence – 3.@@ 9 kg C@@ I@@ 9@@ 5@@ % -@@ 4.@@ 6@@ ; -@@ 3.@@ 3 p < 0.0@@ 0@@ 1@@ )@@ .
The percentage of patients who lost 5@@ % and 10@@ % of their bas@@ eline body weight after 1 year of treatment are given in the table 2.
d In a second trial in treatment na@@ ï@@ ve type 2 di@@ abe@@ tic obe@@ se patients (@@ Ser@@ en@@ ade@@ )@@ , the absolute change in H@@ b@@ A@@ 1@@ c (@@ with a bas@@ eline of 7.@@ 9@@ % for both gro@@ up@@ s@@ ) at six months was -@@ 0.@@ 8 for ri@@ mon@@ ab@@ ant 20 mg and
ise -@@ 0.@@ 3 under pla@@ c@@ eb@@ o (@@ Differ@@ ence -@@ 0.@@ 51 C@@ I@@ 9@@ 5@@ % -@@ 0.@@ 78@@ , -@@ 0.@@ 24 p < 0.0@@ 0@@ 1@@ )@@ .
The percentage of patients reaching H@@ b@@ A@@ 1@@ c < 7@@ % was 5@@ 1@@ % in the ri@@ mon@@ ab@@ ant group and 35@@ % in the pla@@ c@@ eb@@ o gro@@ up@@ .
The difference in mean body weight change between the 20 mg and pla@@ c@@ eb@@ o groups was 3.@@ 8 kg (@@ C@@ I@@ 9@@ 5@@ % -@@ 5@@ .0@@ , -@@ 2.@@ 6 p < 0.0@@ 0@@ 1@@ )@@ .
Ch@@ ang@@ es in H@@ DL@@ -@@ C and TG in this population were similar to that of the non@@ -@@ di@@ abe@@ tic pop@@ ula@@ tion@@ .
It is
or estimated that approximately half of the mean improvement in H@@ b@@ A@@ 1@@ c in patients receiving ri@@ mon@@ ab@@ ant 20 mg was beyond that expected from weight loss al@@ one@@ .
u@@ th 5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
R@@ im@@ on@@ ab@@ ant pharmac@@ ok@@ ine@@ tics are fairly dose propor@@ tional up to about 20 m@@ g.
AU@@ C increased less than in proportion to dose above 20 m@@ g.
ra Ab@@ sor@@ p@@ tion@@ :
R@@ im@@ on@@ ab@@ ant displays high in vit@@ ro per@@ me@@ ability and is not a sub@@ str@@ ate of P@@ -@@ g@@ ly@@ cop@@ rot@@ ein@@ .
The absolute bio@@ availability of ri@@ mon@@ ab@@ ant has not been determin@@ ed@@ .
Following multiple on@@ ce@@ -@@ daily d@@ oses of 20 mg
ge to healthy subjects in the fa@@ sted stat@@ e@@ , maximum p@@ las@@ ma conc@@ ent@@ rations of ri@@ mon@@ ab@@ ant are achieved in approximately 2 hours with steady state p@@ las@@ ma levels achieved within 13 days (@@ C@@ max = 19@@ 6 ± 28.@@ 1 n@@ g@@ / m@@ l@@ ; C@@ tro@@ u@@ gh = 9@@ 1.6 ± 14.@@ 1 n@@ g@@ / m@@ l@@ ; AU@@ C@@ 0@@ -@@ 24 = 29@@ 60 ± 26@@ 8 n@@ g. h@@ / m@@ l@@ )@@ .
Ste@@ ady state ri@@ mon@@ ab@@ ant lon exp@@ os@@ ures are 3.@@ 3@@ -@@ fold higher than those observed after the first d@@ os@@ e@@ .
Pop@@ ulation pharmac@@ ok@@ ine@@ tic analysis demonstrated less flu@@ ctu@@ ation in peak to tro@@ u@@ gh p@@ las@@ ma concentration but no differences in steady state AU@@ C as weight increas@@ es@@ .
As weight increases from 65 to 200 k@@ g@@ , C@@ max is expected to decre@@ ase 24@@ % and C@@ tro@@ u@@ gh is expected to increase by 5@@ %@@ .
Pop@@ ulation no
pharmac@@ ok@@ ine@@ tic analysis indicated that ri@@ mon@@ ab@@ ant pharmac@@ ok@@ ine@@ tics are similar between healthy non@@ -@@ smoking subjects and patients who smo@@ ke@@ .
Administration of ri@@ mon@@ ab@@ ant to healthy subjects in the fa@@ sted state or with a high fat meal demonstrated that C@@ max and AU@@ C were increased 67@@ % and 48@@ % respec@@ ti@@ vel@@ y@@ , under fed condi@@ tions@@ .
In clinical stu@@ dies@@ , AC@@ O@@ MP@@ L@@ IA 20 mg was taken in the morning usually before break@@ fa@@ st@@ . du
Distri@@ bu@@ tion@@ :
The in vit@@ ro human p@@ las@@ ma protein bin@@ ding of ri@@ mon@@ ab@@ ant is high (@@ > 9@@ 9.@@ 9@@ %@@ ) and non@@ -@@ sat@@ ur@@ able over a ro
wide concentration ran@@ ge@@ .
The apparent peri@@ pher@@ al volume of distribution of ri@@ mon@@ ab@@ ant appears to be related to body wei@@ ght@@ , with obe@@ se patients having a higher volume of distribution than normal@@ -@@ weight sub@@ jec@@ ts@@ . l@@ p
Bi@@ ot@@ ran@@ s@@ form@@ ation@@ :
R@@ im@@ on@@ ab@@ ant is met@@ aboli@@ zed by both C@@ Y@@ P@@ 3@@ A and ami@@ do@@ hydro@@ las@@ e (@@ pre@@ domin@@ antly he@@ pati@@ c@@ ) path@@ ways in ina
Cir@@ cul@@ ating met@@ aboli@@ tes do not contribute to its pharmac@@ ologi@@ c activ@@ it@@ y@@ .
Eli@@ min@@ ation@@ :
Only dic
an approxim@@ ate 3@@ % of the dose of ri@@ mon@@ ab@@ ant is elim@@ inated in the ur@@ ine@@ , while approximately 8@@ 6@@ % of the dose is ex@@ cre@@ ted in the fa@@ ec@@ es as un@@ changed drug and met@@ aboli@@ tes@@ .
Me
9 Special Pop@@ ulations Rac@@ e@@ :
In sing@@ le@@ - and repe@@ at@@ -@@ dose stu@@ dies@@ , the C@@ max and AU@@ C of ri@@ mon@@ ab@@ ant were similar in healthy Japanese
d and Cau@@ c@@ asi@@ an sub@@ jec@@ ts@@ , whereas elim@@ ination half@@ -@@ life was shor@@ ter in Japanese subjects (@@ 3@@ -@@ 4 da@@ ys@@ ) compared to Cau@@ c@@ asi@@ an subjects (@@ about 9 da@@ ys@@ )@@ .
The difference in half@@ -@@ life was due to differences in
ise peri@@ pher@@ al volume of distribution as a consequ@@ ence of lower weight in Japanese sub@@ jec@@ ts@@ .
Black patients may have up to a 3@@ 1@@ % lower C@@ max and a 43@@ % lower AU@@ C than patients of other rac@@ es@@ .
Gen@@ der@@ :
or The pharmac@@ ok@@ ine@@ tics of ri@@ mon@@ ab@@ ant are similar in female and male pati@@ ent@@ s.
El@@ der@@ ly@@ :
u@@ th El@@ derly patients have slightly higher exposure than young pati@@ ent@@ s.
Based on a population pharmac@@ ok@@ ine@@ tic analysis (@@ age range 18 - 81 ye@@ ar@@ s@@ ) a 75 year old patient is estimated to have a 21@@ % higher C@@ max and a 27@@ % higher AU@@ C than a 40 year old pati@@ ent@@ .
ra Pati@@ ents with he@@ pati@@ c in@@ suff@@ ici@@ en@@ cy@@ :
Mil@@ d he@@ pati@@ c im@@ pa@@ ir@@ ment does not alter ri@@ mon@@ ab@@ ant exp@@ os@@ ure@@ .
Data are in@@ sufficient to draw conclu@@ sions regarding pharmac@@ ok@@ ine@@ tics in moderate he@@ pati@@ c im@@ pa@@ ir@@ ment@@ .
Pati@@ ents with severe he@@ pati@@ c im@@ pa@@ ir@@ ment were not evalu@@ at@@ ed@@ .
ge Pati@@ ents with ren@@ al im@@ pa@@ ir@@ ment@@ :
The effect of ren@@ al function on the pharmac@@ ok@@ ine@@ tics of ri@@ mon@@ ab@@ ant has not been studied specific@@ all@@ y@@ . lon Based on data from population pharmac@@ ok@@ ine@@ tic stu@@ dies@@ , mild ren@@ al im@@ pa@@ ir@@ ment do not seem to affect the pharmac@@ ok@@ ine@@ tics of ri@@ mon@@ ab@@ ant@@ .
Limited data suggest an increased exposure in patients with moderate ren@@ al im@@ pa@@ ir@@ ment (@@ 40@@ % increase in AU@@ C@@ )@@ .
There are no data in severe ren@@ al im@@ pa@@ ir@@ ment@@ .
Ad@@ verse re@@ actions not observed in clinical stu@@ dies@@ , but seen in animals at exposure levels similar to clinical exposure levels and with possible relev@@ ance to clinical use were as follo@@ w@@ s@@ :
Con@@ vul@@ sions were observed spor@@ adi@@ cally in studies in ro@@ dents and mac@@ aqu@@ es@@ .
No con@@ vul@@ sions were ct
observed in dogs during a 3 month stu@@ dy@@ .
In some@@ , but not all cas@@ es@@ , initi@@ ation of con@@ vul@@ sions appeared to be associated with proce@@ dur@@ al stress such as handling of the anim@@ al@@ s.
A pro@@ con@@ vul@@ s@@ ant activity of ri@@ mon@@ ab@@ ant was found in one of two safety pharmac@@ ology stu@@ dies@@ .
No ad@@ verse effect of ri@@ mon@@ ab@@ ant du
treatment was observed on E@@ EG patterns in rats@@ .
In@@ cre@@ ased inci@@ dence and@@ / or sever@@ ity of clinical signs suggesti@@ ve of increased tac@@ tile hyper@@ es@@ the@@ sia were ro
observed in ro@@ dent stu@@ dies@@ .
A direct effect of ri@@ mon@@ ab@@ ant cannot be ruled out@@ .
in the rat@@ .
In standard fertili@@ ty studies in female rats (@@ d@@ osing for 2 weeks prior to mat@@ ing@@ ) there was ab@@ normal ina
o@@ est@@ ro@@ us cycli@@ city and a decre@@ ase in corpor@@ a lu@@ tea and fertili@@ ty index at d@@ oses of ri@@ mon@@ ab@@ ant that in@@ duced mat@@ ern@@ al tox@@ ic@@ ity (@@ 30 and 60 m@@ g@@ / k@@ g@@ / day@@ )@@ .
Following d@@ osing for a longer treatment dur@@ ation prior to mat@@ ing (@@ 9 wee@@ ks@@ ) that per@@ mitted recovery from the initial effects of ri@@ mon@@ ab@@ ant@@ , no ad@@ verse effects were seen on fertili@@ ty or o@@ est@@ ro@@ us cycli@@ cit@@ y@@ .
Re@@ gar@@ ding re@@ productive par@@ ame@@ ters@@ , at 30 m@@ g@@ / kg no dic
differences were observed between treated animals and contro@@ ls@@ , at 60 m@@ g@@ / kg effects were still observed (@@ decre@@ ased number of corpor@@ a lu@@ te@@ a@@ , im@@ plan@@ t@@ ations@@ , total and vi@@ able fet@@ u@@ ses@@ )@@ .
Spor@@ adi@@ c mal@@ form@@ ations (@@ an@@ en@@ cep@@ hal@@ y@@ , micro@@ -@@ oph@@ th@@ al@@ mi@@ a@@ , wi@@ dened brain vent@@ ri@@ cles and om@@ p@@ hal@@ o@@ cel@@ e@@ ) Me
were observed in the rab@@ bit em@@ br@@ yo@@ fet@@ al tox@@ ic@@ ity studies at d@@ oses resulting in exp@@ os@@ ures compar@@ able with the clinical exp@@ os@@ u@@ res@@ .
Although mat@@ ern@@ al tox@@ ic@@ ity was observed at these d@@ os@@ es@@ , a relation to treatment cannot be exclu@@ de@@ d.
No treat@@ ment@@ -@@ related mal@@ form@@ ations were seen in the rat@@ .
10 Eff@@ ects of ri@@ mon@@ ab@@ ant on pre@@ - and post@@ -@@ nat@@ al development were asse@@ ssed in the rat at d@@ oses up to 10 m@@ g@@ / k@@ g@@ / day@@ .
There was a treatment related increase in p@@ up mort@@ ality in the pre@@ -@@ we@@ aning peri@@ od@@ .
The increased p@@ up mort@@ ality might be attri@@ but@@ able to a failure of the dam to nurse or in@@ gesti@@ on of
d ri@@ mon@@ ab@@ ant in milk and@@ / or in@@ hibition of the su@@ ck@@ ling refle@@ x that is reported in the liter@@ ature to be initi@@ ated in ne@@ on@@ at@@ al mi@@ ce by en@@ do@@ cann@@ abin@@ oid sign@@ alling via C@@ B@@ 1 rec@@ ep@@ tor@@ s.
There are reports in the
The potential relev@@ ance of this to administration of a C@@ B@@ 1 ant@@ agon@@ ist is unk@@ no@@ wn@@ .
In the pre@@ - and post@@ -@@ nat@@ al development study in rats@@ , exposure to ri@@ mon@@ ab@@ ant in uter@@ o and via la@@ ct@@ ation produced no alter@@ ations on learning or mem@@ or@@ y@@ , but equi@@ vocal effects on motor
or activity and audi@@ tory star@@ tle response were observed in the p@@ ups as a result of ri@@ mon@@ ab@@ ant exp@@ os@@ ure@@ .
u@@ th 6.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
6.@@ 1 List of ex@@ cip@@ i@@ ents
ra Tablet cor@@ e@@ : ma@@ i@@ ze star@@ ch@@ , la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate@@ , po@@ vi@@ done K 30 (@@ E@@ 1@@ 201@@ )@@ ,
ge cros@@ car@@ m@@ ell@@ ose so@@ dium (@@ E@@ 46@@ 8@@ )@@ , so@@ dium lau@@ ri@@ l@@ sul@@ fate (@@ E@@ 48@@ 7@@ )@@ , micro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ ose (@@ E@@ 46@@ 0@@ )@@ , magne@@ si@@ um ste@@ ar@@ ate lon Tablet co@@ at@@ ing@@ : la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate@@ , hy@@ pro@@ m@@ ell@@ ose 15 m@@ Pa@@ . s (@@ E@@ 46@@ 4@@ )@@ , no
tit@@ ani@@ um di@@ oxide (@@ E@@ 17@@ 1@@ )@@ , mac@@ ro@@ go@@ l 3000
Tablet poli@@ sh@@ ing@@ : ct
car@@ nau@@ ba wa@@ x (@@ E@@ 90@@ 3@@ )
6.@@ 2 In@@ comp@@ ati@@ bilities du
Not applic@@ able ro
6.@@ 3 Shel@@ f@@ -@@ life
3 years l@@ p
6.@@ 4 Special prec@@ au@@ tions for storage ina
This medic@@ inal product does not require any special storage condi@@ tions@@ .
6.5 Nature and cont@@ ents of container dic
P@@ V@@ C@@ -@@ al@@ uminium bli@@ ster p@@ acks containing 14@@ , 28@@ , 30@@ , 56@@ , 8@@ 4@@ , 90 and 98 film@@ -@@ co@@ ated tab@@ le@@ ts@@ .
70 x 1 film@@ -@@ co@@ ated tab@@ lets in P@@ V@@ C@@ -@@ al@@ uminium per@@ for@@ ated unit dose bli@@ ster pack@@ s.
O@@ pa@@ que white HD@@ PE bottles containing 28@@ , 98 and 500 film@@ -@@ co@@ ated tab@@ le@@ ts@@ .
Me
6.@@ 6 Special prec@@ au@@ tions for dispos@@ al
No special requirements
11 7.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ I@@ Z@@ AT@@ ION H@@ OL@@ DER
d san@@ o@@ fi@@ -@@ av@@ enti@@ s.
17@@ 4 Avenue de France
ise F@@ -@@ 7@@ 50@@ 13 Paris France
8.
or EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 1@@ -@@ 0@@ 11
u@@ th 9.
D@@ AT@@ E O@@ F FI@@ R@@ ST AU@@ TH@@ OR@@ IS@@ AT@@ I@@ ON@@ / RE@@ NE@@ W@@ AL O@@ F THE AU@@ TH@@ OR@@ IS@@ AT@@ ION
19 June 2006
ra 10.
D@@ AT@@ E O@@ F RE@@ V@@ IS@@ ION O@@ F THE TE@@ X@@ T
ge Det@@ ailed information on this product is available on the website of the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ . lon no ct du ro l@@ p ina dic Me
12 d ise or u@@ th ra ge lon AN@@ NE@@ X II
M@@ AN@@ U@@ F@@ AC@@ T@@ UR@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ D@@ ER@@ S RE@@ SP@@ ON@@ S@@ IB@@ LE FO@@ R B@@ AT@@ CH RE@@ LE@@ AS@@ E no
B. l@@ p
CON@@ D@@ IT@@ I@@ ON@@ S O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION ct du ro
13 A.
M@@ AN@@ U@@ F@@ AC@@ T@@ UR@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ D@@ ER@@ S RE@@ SP@@ ON@@ S@@ IB@@ LE FO@@ R B@@ AT@@ CH RE@@ LE@@ AS@@ E
d Name and address of the manufacturers responsible for bat@@ ch release
ise San@@ o@@ fi Win@@ thro@@ p Industrie@@ , 30@@ -@@ 36 Avenue Gusta@@ ve Ei@@ ff@@ el@@ , BP 27@@ 16@@ 6@@ , F@@ -@@ 3@@ 70@@ 71 To@@ urs C@@ e@@ dex 2@@ , France
san@@ o@@ fi@@ -@@ av@@ enti@@ s S. p. A.@@ , Stra@@ da Stat@@ ale 17@@ , K@@ m 22@@ , 6@@ 70@@ 19 Sc@@ opp@@ i@@ to (@@ A@@ Q@@ )@@ , Italy
or The printed package le@@ af@@ let of the medic@@ inal product must state the name and address of the manufacturer responsible for the release of the concerned bat@@ ch@@ .
u@@ th B.
CON@@ D@@ IT@@ I@@ ON@@ S O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION
• CON@@ D@@ IT@@ I@@ ON@@ S O@@ R RE@@ ST@@ R@@ IC@@ TI@@ ON@@ S RE@@ G@@ AR@@ D@@ ING SU@@ P@@ PL@@ Y AND US@@ E I@@ MP@@ O@@ SED ON
ra THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
ge • CON@@ D@@ IT@@ I@@ ON@@ S O@@ R RE@@ ST@@ R@@ IC@@ TI@@ ON@@ S W@@ IT@@ H RE@@ G@@ ARD TO THE S@@ AF@@ E AND E@@ FF@@ EC@@ T@@ IV@@ E US@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T lon Not applic@@ ab@@ le@@ .
• O@@ TH@@ ER CON@@ D@@ IT@@ I@@ ON@@ S no
The MA@@ H must ensure that the system of pharmac@@ o@@ vig@@ il@@ ance is in place and func@@ tioning before the product is placed on the market@@ . ct
The MA@@ H com@@ mits to performing the studies and additional pharmac@@ o@@ vig@@ il@@ ance activities detailed in the P@@ harm@@ ac@@ o@@ vig@@ il@@ ance Plan@@ . du
An updated risk management plan should be provided as per the CH@@ MP gui@@ del@@ ine on risk management systems for medic@@ inal products for human use@@ . ro l@@ p ina dic Me
14 d ise or u@@ th ra ge lon AN@@ NE@@ X III
LA@@ B@@ EL@@ LIN@@ G AND P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T no ct du ro l@@ p ina dic Me
15 Me dic ina l@@ p ro du ct
16 no A.
LA@@ B@@ EL@@ LIN@@ G lon ge ra u@@ th or ise d PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING Car@@ ton for the pres@@ ent@@ ations of 14@@ , 28@@ , 30 56@@ , 70@@ , 8@@ 4@@ , 90 and 98 film@@ -@@ co@@ ated tab@@ lets in bli@@ sters
d ise 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
or AC@@ O@@ MP@@ L@@ IA 20 mg film@@ -@@ co@@ ated tab@@ lets ri@@ mon@@ ab@@ ant
u@@ th 2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE@@ (@@ S@@ )
Each tab@@ let contains 20 mg of ri@@ mon@@ ab@@ ant@@ .
ra 3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
ge Also contains la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate@@ .
See le@@ af@@ let for further inform@@ ation@@ . lon 4.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS
14 film@@ -@@ co@@ ated tab@@ lets no
28 film@@ -@@ co@@ ated tab@@ lets 30 film@@ -@@ co@@ ated tab@@ lets 56 film@@ -@@ co@@ ated tab@@ lets 70@@ x@@ 1 film co@@ at@@ ed@@ -@@ tab@@ lets ct
84 film@@ -@@ co@@ ated tab@@ lets 90 film@@ -@@ co@@ ated tab@@ lets du
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION ro
O@@ ral use@@ . l@@ p
Read the package le@@ af@@ let before use ina
6.
SP@@ EC@@ I@@ AL W@@ AR@@ N@@ ING TH@@ AT THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T M@@ US@@ T BE ST@@ OR@@ ED O@@ UT O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ . dic
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y Me
17 8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P {@@ M@@ M@@ / Y@@ Y@@ Y@@ Y@@ }
d ise 9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
or 10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
u@@ th 11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
ra san@@ o@@ fi@@ -@@ av@@ enti@@ s 17@@ 4 av@@ en@@ ue de France F@@ -@@ 7@@ 50@@ 13 Paris
12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ ) lon EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 1 EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 2 EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 3 EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 4 no
EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 5 EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 6 EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 0@@ 10 EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 0@@ 11 ct du
13.
B@@ AT@@ CH N@@ UM@@ BER
Lo@@ t ro
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y l@@ p
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ . ina
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E dic
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
AC@@ O@@ MP@@ L@@ IA Me
18 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON BL@@ IS@@ TER@@ S O@@ R ST@@ RI@@ PS
d Bli@@ sters of the pres@@ ent@@ ations of 14@@ , 28@@ , 56@@ , 84 and 98 film@@ -@@ co@@ ated tab@@ lets
ise 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AC@@ O@@ MP@@ L@@ IA 20 mg film@@ -@@ co@@ ated tab@@ lets
u@@ th 2.
N@@ AM@@ E O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
san@@ o@@ fi@@ -@@ av@@ enti@@ s
ra 3.
EX@@ P@@ IR@@ Y D@@ AT@@ E
ge EX@@ P {@@ M@@ M@@ / Y@@ Y@@ Y@@ Y@@ }
4.
B@@ AT@@ CH N@@ UM@@ BER lon Lo@@ t
5.
O@@ TH@@ ER no
Monday Tuesday Wednesday ct
Thursday Friday du
Saturday Sunday ro l@@ p ina dic Me
19 M@@ IN@@ IM@@ U@@ M PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON BL@@ IS@@ TER@@ S O@@ R ST@@ RI@@ PS
d Bli@@ sters of the pres@@ ent@@ ations of 30@@ , 70 x 1 and 90 film@@ -@@ co@@ ated tab@@ lets
ise 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
AC@@ O@@ MP@@ L@@ IA 20 mg film@@ -@@ co@@ ated tab@@ lets
u@@ th 2.
N@@ AM@@ E O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
san@@ o@@ fi@@ -@@ av@@ enti@@ s
ra 3.
EX@@ P@@ IR@@ Y D@@ AT@@ E
ge EX@@ P {@@ M@@ M@@ / Y@@ Y@@ Y@@ Y@@ }
4.
B@@ AT@@ CH N@@ UM@@ BER lon Lo@@ t
5.
O@@ TH@@ ER no ct du ro l@@ p ina dic Me
20 PAR@@ T@@ IC@@ UL@@ AR@@ S TO AP@@ P@@ E@@ AR ON THE O@@ U@@ T@@ ER P@@ AC@@ K@@ AG@@ ING AND ON THE IM@@ ME@@ DI@@ AT@@ E P@@ AC@@ K@@ AG@@ ING
d Car@@ ton of the pres@@ ent@@ ations of 28@@ , 98 and 500 film@@ -@@ co@@ ated tab@@ lets in HD@@ PE bottles / HD@@ PE bottle
1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
or AC@@ O@@ MP@@ L@@ IA 20 mg film@@ -@@ co@@ ated tab@@ lets ri@@ mon@@ ab@@ ant
u@@ th 2.
ST@@ AT@@ EM@@ EN@@ T O@@ F AC@@ T@@ IV@@ E SU@@ B@@ ST@@ AN@@ CE@@ (@@ S@@ )
ra Each tab@@ let contains 20 mg of ri@@ mon@@ ab@@ ant@@ .
ge 3.
L@@ IS@@ T O@@ F EX@@ C@@ IP@@ I@@ EN@@ TS
Also contains la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate@@ .
See le@@ af@@ let for further inform@@ ation@@ .
lon
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M AND CON@@ T@@ EN@@ TS no
28 film@@ -@@ co@@ ated tab@@ lets 98 film@@ -@@ co@@ ated tab@@ lets 500 film@@ -@@ co@@ ated tab@@ lets ct
5.
ME@@ TH@@ O@@ D AND RO@@ U@@ TE@@ (@@ S@@ ) O@@ F AD@@ M@@ IN@@ IS@@ TR@@ AT@@ ION du
O@@ ral use@@ .
Read the package le@@ af@@ let before use@@ . ro
6.
O@@ F THE RE@@ AC@@ H AND S@@ IG@@ H@@ T O@@ F CH@@ IL@@ D@@ RE@@ N
Keep out of the reach and sight of chil@@ dr@@ en@@ . ina
7.
O@@ TH@@ ER SP@@ EC@@ I@@ AL W@@ AR@@ N@@ IN@@ G@@ (@@ S@@ )@@ , I@@ F NE@@ C@@ ES@@ S@@ AR@@ Y dic
8.
EX@@ P@@ IR@@ Y D@@ AT@@ E
EX@@ P {@@ M@@ M@@ / Y@@ Y@@ Y@@ Y@@ } Me
9.
SP@@ EC@@ I@@ AL ST@@ OR@@ AG@@ E CON@@ D@@ IT@@ I@@ ON@@ S
21 10.
SP@@ EC@@ I@@ AL PRE@@ C@@ AU@@ TI@@ ON@@ S FO@@ R DI@@ SP@@ OS@@ AL O@@ F UN@@ US@@ ED ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS O@@ R W@@ A@@ ST@@ E M@@ AT@@ ER@@ I@@ AL@@ S D@@ ER@@ IV@@ ED F@@ RO@@ M SU@@ CH ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ TS@@ , I@@ F
d AP@@ P@@ RO@@ PR@@ I@@ AT@@ E
ise 11.
N@@ AM@@ E AND AD@@ D@@ RE@@ SS O@@ F THE MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION H@@ OL@@ DER
or 17@@ 4 av@@ en@@ ue de France F@@ -@@ 7@@ 50@@ 13 Paris France
u@@ th 12.
MAR@@ K@@ ET@@ ING AU@@ TH@@ OR@@ IS@@ AT@@ ION N@@ UM@@ BER@@ (@@ S@@ )
ra EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 7 EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 8 EU@@ / 1@@ / 06@@ / 34@@ 4@@ / 00@@ 9
ge 13.
lon
14.
G@@ EN@@ ER@@ AL CL@@ AS@@ SI@@ F@@ IC@@ AT@@ ION FO@@ R SU@@ P@@ PL@@ Y no
Medic@@ inal product subject to medical prescri@@ p@@ tion@@ .
15.
IN@@ ST@@ R@@ UC@@ TI@@ ON@@ S ON US@@ E ct du
16.
IN@@ F@@ OR@@ M@@ AT@@ ION IN B@@ RA@@ IL@@ LE
AC@@ O@@ MP@@ L@@ IA ro l@@ p ina dic Me
22 Me dic ina l@@ p ro du ct
23 no B.
P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T lon ge ra u@@ th or ise d P@@ AC@@ K@@ AG@@ E LE@@ AF@@ LE@@ T@@ :
IN@@ F@@ OR@@ M@@ AT@@ ION FO@@ R THE US@@ ER
AC@@ O@@ MP@@ L@@ IA 20 mg film@@ -@@ co@@ ated tab@@ lets
d (@@ ri@@ mon@@ ab@@ ant@@ )
ise Read all of this le@@ af@@ let carefully before you start taking this medic@@ ine@@ .
- Keep this le@@ af@@ let@@ .
You may need to read it aga@@ in@@ .
- If you have any further questi@@ ons@@ , ask your doctor or pharmac@@ ist@@ .
- This medicine has been prescri@@ bed for you@@ .
It may harm them@@ , even if
or their symptoms are the same as yo@@ urs@@ .
- If any of the side effects get seri@@ ous@@ , or if you notice any side effect not listed in this le@@ af@@ let@@ , please
tell your doctor or pharmac@@ ist@@ .
u@@ th
- You are advised to share the information in this le@@ af@@ let with relatives or other relevant person@@ s.
In this le@@ af@@ let@@ :
ra 1.
What AC@@ O@@ MP@@ L@@ IA is and what it is used for 2.
Before you take AC@@ O@@ MP@@ L@@ IA 3.
How to take AC@@ O@@ MP@@ L@@ IA 4.
Pos@@ sible side effects
1.
Further information WH@@ AT AC@@ O@@ MP@@ L@@ IA IS AND WH@@ AT IT IS US@@ ED FO@@ R
lon
The active ing@@ re@@ dient of AC@@ O@@ MP@@ L@@ IA is ri@@ mon@@ ab@@ ant@@ .
It works by blocking specific rec@@ ep@@ tors in the brain and fat tis@@ su@@ es called C@@ B@@ 1 rec@@ ep@@ tor@@ s.
AC@@ O@@ MP@@ L@@ IA is indicated in the treatment of obe@@ se or no
over@@ weight patients with additional risk factors such as diabetes or high levels of fat@@ ty sub@@ stances in the blood called li@@ pi@@ ds (@@ dy@@ sli@@ pi@@ da@@ emi@@ a@@ ; mainly chol@@ ester@@ ol and trig@@ ly@@ c@@ eri@@ des@@ ) as ad@@ jun@@ ct to diet and exer@@ ci@@ se@@ . ct
2.
BE@@ F@@ ORE Y@@ O@@ U T@@ AK@@ E AC@@ O@@ MP@@ L@@ IA du
Do not take AC@@ O@@ MP@@ L@@ IA − if you currently suffer from depression − if you are currently being treated for depression ro
− if you are aller@@ gic (@@ hyper@@ sensi@@ ti@@ ve@@ ) to ri@@ mon@@ ab@@ ant@@ , or any of the other ingredients of AC@@ O@@ MP@@ L@@ IA − if you are bre@@ ast@@ -@@ fe@@ ed@@ ing@@ . l@@ p
Take special care with AC@@ O@@ MP@@ L@@ IA T@@ ell your doctor before you start to take this medicine − if you have previously suffered from depression or have had suici@@ dal thoughts ina
− if you have im@@ paired liver function − if you have severely im@@ paired ren@@ al function − if you have diabetes (@@ see section 4@@ ) − if you are currently being treated for ep@@ ile@@ p@@ sy dic
− if you are less than 18 years of age@@ .
Me
Seri@@ ous psychiatri@@ c events including depression or mood changes have been reported in patients taking AC@@ O@@ MP@@ L@@ IA (@@ see section P@@ OS@@ S@@ IB@@ LE SI@@ DE E@@ FF@@ EC@@ TS@@ )@@ .
If you experience symptoms of depression (@@ see bel@@ ow@@ ) during treatment with AC@@ O@@ MP@@ L@@ IA you should contact your doctor and stop the treat@@ ment@@ .
24 Sig@@ ns and symptoms associated with depression could be@@ :
Sad@@ ness@@ , depres@@ sed m@@ ood@@ ; loss of interest in previously pleas@@ ur@@ able activi@@ ti@@ es@@ ; ag@@ it@@ ation@@ ; irrit@@ abili@@ ty@@ ;
d slo@@ we@@ d@@ , in@@ hi@@ bited ac@@ tions@@ ; poor conc@@ ent@@ ration@@ ; anx@@ ie@@ ty@@ ; difficulty in sleeping (@@ ins@@ om@@ ni@@ a@@ )@@ ; thoughts or words about death or suici@@ de.
ise You should in@@ form your doctor if any of the symptoms listed above develop or wor@@ sen after treatment has beg@@ un@@ .
Taking other medic@@ ines
or The activity of AC@@ O@@ MP@@ L@@ IA is increased by simul@@ tane@@ ous use of some drugs (@@ so@@ -@@ called C@@ Y@@ P@@ 3@@ A4 in@@ hi@@ bit@@ or@@ s@@ ) such as@@ : − it@@ ra@@ con@@ az@@ ole (@@ anti@@ f@@ ung@@ al medic@@ ine@@ )
u@@ th − ket@@ o@@ con@@ az@@ ole (@@ anti@@ f@@ ung@@ al medic@@ ine@@ ) − rit@@ on@@ avi@@ r (@@ medicine for the treatment of HIV inf@@ ec@@ tions@@ ) − tel@@ i@@ thro@@ my@@ c@@ in (@@ anti@@ bio@@ tic@@ ) − clari@@ thro@@ my@@ c@@ in (@@ anti@@ bio@@ tic@@ )
ra − ne@@ fa@@ zo@@ done (@@ anti@@ -@@ depres@@ sor@@ ) Please in@@ form your doctor or pharmac@@ ist if you are taking or have recently taken the above mentioned medic@@ ines or any other medi@@ cin@@ es@@ , including those obtained without a prescription such as St John ’ s
Pre@@ gn@@ ancy and bre@@ ast@@ -@@ feeding AC@@ O@@ MP@@ L@@ IA should not be taken during pregn@@ anc@@ y@@ .
lon
Contact your doctor immediately if you become pregn@@ ant@@ , think you might be pregnant or are planning to become pregnant while taking AC@@ O@@ MP@@ LI@@ A. no
Do not take this medicine when bre@@ ast@@ -@@ fe@@ ed@@ ing@@ .
T@@ ell your doctor if you are bre@@ ast@@ -@@ feeding or if you are planning to bre@@ ast@@ -@@ feed your bab@@ y@@ .
Dri@@ ving and using machines ct
At the recommended d@@ os@@ e@@ , AC@@ O@@ MP@@ L@@ IA is not expected to reduce your ability to drive and use mach@@ in@@ es@@ . du
Imp@@ ort@@ ant information about some of the ingredients of AC@@ O@@ MP@@ L@@ IA AC@@ O@@ MP@@ L@@ IA tab@@ lets include la@@ ct@@ os@@ e@@ .
If you are int@@ oler@@ ant to some su@@ gar@@ s@@ , contact your doctor before taking this medic@@ ine@@ . ro l@@ p
3.
HO@@ W TO T@@ AK@@ E AC@@ O@@ MP@@ L@@ IA
Al@@ ways take AC@@ O@@ MP@@ L@@ IA exactly as your doctor has told you@@ .
You should check with your doctor or pharmac@@ ist if you are not su@@ re@@ .
The usual dose is one 20 mg tab@@ let to be taken once daily in the ina
morning before break@@ fa@@ st@@ .
S@@ wal@@ low the tab@@ let whol@@ e@@ .
You need to start and continue a reduced cal@@ orie diet and a physical activity program to get best resul@@ ts@@ .
Your doctor should recommend the type of diet and the level of physical activity requi@@ red@@ , that dic
suits your specific condition and overall health@@ .
Me
If you take more AC@@ O@@ MP@@ L@@ IA than you should If you take more AC@@ O@@ MP@@ L@@ IA than you should tell a doctor or pharmac@@ ist@@ .
25 If you forget to take AC@@ O@@ MP@@ L@@ IA Take it as soon as you remember but do not take a double dose to make up for any forgotten d@@ os@@ e@@ .
d If you have any further questions on the use of this product ask your doctor or your pharmac@@ ist@@ .
ise 4.
P@@ OS@@ S@@ IB@@ LE SI@@ DE E@@ FF@@ EC@@ TS
Like all medi@@ cin@@ es@@ , AC@@ O@@ MP@@ L@@ IA can cause side effec@@ ts@@ , although not everybody gets them
or Very common side effec@@ ts@@ , that affect more than 1 per 10@@ , that have occurred in patients on AC@@ O@@ MP@@ L@@ IA inclu@@ de@@ : nau@@ sea and upper resp@@ ir@@ atory tra@@ ct inf@@ ec@@ tion@@ .
u@@ th Comm@@ on side effec@@ ts@@ , that affect more than 1 per 100 but less than@@ 1 per 10@@ , that have occurred in patients on AC@@ O@@ MP@@ L@@ IA inclu@@ de@@ : upset stom@@ ach@@ , vo@@ mit@@ ing@@ , trouble with sle@@ ep@@ ing@@ , nerv@@ ous@@ ness@@ , depres@@ sion@@ , irrit@@ abili@@ ty@@ , di@@ zz@@ in@@ ess@@ ,
ra di@@ arr@@ ho@@ e@@ a@@ , anx@@ ie@@ ty@@ , it@@ ch@@ ing@@ , excessive swe@@ at@@ ing@@ , muscle cra@@ mps or sp@@ as@@ m@@ , f@@ ati@@ gu@@ e@@ , bru@@ is@@ ing@@ , ten@@ don pain and infl@@ amm@@ ation (@@ ten@@ d@@ oni@@ tis@@ )@@ , memory los@@ s@@ , back pain (@@ sci@@ ati@@ ca@@ )@@ , al@@ tered sensi@@ tivity (@@ less sensi@@ tivity or ab@@ normal burning or pri@@ ck@@ ling sensation@@ ) of the hands and fe@@ et@@ , hot fl@@ ush@@ , fall@@ , influ@@ enz@@ a@@ , and joint spra@@ in@@ .
ge Un@@ common side effec@@ ts@@ , that affect less than 1 per 100 but more than@@ 1 per 10@@ 00@@ , that have occurred in patients on AC@@ O@@ MP@@ L@@ IA inclu@@ de@@ : lon S@@ le@@ ep@@ iness (@@ le@@ th@@ ar@@ gy@@ )@@ , tre@@ mor@@ , night swe@@ ats@@ , panic symp@@ tom@@ s@@ , h@@ ic@@ cup@@ s@@ , an@@ ger@@ , rest@@ less@@ ness (@@ dy@@ sph@@ ori@@ a@@ )@@ , emotional disor@@ der@@ , suici@@ dal thou@@ gh@@ ts@@ , aggres@@ si@@ veness or aggressive behavi@@ our@@ , hypo@@ g@@ ly@@ ca@@ emi@@ a (@@ low blood su@@ gar@@ )@@ .
R@@ are side effec@@ ts@@ , that affect less than 1 per 10@@ 00@@ , that have occurred in patients on AC@@ O@@ MP@@ L@@ IA no
inclu@@ de@@ : hall@@ u@@ cin@@ ations@@ .
During post@@ -@@ marketing experience the following side effects have also been reported (@@ frequ@@ ency not kno@@ wn@@ )@@ : ct
Con@@ vul@@ sion@@ , distur@@ b@@ ance in atten@@ tion@@ , del@@ u@@ sion (@@ false belie@@ f@@ )@@ , par@@ ano@@ i@@ a@@ , ra@@ sh@@ , hea@@ da@@ che and stomach pain@@ . du
If any of the side effects gets seri@@ ous@@ , or if you notice any side effects not listed in this le@@ af@@ let@@ , please tell your doctor or pharmac@@ ist@@ . ro
5.
HO@@ W TO ST@@ ORE AC@@ O@@ MP@@ L@@ IA l@@ p
Keep out of the reach and sight of chil@@ dr@@ en@@ .
The ina
exp@@ iry date ref@@ ers to the last day of that mon@@ th@@ .
This medic@@ inal product does not require any special storage conditions dic
Medic@@ ines should not be disp@@ osed of via wa@@ ste@@ water or household wa@@ ste@@ .
As@@ k your pharmac@@ ist how to disp@@ ose of medic@@ ines no longer requi@@ re@@ d.
Me
F@@ UR@@ TH@@ ER IN@@ F@@ OR@@ M@@ AT@@ ION
What AC@@ O@@ MP@@ L@@ IA contains
d The active substance is ri@@ mon@@ ab@@ ant@@ .
One film@@ -@@ co@@ ated tab@@ let contains 20 mg ri@@ mon@@ ab@@ ant@@ .
The other ingredients are@@ :
ise Tablet cor@@ e@@ : ma@@ i@@ ze star@@ ch@@ , la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate@@ , po@@ vi@@ done K 30 (@@ E@@ 1@@ 201@@ )@@ , cros@@ car@@ m@@ ell@@ ose so@@ dium (@@ E@@ 46@@ 8@@ )@@ , so@@ dium lau@@ ri@@ l@@ sul@@ fate (@@ E@@ 48@@ 7@@ )@@ , micro@@ cr@@ yst@@ all@@ ine cell@@ ul@@ ose (@@ E@@ 46@@ 0@@ )@@ , magne@@ si@@ um ste@@ ar@@ ate Tablet co@@ at@@ ing@@ : la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate@@ , hy@@ pro@@ m@@ ell@@ ose 15 m@@ Pa@@ . s (@@ E@@ 46@@ 4@@ )@@ , tit@@ ani@@ um di@@ oxide (@@ E@@ 17@@ 1@@ )@@ , mac@@ ro@@ go@@ l 3000
or Tablet poli@@ sh@@ ing@@ : car@@ nau@@ ba wa@@ x (@@ E@@ 90@@ 3@@ )
What AC@@ O@@ MP@@ L@@ IA looks like and cont@@ ents of the pack
u@@ th AC@@ O@@ MP@@ L@@ IA 20 mg is supp@@ lied as te@@ ard@@ rop@@ -@@ shap@@ ed@@ , white film@@ -@@ co@@ ated tab@@ lets deb@@ os@@ sed with “ 20 ” on one si@@ de.
AC@@ O@@ MP@@ L@@ IA is available in bli@@ ster p@@ acks of 14@@ , 28@@ , 30@@ , 56@@ , 8@@ 4@@ , 90 and 98 tab@@ le@@ ts@@ , in per@@ for@@ ated unit
ra dose bli@@ ster p@@ acks containing 70 x 1 tab@@ le@@ ts@@ , and in white plastic bottles containing 28@@ , 98 and 500 tab@@ le@@ ts@@ .
Not all pack si@@ zes may be mar@@ ke@@ te@@ d.
ge Marketing Auth@@ or@@ isation Hol@@ der and Manu@@ fac@@ tur@@ er lon Marketing Auth@@ or@@ isation Hol@@ der san@@ o@@ fi@@ -@@ av@@ enti@@ s 17@@ 4@@ , av@@ en@@ ue de France F@@ -@@ 7@@ 50@@ 13 Paris France no
Manu@@ fac@@ tur@@ ers San@@ o@@ fi Win@@ thro@@ p Industrie ct
30@@ -@@ 36@@ , av@@ en@@ ue Gusta@@ ve Ei@@ ff@@ el – BP 27@@ 16@@ 6 F@@ -@@ 3@@ 70@@ 71 To@@ urs C@@ e@@ dex 2 France du
san@@ o@@ fi@@ -@@ av@@ enti@@ s S. p. A.
Stra@@ da Stat@@ ale 17@@ , K@@ m 22 ro
6@@ 70@@ 19 Sc@@ opp@@ i@@ to (@@ A@@ Q@@ ) Italy l@@ p
For any information about this medic@@ inal produc@@ t@@ , please contact the local representative of the Marketing Auth@@ or@@ isation Hol@@ der@@ : ina dic Me
27 Belgi@@ ë@@ / Belgi@@ qu@@ e@@ / Belgien san@@ o@@ fi@@ -@@ av@@ enti@@ s Belgium T@@ é@@ l@@ / Tel@@ : +@@ 32 (@@ 0@@ )@@ 2 7@@ 10 54 00
Luxem@@ bour@@ g@@ / Luxemburg san@@ o@@ fi@@ -@@ av@@ enti@@ s Belgium T@@ é@@ l@@ / Tel@@ : +@@ 32 (@@ 0@@ )@@ 2 7@@ 10 54 00 (@@ Belgi@@ qu@@ e@@ / Belgi@@ en@@ )
d Б@@ ъ@@ л@@ г@@ а@@ р@@ и@@ я
Mag@@ y@@ ar@@ or@@ sz@@ á@@ g
ise san@@ o@@ fi@@ -@@ av@@ enti@@ s Bulgaria E@@ O@@ O@@ D Т@@ е@@ л@@ .@@ : +@@ 3@@ 59 (@@ 0@@ )@@ 2 9@@ 70 53 00
san@@ o@@ fi@@ -@@ av@@ enti@@ s z@@ rt@@ .@@ , Mag@@ y@@ ar@@ or@@ sz@@ á@@ g Tel@@ .@@ : +@@ 36 1 50@@ 5 00@@ 50
Č es@@ k@@ á republi@@ ka
Malta
Tel@@ : +@@ 4@@ 20 2@@ 33 0@@ 86 111
Tel@@ : +@@ 3@@ 56 2@@ 14@@ 9@@ 30@@ 22
u@@ th Dan@@ mark san@@ o@@ fi@@ -@@ av@@ enti@@ s Denmark A@@ / S T@@ l@@ f@@ : +@@ 45 45 16 70 00
Ne@@ der@@ land san@@ o@@ fi@@ -@@ av@@ enti@@ s Netherlands B. V.
Tel@@ : +@@ 31 (@@ 0@@ )@@ 18@@ 2 5@@ 57 7@@ 55
ra Deutschland San@@ o@@ fi@@ -@@ Av@@ enti@@ s Deutschland GmbH Tel@@ : +@@ 49 (@@ 0@@ )@@ 180 2 22@@ 2010
Nor@@ ge san@@ o@@ fi@@ -@@ av@@ enti@@ s Nor@@ ge AS T@@ l@@ f@@ : +@@ 47 67 10 71 00
ge E@@ est@@ i san@@ o@@ fi@@ -@@ av@@ enti@@ s Est@@ onia O@@ Ü Tel@@ : +@@ 3@@ 72 6@@ 27 34 88
Österreich san@@ o@@ fi@@ -@@ av@@ enti@@ s GmbH Tel@@ : +@@ 43 1 80 185 – 0 lon
Ε@@ λ@@ λ@@ ά@@ δ@@ α san@@ o@@ fi@@ -@@ av@@ enti@@ s A@@ E@@ BE Τ@@ η@@ λ@@ : +@@ 30 210 900 16 00
Pol@@ ska san@@ o@@ fi@@ -@@ av@@ enti@@ s Sp@@ . z o. o.
Tel@@ .@@ : +@@ 48 22 5@@ 41 46 00
E@@ spa@@ ñ@@ a san@@ o@@ fi@@ -@@ av@@ enti@@ s@@ , S. A.
Tel@@ : +@@ 34 93 4@@ 85 94 00
ct
Portugal san@@ o@@ fi@@ -@@ av@@ enti@@ s - Pro@@ d@@ ut@@ os Far@@ mac@@ ê@@ u@@ tic@@ os@@ , S. A.
Tel@@ : +@@ 3@@ 51 21 35 89 400
France san@@ o@@ fi@@ -@@ av@@ enti@@ s France T@@ é@@ l@@ :
0 800 2@@ 22 5@@ 55
Rom@@ â@@ nia san@@ o@@ fi@@ -@@ av@@ enti@@ s Rom@@ â@@ nia S. R. L.
Tel@@ : +@@ 40 (@@ 0@@ ) 21 3@@ 17 31 36
Ireland
Slo@@ ven@@ i@@ ja
Tel@@ : +@@ 3@@ 53 (@@ 0@@ ) 1 4@@ 03 56 00 l@@ p
Tel@@ : +@@ 38@@ 6 1 5@@ 60 48 00
Í@@ s@@ land V@@ ist@@ or hf@@ .
S@@ í@@ mi@@ : +@@ 3@@ 54 5@@ 35 7000 ina
Slo@@ ven@@ sk@@ á republi@@ ka san@@ o@@ fi@@ -@@ av@@ enti@@ s Phar@@ ma Slovakia s. r. o.
Tel@@ : +@@ 4@@ 21 2 57 103 7@@ 77
Itali@@ a san@@ o@@ fi@@ -@@ av@@ enti@@ s S. p. A.
Tel@@ : +@@ 39 02 3@@ 93 91 dic
Su@@ omi@@ / Fin@@ land san@@ o@@ fi@@ -@@ av@@ enti@@ s O@@ y Pu@@ h@@ / Tel@@ : +@@ 3@@ 58 (@@ 0@@ ) 20@@ 1 200 300
Κ@@ ύ@@ π@@ ρ@@ ο@@ ς san@@ o@@ fi@@ -@@ av@@ enti@@ s C@@ yp@@ rus L@@ t@@ d.
Τ@@ η@@ λ@@ : +@@ 3@@ 57 22 8@@ 7@@ 16@@ 00 Me
S@@ ver@@ ige san@@ o@@ fi@@ -@@ av@@ enti@@ s AB Tel@@ : +@@ 46 (@@ 0@@ )@@ 8 6@@ 34 50 00
Lat@@ vi@@ ja san@@ o@@ fi@@ -@@ av@@ enti@@ s Lat@@ via S@@ IA Tel@@ : +@@ 3@@ 71 67 33 24 51
United Kingdom san@@ o@@ fi@@ -@@ av@@ enti@@ s Tel@@ : +@@ 44 (@@ 0@@ ) 14@@ 83 50@@ 5 5@@ 15
28 Lie@@ tu@@ va U@@ AB san@@ o@@ fi@@ -@@ av@@ enti@@ s Lie@@ tu@@ va Tel@@ : +@@ 370 5 27@@ 55@@ 2@@ 24
d ise This le@@ af@@ let was last approved in
or Det@@ ailed information on this medicine is available on the European Medic@@ ines Agency (@@ E@@ ME@@ A@@ ) web si@@ te@@ : htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . eu@@ .
u@@ th ra ge lon no ct du ro l@@ p ina dic Me
29
European Medic@@ ines Agency
E@@ ME@@ A@@ / H@@ / C@@ / 28@@ 5
EU@@ RO@@ P@@ E@@ AN P@@ U@@ BL@@ IC AS@@ S@@ ES@@ SM@@ EN@@ T RE@@ P@@ OR@@ T (@@ EP@@ AR@@ )
AC@@ T@@ OS
It explains how the Committee for Medic@@ inal Produc@@ ts for Human Use (@@ CH@@ MP@@ ) asse@@ ssed the studies per@@ for@@ med@@ , to reach their recommendations on how to use the medic@@ ine@@ .
If you need more information about your medical condition or your treat@@ ment@@ , read the Pack@@ age Le@@ af@@ let (@@ also part of the EP@@ AR@@ ) or contact your doctor or pharmac@@ ist@@ .
If you want more information on the basis of the CH@@ MP recommend@@ ations@@ , read the Scienti@@ fic Dis@@ c@@ ussion (@@ also part of the EP@@ AR@@ )@@ .
What is Act@@ os@@ ?
Ac@@ tos is a medicine containing the active substance pi@@ o@@ gli@@ ta@@ z@@ one@@ .
The wh@@ it@@ e@@ , round tab@@ lets contain 15@@ , 30 or 45 mg of pi@@ o@@ gli@@ ta@@ z@@ one@@ .
What is Ac@@ tos used for@@ ?
Ac@@ tos is used to treat type 2 diabetes (@@ also known as non insu@@ lin@@ -@@ dependent di@@ abet@@ es@@ )@@ . • It can be used on its own (@@ mon@@ o@@ therap@@ y@@ ) in patients (@@ particularly those who are over@@ wei@@ ght@@ ) who cannot use met@@ form@@ in (@@ an anti@@ di@@ abe@@ tic medic@@ ine@@ )@@ . • It can be used together with one other anti@@ di@@ abe@@ tic medicine (@@ dual therap@@ y@@ )@@ .
It can be added to met@@ form@@ in in patients (@@ particularly those who are over@@ wei@@ ght@@ ) who are not satis@@ fac@@ tor@@ ily controlled on met@@ form@@ in used on its own and at the maximum toler@@ ated d@@ os@@ e@@ .
Altern@@ ati@@ vel@@ y@@ , it can be added to a sul@@ ph@@ on@@ y@@ lu@@ re@@ a (@@ another anti@@ di@@ abe@@ tic medic@@ ine@@ ) in patients for whom met@@ form@@ in is not suitable and who are not satis@@ fac@@ tor@@ ily controlled with the sul@@ ph@@ on@@ y@@ lu@@ re@@ a used on its own at the maximum toler@@ ated d@@ os@@ e@@ . • It can be used together with two other anti@@ di@@ abe@@ tic medi@@ cin@@ es@@ , met@@ form@@ in and a sul@@ ph@@ on@@ y@@ lu@@ re@@ a@@ , as triple therapy in patients (@@ particularly those who are over@@ wei@@ ght@@ ) who are not satis@@ fac@@ tor@@ ily controlled with these two medi@@ cin@@ es@@ . • It can be used together with insu@@ lin in patients who are not satis@@ fac@@ tor@@ ily controlled with insu@@ lin alone and cannot take met@@ for@@ min@@ .
How is Ac@@ tos use@@ d@@ ?
Ac@@ tos is taken once daily with or without f@@ ood@@ .
The dose is adjusted to give the best contro@@ l.
The recommended starting dose is 15 mg or 30 mg once da@@ ily@@ .
This dose may need to be increased after one or two weeks to up to 45 mg once da@@ ily@@ .
In combination with met@@ for@@ min@@ , the current met@@ form@@ in dose can be continued when starting Ac@@ tos treat@@ ment@@ .
In combination with a sul@@ ph@@ on@@ y@@ lu@@ re@@ a or insu@@ lin@@ , the current sul@@ ph@@ on@@ y@@ lu@@ re@@ a or insu@@ lin dose can be continued when starting Ac@@ tos treatment unless the patient has hypo@@ g@@ ly@@ ca@@ emi@@ a (@@ low blood glu@@ cos@@ e@@ )@@ , when the dose of the sul@@ ph@@ on@@ y@@ lu@@ re@@ a or insu@@ lin should be decre@@ as@@ ed@@ .
How does Ac@@ tos work@@ ?
Pi@@ o@@ gli@@ ta@@ z@@ one@@ , the active ing@@ re@@ dient in Act@@ os@@ , makes the cells more sensitive to
7 West@@ fer@@ ry Cir@@ cus@@ , Can@@ ary W@@ har@@ f@@ , London E@@ 14 4@@ HB@@ , UK Tel@@ .
(@@ 44@@ -@@ 20@@ ) 74 18 84 00 Fax (@@ 44@@ -@@ 20@@ ) 74 18 84 16 E@@ -@@ mail@@ : mail@@ @@@ eme@@ a. europa@@ . e@@ u htt@@ p@@ : / /@@ ww@@ w@@ . eme@@ a. europa@@ . e@@ u ©@@ E@@ ME@@ A 2007 Re@@ production and@@ / or distribution of this document is author@@ ised for non commercial purposes only provided the E@@ ME@@ A is acknowledged insu@@ lin@@ , which means that the body makes better use of the insu@@ lin it produc@@ es@@ , the blood glu@@ c@@ ose is reduced and this helps to control type 2 di@@ abet@@ es@@ .
How has Ac@@ tos been studi@@ ed@@ ?
Ac@@ tos has been studied in clinical pharmac@@ ology studies and in clinical tri@@ al@@ s.
Almost 7,000 patients received Ac@@ tos in all trials com@@ bin@@ ed@@ .
The studies compared Ac@@ tos to pla@@ c@@ eb@@ o (@@ a dum@@ my treat@@ ment@@ )@@ , or to other anti@@ di@@ abe@@ tic medic@@ ines (@@ met@@ for@@ min@@ , gli@@ cla@@ zi@@ de@@ )@@ .
Some studies also looked at comb@@ ining Ac@@ tos with other anti@@ di@@ abe@@ tic medic@@ ines (@@ sul@@ ph@@ on@@ y@@ lu@@ reas@@ , insu@@ lin@@ , met@@ for@@ min@@ )@@ .
Further studies also looked at long@@ -@@ term use of Act@@ os@@ .
In triple therap@@ y@@ , the effec@@ tiveness of Ac@@ tos was studied in more than 1,@@ 400 patients who were receiving a combination of met@@ form@@ in and a sul@@ ph@@ on@@ y@@ lu@@ re@@ a@@ , to which was added either Ac@@ tos or pla@@ c@@ eb@@ o for up to 3.5 ye@@ ar@@ s.
The studies measured the level in the blood of a substance (@@ g@@ ly@@ cos@@ y@@ lated ha@@ emo@@ glob@@ in@@ , H@@ b@@ A@@ 1@@ c@@ )@@ , which gives an indication of how well the blood glu@@ c@@ ose is contro@@ lle@@ d.
What benefit has Ac@@ tos shown during the stu@@ dies@@ ?
Ac@@ tos led to a decre@@ ase in the level of H@@ b@@ A@@ 1@@ c@@ , indic@@ ating that blood glu@@ c@@ ose levels had been reduced at d@@ oses of 15 m@@ g@@ , 30 mg and 45 m@@ g.
D@@ oses below 15 mg were not effec@@ ti@@ ve@@ , and d@@ oses above 45 mg (@@ once da@@ ily@@ ) did not show additional benef@@ it@@ .
Ac@@ tos on its own was shown to be as effective as met@@ form@@ in and gli@@ cla@@ zi@@ de.
In com@@ bin@@ ation@@ , Ac@@ tos showed that it impro@@ ves the control obtained in type 2 diabetes when added to existing treat@@ ment@@ .
At the end of the triple therapy stu@@ dy@@ , the effect of adding Ac@@ tos to the existing treatment with met@@ form@@ in and a sul@@ ph@@ on@@ y@@ lu@@ re@@ a was a 0.@@ 9@@ 4@@ % reduction in H@@ b@@ A@@ 1@@ c level@@ s@@ , while adding pla@@ c@@ eb@@ o led to a 0.@@ 35@@ % re@@ duc@@ tion@@ .
In a small study exam@@ ining the combination of Ac@@ tos and insu@@ lin in 28@@ 9 pati@@ ent@@ s@@ , patients adding Ac@@ tos to insu@@ lin had a 0.@@ 69@@ % reduction in H@@ b@@ A@@ 1@@ c levels after 6 mon@@ th@@ s@@ , compared to 0.@@ 14@@ % in those adding pla@@ c@@ ebo@@ .
What is the risk associated with Act@@ os@@ ?
The most common side effects with Ac@@ tos are visual distur@@ b@@ anc@@ e@@ , upper resp@@ ir@@ atory tra@@ ct infection (@@ col@@ ds@@ )@@ , weight increas@@ e@@ , and hypo@@ aes@@ the@@ sia (@@ decre@@ ased sensi@@ tivity to a stimul@@ us@@ )@@ .
For the full list of all side effects reported with Act@@ os@@ , see the Pack@@ age Le@@ af@@ let@@ .
Ac@@ tos should not be used in people who may be hyper@@ sensitive (@@ aller@@ gi@@ c@@ ) to pi@@ o@@ gli@@ ta@@ zone or any of the other ingredi@@ ent@@ s@@ , or in patients with liver proble@@ ms@@ , heart failure or di@@ abe@@ tic ket@@ o@@ aci@@ do@@ sis (@@ high levels of ket@@ ones [@@ aci@@ ds@@ ] in the bloo@@ d@@ )@@ .
Why has Ac@@ tos been appro@@ v@@ ed@@ ?
The committee recommended that Ac@@ tos be given marketing author@@ is@@ ation@@ .
In mon@@ o@@ therapy (@@ used on its ow@@ n@@ )@@ , the committee decided that Ac@@ tos should be an alternative to the standard treat@@ ment@@ , met@@ for@@ min@@ , to be used when patients cannot take met@@ for@@ min@@ .
Other information about Act@@ os@@ :
The European Commission granted a marketing author@@ isation val@@ id throughout the European Uni@@ on@@ , for Ac@@ tos to Tak@@ eda Europe R & D Centre Limited on 13 October 200@@ 0@@ .
The marketing author@@ isation was renewed on 13 October 200@@ 5.
The full EP@@ AR for Ac@@ tos is available here
This sum@@ mary was last updated in 0@@ 1@@ -@@ 200@@ 7.
©@@ E@@ ME@@ A 2007
2@@ / 2
AN@@ NE@@ X I
SU@@ M@@ MAR@@ Y O@@ F P@@ RO@@ D@@ UC@@ T CH@@ AR@@ AC@@ TER@@ IS@@ T@@ IC@@ S
1 1.
N@@ AM@@ E O@@ F THE ME@@ D@@ IC@@ IN@@ AL P@@ RO@@ D@@ UC@@ T
Ac@@ tos 15 mg tab@@ le@@ ts@@ .
2.
Q@@ U@@ AL@@ IT@@ AT@@ IV@@ E AND Q@@ U@@ AN@@ T@@ IT@@ AT@@ IV@@ E CO@@ MP@@ OS@@ IT@@ ION
Each tab@@ let contains 15 mg of pi@@ o@@ gli@@ ta@@ zone as hydro@@ ch@@ l@@ ori@@ de.
For a full list of ex@@ cip@@ i@@ ent@@ s@@ , see 6.@@ 1.
3.
PH@@ AR@@ M@@ AC@@ EU@@ T@@ IC@@ AL F@@ OR@@ M
Tab@@ let@@ .
The tab@@ lets are white to off@@ -@@ wh@@ it@@ e@@ , ro@@ und@@ , con@@ ve@@ x and marked ‘ 15@@ ’ on one face and ‘ AC@@ T@@ OS@@ ’ on the other fac@@ e@@ .
4.
C@@ LIN@@ IC@@ AL PAR@@ T@@ IC@@ UL@@ AR@@ S
4.@@ 1 Therap@@ eu@@ tic indic@@ ations
Pi@@ o@@ gli@@ ta@@ zone is indicated in the treatment of type 2 diabetes mel@@ li@@ t@@ us@@ :
- in patients (@@ particularly over@@ weight pati@@ ent@@ s@@ ) in@@ adequ@@ ately controlled by diet and exercise
for whom met@@ form@@ in is inappropriate because of contra@@ indic@@ ations or int@@ oler@@ ance
as dual oral therapy in combination with
- met@@ for@@ min@@ , in patients (@@ particularly over@@ weight pati@@ ent@@ s@@ ) with in@@ sufficient g@@ ly@@ ca@@ e@@ mic
control despite maximal toler@@ ated dose of mon@@ o@@ therapy with met@@ form@@ in
- a sul@@ ph@@ on@@ y@@ lu@@ re@@ a@@ , only in patients who show int@@ oler@@ ance to met@@ form@@ in or for whom
met@@ form@@ in is contra@@ indi@@ cat@@ ed@@ , with in@@ sufficient g@@ ly@@ ca@@ e@@ mic control despite maximal toler@@ ated dose of mon@@ o@@ therapy with a sul@@ ph@@ on@@ y@@ lu@@ re@@ a.
as triple oral therapy in combination with
- met@@ form@@ in and a sul@@ ph@@ on@@ y@@ lu@@ re@@ a@@ , in patients (@@ particularly over@@ weight pati@@ ent@@ s@@ ) with in@@ sufficient
g@@ ly@@ ca@@ e@@ mic control despite dual oral therap@@ y@@ .
Pi@@ o@@ gli@@ ta@@ zone is also indicated for combination with insu@@ lin in type 2 diabetes mel@@ li@@ tus patients with in@@ sufficient g@@ ly@@ ca@@ e@@ mic control on insu@@ lin for whom met@@ form@@ in is inappropriate because of contra@@ indic@@ ations or int@@ oler@@ ance (@@ see section 4.@@ 4@@ )@@ .
4.@@ 2 Pos@@ ology and method of administration
Pi@@ o@@ gli@@ ta@@ zone tab@@ lets are taken or@@ ally once daily with or without f@@ ood@@ .
Pi@@ o@@ gli@@ ta@@ zone may be initi@@ ated at 15@@ mg or 30@@ mg once da@@ ily@@ .
The dose may be increased in incre@@ ments up to 45@@ mg once da@@ ily@@ .
2 In combination with insu@@ lin@@ , the current insu@@ lin dose can be continued upon initi@@ ation of pi@@ o@@ gli@@ ta@@ zone therap@@ y@@ .
If patients report hypo@@ g@@ ly@@ ca@@ emi@@ a@@ , the dose of insu@@ lin should be decre@@ as@@ ed@@ .
El@@ der@@ ly@@ :
No d@@ os@@ age adju@@ st@@ ment is necessary for elderly patients (@@ see section 5.@@ 2@@ )@@ .
Pati@@ ents with ren@@ al im@@ pa@@ ir@@ ment@@ :
No d@@ os@@ age adju@@ st@@ ment is necessary in patients with im@@ paired ren@@ al function (@@ cre@@ at@@ in@@ ine clear@@ ance > 4 m@@ l@@ / min@@ ) (@@ see section 5.@@ 2@@ )@@ .
No information is available from di@@ aly@@ sed patients therefore pi@@ o@@ gli@@ ta@@ zone should not be used in such pati@@ ent@@ s.
Pati@@ ents with he@@ pati@@ c im@@ pa@@ ir@@ ment@@ :
Pi@@ o@@ gli@@ ta@@ zone should not be used in patients with he@@ pati@@ c im@@ pa@@ ir@@ ment (@@ see section 4.@@ 4@@ )@@ .
Children and adol@@ es@@ cent@@ s@@ :
There are no data available on the use of pi@@ o@@ gli@@ ta@@ zone in patients under 18 years of age@@ , and therefore its use is not recommended in this age gro@@ up@@ .
4.@@ 3 Con@@ tra@@ indic@@ ations
Pi@@ o@@ gli@@ ta@@ zone is contra@@ indicated in patients with@@ :
- hyper@@ sensi@@ tivity to the active substance or to any of the ex@@ cip@@ i@@ ents
- cardi@@ ac failure or history of cardi@@ ac failure (@@ NY@@ H@@ A stages I to IV@@ )
- he@@ pati@@ c im@@ pa@@ ir@@ ment
- di@@ abe@@ tic ket@@ o@@ aci@@ do@@ si@@ s.
4.@@ 4 Special warnings and prec@@ au@@ tions for use
Flu@@ id re@@ tention and cardi@@ ac fail@@ ure@@ :
Pi@@ o@@ gli@@ ta@@ zone can cause flu@@ id re@@ ten@@ tion@@ , which may exac@@ erb@@ ate or pre@@ cip@@ it@@ ate heart fail@@ ure@@ .
When treating patients who have at least one risk factor for development of con@@ gesti@@ ve heart failure (@@ e@@ . g. prior m@@ yo@@ cardi@@ al inf@@ ar@@ ction or symp@@ tom@@ atic cor@@ on@@ ary ar@@ tery dise@@ as@@ e@@ )@@ , physi@@ cians should start with the lowest available dose and increase the dose gradu@@ all@@ y@@ .
Pati@@ ents should be observed for signs and symptoms of heart fail@@ ure@@ , weight gain or oe@@ de@@ ma particularly those with reduced cardi@@ ac reser@@ ve@@ .
There have been cases of cardi@@ ac failure reported from the market when pi@@ o@@ gli@@ ta@@ zone was used in combination with insu@@ lin@@ or in patients with a history of cardi@@ ac fail@@ ure@@ ; patients should be observed for signs and symptoms of heart fail@@ ure@@ , weight gain and oe@@ de@@ ma when pi@@ o@@ gli@@ ta@@ zone is used in combination with insu@@ lin@@ .
Since insu@@ lin and pi@@ o@@ gli@@ ta@@ zone are associated with flu@@ id re@@ ten@@ tion@@ , con@@ co@@ mit@@ ant administration may increase the risk of oe@@ de@@ ma@@ .
Pi@@ o@@ gli@@ ta@@ zone should be dis@@ continued if any deterior@@ ation in cardi@@ ac status occ@@ urs@@ .
A cardi@@ ov@@ as@@ cular outcome study of pi@@ o@@ gli@@ ta@@ zone has been performed in patients under 75 years with type 2 diabetes mel@@ li@@ tus and pre@@ -@@ existing major mac@@ ro@@ v@@ as@@ cular dise@@ as@@ e@@ .
Pi@@ o@@ gli@@ ta@@ zone or pla@@ c@@ eb@@ o was added to existing anti@@ di@@ abe@@ tic and cardi@@ ov@@ as@@ cular therapy for up to 3.5 ye@@ ar@@ s.
This study showed an increase in reports of heart fail@@ ure@@ , however this did not lead to an increase in mort@@ ality in this stu@@ dy@@ .
Cau@@ tion should be exerc@@ ised in patients over 75 years because of the limited experience in this patient gro@@ up@@ .
3 Mon@@ it@@ oring of liver func@@ tion@@ :
There have been rare reports of he@@ pat@@ oc@@ ell@@ ular dys@@ function during post@@ -@@ marketing experience (@@ see section 4.@@ 8@@ )@@ .
It is recommen@@ de@@ d@@ , ther@@ e@@ fore@@ , that patients treated with pi@@ o@@ gli@@ ta@@ zone under@@ go perio@@ dic monitoring of liver enz@@ ym@@ es@@ .
Li@@ ver enz@@ ym@@ es should be checked prior to the initi@@ ation of therapy with pi@@ o@@ gli@@ ta@@ zone in all pati@@ ent@@ s.
Therap@@ y with pi@@ o@@ gli@@ ta@@ zone should not be initi@@ ated in patients with increased bas@@ eline liver enz@@ y@@ me levels (@@ AL@@ T > 2.5 X upper limit of normal@@ ) or with any other evidence of liver dise@@ as@@ e@@ .
Following initi@@ ation of therapy with pi@@ o@@ gli@@ ta@@ z@@ one@@ , it is recommended that liver enz@@ ym@@ es be monit@@ ored perio@@ di@@ cally based on clinical jud@@ gem@@ ent@@ .
If AL@@ T levels are increased to 3 X upper limit of normal during pi@@ o@@ gli@@ ta@@ zone therap@@ y@@ , liver enz@@ y@@ me levels should be re@@ asse@@ ssed as soon as possi@@ ble@@ .
If AL@@ T levels remain > 3 X the upper limit of normal@@ , therapy should be dis@@ continu@@ ed@@ .
If any patient develop@@ s symptoms suggesting he@@ pati@@ c dys@@ func@@ tion@@ , which may include un@@ explained nau@@ se@@ a@@ , vo@@ mit@@ ing@@ , ab@@ dom@@ inal pain@@ , f@@ ati@@ gu@@ e@@ , an@@ or@@ ex@@ ia and@@ / or dark ur@@ ine@@ , liver enz@@ ym@@ es should be che@@ ck@@ ed@@ .
The decision whether to continue the patient on therapy with pi@@ o@@ gli@@ ta@@ zone should be guided by clinical jud@@ gement pending lab@@ oratory evalu@@ ations@@ .
If ja@@ un@@ di@@ ce is observ@@ ed@@ , drug therapy should be dis@@ continu@@ ed@@ .
Wei@@ ght ga@@ in@@ :
In clinical trials with pi@@ o@@ gli@@ ta@@ zone there was evidence of dose related weight ga@@ in@@ , which may be due to fat accum@@ ulation and in some cases associated with flu@@ id re@@ ten@@ tion@@ .
In some cases weight increase may be a symp@@ tom of cardi@@ ac fail@@ ure@@ , therefore weight should be closely monit@@ or@@ ed@@ .
Part of the treatment of diabetes is di@@ etary contro@@ l.
Pati@@ ents should be advised to ad@@ here stri@@ ctly to a cal@@ or@@ ie@@ -@@ controlled di@@ et@@ .
Ha@@ em@@ at@@ olog@@ y@@ :
There was a small reduction in mean ha@@ emo@@ glob@@ in (@@ 4@@ % relative re@@ duc@@ tion@@ ) and ha@@ em@@ at@@ o@@ cri@@ t (@@ 4.@@ 1@@ % relative re@@ duc@@ tion@@ ) during therapy with pi@@ o@@ gli@@ ta@@ z@@ one@@ , consistent with ha@@ emo@@ di@@ lu@@ tion@@ .
Simi@@ lar changes were seen in met@@ form@@ in (@@ ha@@ emo@@ glob@@ in 3 - 4@@ % and ha@@ em@@ at@@ o@@ cri@@ t 3.@@ 6 – 4.@@ 1@@ % relative re@@ duc@@ tions@@ ) and to a less@@ er extent sul@@ ph@@ on@@ y@@ lu@@ re@@ a and insu@@ lin (@@ ha@@ emo@@ glob@@ in 1 – 2@@ % and ha@@ em@@ at@@ o@@ cri@@ t 1 – 3.@@ 2@@ % relative re@@ duc@@ tions@@ ) treated patients in compar@@ ative controlled trials with pi@@ o@@ gli@@ ta@@ z@@ one@@ .
Hy@@ po@@ g@@ ly@@ ca@@ emi@@ a
As a consequ@@ ence of increased insu@@ lin sensi@@ tiv@@ it@@ y@@ , patients receiving pi@@ o@@ gli@@ ta@@ zone in dual or triple oral therapy with a sul@@ ph@@ on@@ y@@ lu@@ re@@ a or in dual therapy with insu@@ lin may be at risk for d@@ os@@ e@@ -@@ related hypo@@ g@@ ly@@ ca@@ emi@@ a@@ , and a reduction in the dose of the sul@@ ph@@ on@@ y@@ lu@@ re@@ a or insu@@ lin may be necess@@ ar@@ y@@ .
E@@ ye disor@@ der@@ s@@ :
Post@@ -@@ marketing reports of new@@ -@@ on@@ set or wor@@ sen@@ ing di@@ abe@@ tic mac@@ ular oe@@ de@@ ma with decre@@ ased visual ac@@ u@@ ity have been reported with thi@@ az@@ oli@@ d@@ ine@@ di@@ on@@ es@@ , including pi@@ o@@ gli@@ ta@@ z@@ one@@ .
Many of these patients reported con@@ current peri@@ pher@@ al oe@@ de@@ ma@@ .
It is unclear whether or not there is a direct association between pi@@ o@@ gli@@ ta@@ zone and mac@@ ular oe@@ de@@ ma but prescri@@ bers should be alert to the possibility of mac@@ ular oe@@ de@@ ma if patients report distur@@ ban@@ ces in visual ac@@ u@@ it@@ y@@ ; an appropriate oph@@ th@@ al@@ m@@ ological refer@@ ral should be consider@@ ed@@ .
O@@ ther@@ s@@ :
An increased inci@@ dence in bone frac@@ tures in women was seen in a po@@ ol@@ ed analysis of ad@@ verse event reports of bone fra@@ cture from rand@@ omi@@ se@@ d@@ , contro@@ lle@@ d@@ , double blind clinical trials in over 8@@ 100 pi@@ o@@ gli@@ ta@@ zone and 7@@ 400 compar@@ ator treated pati@@ ent@@ s@@ , on treatment for up to 3.5 ye@@ ar@@ s.
Fra@@ c@@ tures were observed in 2.@@ 6@@ % of women taking pi@@ o@@ gli@@ ta@@ zone compared to 1.@@ 7@@ % of women treated with a compar@@ ator@@ .
No increase in fra@@ cture rates was observed in men treated with pi@@ o@@ gli@@ ta@@ zone (@@ 1.@@ 3@@ %@@ ) versus compar@@ ator (@@ 1.@@ 5@@ %@@ )@@ .
4 The fra@@ cture inci@@ dence calcul@@ ated was 1.@@ 9 frac@@ tures per 100 patient years in women treated with pi@@ o@@ gli@@ ta@@ zone and 1.1 frac@@ tures per 100 patient years in women treated with a compar@@ ator@@ .
The observed excess risk of frac@@ tures for women in this dat@@ as@@ et on pi@@ o@@ gli@@ ta@@ zone is therefore 0.@@ 8 frac@@ tures per 100 patient years of use@@ .
In the 3.5 year cardi@@ ov@@ as@@ cular risk P@@ RO@@ active stu@@ dy@@ , 44@@ / 8@@ 70 (@@ 5.@@ 1@@ %@@ ; 1.@@ 0 frac@@ tures per 100 patient ye@@ ar@@ s@@ ) of pi@@ o@@ gli@@ ta@@ z@@ one@@ -@@ treated female patients experienced frac@@ tures compared to 23@@ / 9@@ 05 (@@ 2.@@ 5@@ %@@ ; 0.5 frac@@ tures per 100 patient ye@@ ar@@ s@@ ) of female patients treated with compar@@ ator@@ .
No increase in fra@@ cture rates was observed in men treated with pi@@ o@@ gli@@ ta@@ zone (@@ 1.@@ 7@@ %@@ ) versus compar@@ ator (@@ 2.@@ 1@@ %@@ )@@ .
The risk of frac@@ tures should be considered in the long term care of women treated with pi@@ o@@ gli@@ ta@@ z@@ one@@ .
As a consequ@@ ence of enh@@ ancing insu@@ lin ac@@ tion@@ , pi@@ o@@ gli@@ ta@@ zone treatment in patients with poly@@ cy@@ stic o@@ vari@@ an syn@@ drome may result in resu@@ mption of ov@@ ula@@ tion@@ .
These patients may be at risk of pregn@@ anc@@ y@@ .
Pati@@ ents should be aware of the risk of pregnancy and if a patient wishes to become pregnant or if pregnancy occ@@ urs@@ , the treatment should be dis@@ continued (@@ see section 4.@@ 6@@ )@@ .
Pi@@ o@@ gli@@ ta@@ zone should be used with caution during con@@ co@@ mit@@ ant administration of cy@@ to@@ ch@@ rome P@@ 450 2@@ C@@ 8 in@@ hi@@ bit@@ ors (@@ e@@ . g. gem@@ fi@@ bro@@ z@@ il@@ ) or in@@ duc@@ ers (@@ e@@ . g. ri@@ f@@ amp@@ ic@@ in@@ )@@ .
G@@ ly@@ ca@@ e@@ mic control should be monit@@ ored clos@@ el@@ y@@ .
Pi@@ o@@ gli@@ ta@@ zone dose adju@@ st@@ ment within the recommended pos@@ ology or changes in di@@ abe@@ tic treatment should be considered (@@ see section 4.@@ 5@@ )@@ .
Ac@@ tos tab@@ lets contain la@@ ct@@ ose mon@@ oh@@ y@@ dr@@ ate and therefore should not be administ@@ ered to patients with rare her@@ edi@@ tary problems of gal@@ act@@ ose int@@ oler@@ anc@@ e@@ , the L@@ app la@@ ct@@ ase def@@ ici@@ ency or glu@@ cos@@ e@@ -@@ gal@@ act@@ ose mal@@ absor@@ p@@ tion@@ .
4.@@ 5 Inter@@ action with other medic@@ inal products and other forms of inter@@ action
Inter@@ action studies have shown that pi@@ o@@ gli@@ ta@@ zone has no relevant effect on either the pharmac@@ ok@@ ine@@ tics or pharmac@@ o@@ dy@@ nami@@ cs of di@@ go@@ x@@ in@@ , war@@ far@@ in@@ , phen@@ pro@@ cou@@ mon and met@@ for@@ min@@ .
Co@@ -@@ administration of pi@@ o@@ gli@@ ta@@ zone with sul@@ ph@@ on@@ y@@ lu@@ re@@ as does not appear to affect the pharmac@@ ok@@ ine@@ tics of the sul@@ ph@@ on@@ y@@ lu@@ re@@ a.
Studies in man suggest no in@@ duction of the main indu@@ ci@@ ble cy@@ to@@ ch@@ rome P@@ 4@@ 50@@ , 1@@ A@@ , 2@@ C@@ 8@@ / 9 and 3@@ A@@ 4.
In vit@@ ro studies have shown no in@@ hibition of any sub@@ type of cy@@ to@@ ch@@ rome P@@ 4@@ 50.
Inter@@ actions with sub@@ stances met@@ aboli@@ sed by these enz@@ ym@@ es@@ , e@@ . g. oral contra@@ cep@@ tiv@@ es@@ , cy@@ clos@@ por@@ in@@ , cal@@ ci@@ um channel blo@@ cker@@ s@@ , and H@@ M@@ G@@ Co@@ A re@@ duc@@ t@@ ase in@@ hi@@ bit@@ ors are not to be expec@@ te@@ d.
Co@@ -@@ administration of pi@@ o@@ gli@@ ta@@ zone with gem@@ fi@@ bro@@ zil (@@ an in@@ hi@@ bit@@ or of cy@@ to@@ ch@@ rome P@@ 450 2@@ C@@ 8@@ ) is reported to result in a 3@@ -@@ fold increase in AU@@ C of pi@@ o@@ gli@@ ta@@ z@@ one@@ .
Since there is a potential for an increase in d@@ os@@ e@@ -@@ related ad@@ verse event@@ s@@ , a decre@@ ase in the dose of pi@@ o@@ gli@@ ta@@ zone may be needed when gem@@ fi@@ bro@@ zil is con@@ co@@ mit@@ antly administ@@ er@@ ed@@ .
C@@ lose monitoring of g@@ ly@@ ca@@ e@@ mic control should be considered (@@ see section 4.@@ 4@@ )@@ .
Co@@ - administration of pi@@ o@@ gli@@ ta@@ zone with ri@@ f@@ amp@@ ic@@ in (@@ an in@@ duc@@ er of cy@@ to@@ ch@@ rome P@@ 450 2@@ C@@ 8@@ ) is reported to result in a 54@@ % decre@@ ase in AU@@ C of pi@@ o@@ gli@@ ta@@ z@@ one@@ .
The pi@@ o@@ gli@@ ta@@ zone dose may need to be increased when ri@@ f@@ amp@@ ic@@ in is con@@ co@@ mit@@ antly administ@@ er@@ ed@@ .
C@@ lose monitoring of g@@ ly@@ ca@@ e@@ mic control should be considered (@@ see section 4.@@ 4@@ )@@ .
4.@@ 6 Pre@@ gn@@ ancy and la@@ ct@@ ation
Use in pregn@@ anc@@ y@@ :
Fo@@ et@@ al growth restri@@ ction was apparent in animal studies with pi@@ o@@ gli@@ ta@@ z@@ one@@ .
This was attri@@ but@@ able to the action of pi@@ o@@ gli@@ ta@@ zone in di@@ mini@@ shing the mat@@ ern@@ al hyper@@ insu@@ lin@@ a@@ emi@@ a and increased insu@@ lin resistance that occ@@ urs during pregnancy ther@@ eby reducing the availability of met@@ aboli@@ c sub@@ str@@ ates for fo@@ et@@ al gro@@ w@@ th@@ .
The relev@@ ance of such a mechan@@ ism in humans is unclear and pi@@ o@@ gli@@ ta@@ zone should not be used in pregn@@ anc@@ y@@ .
5 Use in bre@@ ast@@ -@@ fe@@ ed@@ ing@@ :
Pi@@ o@@ gli@@ ta@@ zone has been shown to be present in the milk of la@@ ct@@ ating rats@@ .
It is not known whether pi@@ o@@ gli@@ ta@@ zone is secre@@ ted in human mil@@ k@@ .
Ther@@ e@@ fore@@ , pi@@ o@@ gli@@ ta@@ zone should not be administ@@ ered to bre@@ ast@@ -@@ feeding wom@@ en@@ .
4.@@ 7 Eff@@ ects on ability to drive and use machines
No effects on ability to drive and use machines have been observ@@ ed@@ .
4.@@ 8 Un@@ desi@@ rable effects
Ad@@ verse re@@ actions reported in excess (@@ > 0.@@ 5@@ %@@ ) of pla@@ c@@ eb@@ o and as more than an isolated case in patients receiving pi@@ o@@ gli@@ ta@@ zone in dou@@ ble@@ -@@ blind studies are listed below as Med@@ DR@@ A preferred term by system organ class and absolute frequ@@ en@@ cy@@ .
Fre@@ qu@@ en@@ cies are defined as@@ : very common > 1@@ / 10@@ ; common > 1@@ / 100 ,@@ < 1@@ /@@ 10@@ ; un@@ common > 1@@ /@@ 1000 ,@@ < 1@@ /@@ 100@@ ; rare > 1@@ / 10@@ 000 ,@@ < 1@@ /@@ 10@@ 00@@ ; very rare < 1@@ /@@ 10@@ 00@@ 0@@ ; not known (@@ cannot be estimated from the available dat@@ a@@ )@@ .
Within each frequ@@ ency gro@@ up@@ ing@@ , un@@ desi@@ rable effects are presented in order of decre@@ asing seri@@ ous@@ ness@@ .
P@@ IO@@ G@@ L@@ IT@@ A@@ Z@@ ON@@ E M@@ ON@@ O@@ TH@@ ER@@ AP@@ Y E@@ ye disor@@ ders
Common@@ :
visual distur@@ b@@ ance
Inf@@ ection and in@@ fest@@ ations
Common@@ :
upper resp@@ ir@@ atory tra@@ ct infection
Un@@ common@@ : sin@@ usi@@ tis
Investig@@ ations
Common@@ :
weight increased
Ner@@ v@@ ous system disor@@ ders
Common@@ :
hypo@@ aes@@ the@@ sia
Un@@ common@@ : ins@@ om@@ nia
P@@ IO@@ G@@ L@@ IT@@ A@@ Z@@ ON@@ E IN CO@@ M@@ B@@ IN@@ AT@@ ION TH@@ ER@@ AP@@ Y W@@ IT@@ H ME@@ T@@ F@@ OR@@ M@@ IN Bloo@@ d and lymp@@ h@@ atic system disor@@ ders
Common@@ :
an@@ a@@ emi@@ a
E@@ ye disor@@ ders
Common@@ :
visual distur@@ b@@ ance
Gast@@ ro@@ inte@@ st@@ inal disor@@ ders
Un@@ common@@ : flat@@ ul@@ ence
Investig@@ ations
Common@@ :
weight increased
6 Mus@@ cul@@ os@@ kel@@ et@@ al system and connec@@ tive tissue disor@@ ders
Common@@ :
ar@@ th@@ r@@ al@@ gia
Ner@@ v@@ ous system disor@@ ders
Common@@ :
hea@@ da@@ che
Ren@@ al and ur@@ inary disor@@ ders
Common@@ :
ha@@ em@@ at@@ uri@@ a
Re@@ productive system and breast disor@@ ders
Common@@ :
er@@ ec@@ tile dys@@ function
P@@ IO@@ G@@ L@@ IT@@ A@@ Z@@ ON@@ E IN CO@@ M@@ B@@ IN@@ AT@@ ION TH@@ ER@@ AP@@ Y W@@ IT@@ H SU@@ L@@ PH@@ ON@@ Y@@ L@@ UR@@ EA E@@ ar and lab@@ y@@ r@@ inth disor@@ ders
Un@@ common@@ : verti@@ go
E@@ ye disor@@ ders
Un@@ common@@ : visual distur@@ b@@ ance
Gast@@ ro@@ inte@@ st@@ inal disor@@ ders
Common@@ :
flat@@ ul@@ ence
General disor@@ ders and administration site conditions
Un@@ common@@ : f@@ ati@@ gue
Investig@@ ations
Common@@ :
weight increased
Un@@ common@@ : increased la@@ ctic de@@ hydro@@ gen@@ ase
Met@@ aboli@@ sm and nutri@@ tional disor@@ ders
Un@@ common@@ : appeti@@ te increas@@ ed@@ , hypo@@ g@@ ly@@ ca@@ emi@@ a
Ner@@ v@@ ous system disor@@ ders
Common@@ :
di@@ zz@@ iness
Un@@ common@@ : hea@@ da@@ che
Ren@@ al and ur@@ inary disor@@ ders
Un@@ common@@ : g@@ ly@@ cos@@ uri@@ a@@ , prot@@ ein@@ uri@@ a
7 Sk@@ in and sub@@ cut@@ an@@ e@@ ous tissue disor@@ ders
Un@@ common@@ :
swe@@ ating
P@@ IO@@ G@@ L@@ IT@@ A@@ Z@@ ON@@ E IN TR@@ IP@@ LE OR@@ AL CO@@ M@@ B@@ IN@@ AT@@ ION TH@@ ER@@ AP@@ Y W@@ IT@@ H ME@@ T@@ F@@ OR@@ M@@ IN AND SU@@ L@@ PH@@ ON@@ Y@@ L@@ UR@@ EA
Investig@@ ations
Common@@ :
weight increas@@ ed@@ , blood cre@@ at@@ ine ph@@ osp@@ ho@@ kin@@ ase increased
Met@@ aboli@@ sm and nutri@@ tion disor@@ ders
Very common@@ :
hypo@@ g@@ ly@@ ca@@ emi@@ a
connec@@ tive tissue disor@@ ders
Common@@ :
ar@@ th@@ r@@ al@@ gia
P@@ IO@@ G@@ L@@ IT@@ A@@ Z@@ ON@@ E IN CO@@ M@@ B@@ IN@@ AT@@ ION TH@@ ER@@ AP@@ Y W@@ IT@@ H IN@@ SU@@ L@@ IN Met@@ aboli@@ sm and nutri@@ tion disor@@ ders
Common@@ :
hypo@@ g@@ ly@@ ca@@ emi@@ a
General disor@@ ders and administration site conditions
Very common@@ : oe@@ de@@ ma
Inf@@ ections and in@@ fest@@ ations
Common@@ :
bron@@ chi@@ tis
Investig@@ ations
Common@@ :
weight increase
Mus@@ cul@@ os@@ kel@@ et@@ al system and connec@@ tive tissue disor@@ ders
Common@@ :
back pain@@ , ar@@ th@@ r@@ al@@ gia
Res@@ pir@@ ator@@ y@@ , thor@@ ac@@ ic and medi@@ ast@@ inal disor@@ ders
Common@@ :
dy@@ sp@@ no@@ ea
Cardi@@ ac disor@@ ders
Common@@ :
heart failure
PO@@ ST@@ -@@ MAR@@ K@@ ET@@ ING D@@ AT@@ A
E@@ ye disor@@ ders Mac@@ ular oe@@ de@@ ma@@ : not known
8 O@@ e@@ de@@ ma was reported in 6 – 9@@ % of patients treated with pi@@ o@@ gli@@ ta@@ zone over one year in controlled clinical tri@@ al@@ s.
The oe@@ de@@ ma rates for compar@@ ator groups (@@ sul@@ ph@@ on@@ y@@ lu@@ re@@ a@@ , met@@ for@@ min@@ ) were 2 – 5@@ %@@ .
The reports of oe@@ de@@ ma were generally mild to moderate and usually did not require dis@@ continu@@ ation of treat@@ ment@@ .
In active compar@@ ator controlled trials mean weight increase with pi@@ o@@ gli@@ ta@@ zone given as mon@@ o@@ therapy was 2 – 3 kg over one ye@@ ar@@ .
This is similar to that seen in a sul@@ ph@@ on@@ y@@ lu@@ re@@ a active compar@@ ator gro@@ up@@ .
In combination trials pi@@ o@@ gli@@ ta@@ zone added to met@@ form@@ in resulted in mean weight increase over one year of 1.5 kg and added to a sul@@ ph@@ on@@ y@@ lu@@ re@@ a of 2.@@ 8 k@@ g.
In compar@@ ator groups addition of sul@@ ph@@ on@@ y@@ lu@@ re@@ a to met@@ form@@ in resulted in a mean weight gain of 1.3 kg and addition of met@@ form@@ in to a sul@@ ph@@ on@@ y@@ lu@@ re@@ a a mean weight loss of 1.@@ 0 k@@ g.
Vi@@ su@@ al distur@@ b@@ ance has been reported mainly early in treatment and is related to changes in blood glu@@ c@@ ose due to temporary alter@@ ation in the tur@@ gi@@ dity and re@@ fra@@ ctive index of the l@@ ens as seen with other hypo@@ g@@ ly@@ ca@@ e@@ mic ag@@ ent@@ s.
In clinical trials with pi@@ o@@ gli@@ ta@@ zone the inci@@ dence of elev@@ ations of AL@@ T greater than three times the upper limit of normal was equal to pla@@ c@@ eb@@ o but less than that seen in met@@ form@@ in or sul@@ ph@@ on@@ y@@ lu@@ re@@ a compar@@ ator gro@@ up@@ s.
Me@@ an levels of liver enz@@ ym@@ es decre@@ ased with treatment with pi@@ o@@ gli@@ ta@@ z@@ one@@ .
R@@ are cases of elev@@ ated liver enz@@ ym@@ es and he@@ pat@@ oc@@ ell@@ ular dys@@ function have occurred in post@@ -@@ marketing experi@@ en@@ ce@@ .
Although in very rare cases fatal outcome has been repor@@ te@@ d@@ , caus@@ al relationship has not been establi@@ sh@@ ed@@ .
In controlled clinical trials the inci@@ dence of reports of heart failure with pi@@ o@@ gli@@ ta@@ zone treatment was the same as in pla@@ c@@ ebo@@ , met@@ form@@ in and sul@@ ph@@ on@@ y@@ lu@@ re@@ a treatment gro@@ up@@ s@@ , but was increased when used in combination therapy with insu@@ lin@@ .
In an outcome study of patients with pre@@ -@@ existing major mac@@ ro@@ v@@ as@@ cular dise@@ as@@ e@@ , the inci@@ dence of serious heart failure was 1.@@ 6@@ % higher with pi@@ o@@ gli@@ ta@@ zone than with pla@@ c@@ ebo@@ , when added to therapy that included insu@@ lin@@ .
Ho@@ we@@ ver@@ , this did not lead to an increase in mort@@ ality in this stu@@ dy@@ .
Heart failure has been reported rarely with marketing use of pi@@ o@@ gli@@ ta@@ z@@ one@@ , but more frequently when pi@@ o@@ gli@@ ta@@ zone was used in combination with insu@@ lin or in patients with a history of cardi@@ ac fail@@ ure@@ .
A po@@ ol@@ ed analysis was conducted of ad@@ verse event reports of bone frac@@ tures from rand@@ omi@@ se@@ d@@ , compar@@ ator contro@@ lle@@ d@@ , double blind clinical trials in over 8@@ 100 patients in the pi@@ o@@ gli@@ ta@@ z@@ one@@ -@@ treated groups and 7@@ 400 in the compar@@ ator@@ -@@ treated groups of up to 3.5 years dur@@ ation@@ .
A higher rate of frac@@ tures was observed in women taking pi@@ o@@ gli@@ ta@@ zone (@@ 2.@@ 6@@ %@@ ) versus compar@@ ator (@@ 1.@@ 7@@ %@@ )@@ .
No increase in fra@@ cture rates was observed in men treated with pi@@ o@@ gli@@ ta@@ zone (@@ 1.@@ 3@@ %@@ ) versus compar@@ ator (@@ 1.@@ 5@@ %@@ )@@ .
In the 3.5 year P@@ RO@@ active stu@@ dy@@ , 44@@ / 8@@ 70 (@@ 5.@@ 1@@ %@@ ) of pi@@ o@@ gli@@ ta@@ z@@ one@@ -@@ treated female patients experienced frac@@ tures compared to 23@@ / 9@@ 05 (@@ 2.@@ 5@@ %@@ ) of female patients treated with compar@@ ator@@ .
No increase in fra@@ cture rates was observed in men treated with pi@@ o@@ gli@@ ta@@ zone (@@ 1.@@ 7@@ %@@ ) versus compar@@ ator (@@ 2.@@ 1@@ %@@ )@@ .
4.@@ 9 Over@@ dose
Pati@@ ents have taken pi@@ o@@ gli@@ ta@@ zone at higher than the recommended highest dose of 45 mg da@@ ily@@ .
The maximum reported dose of 120 m@@ g@@ / day for four da@@ ys@@ , then 180 m@@ g@@ / day for seven days was not associated with any symp@@ tom@@ s.
Hy@@ po@@ g@@ ly@@ ca@@ emi@@ a may occur in combination with sul@@ ph@@ on@@ y@@ lu@@ re@@ as or insu@@ lin@@ .
Symp@@ tom@@ atic and general supportive measures should be taken in case of over@@ d@@ os@@ e@@ .
5.
PH@@ AR@@ M@@ AC@@ OL@@ O@@ G@@ IC@@ AL P@@ RO@@ P@@ ER@@ T@@ IE@@ S
5.@@ 1 P@@ harm@@ ac@@ o@@ dynamic properties
P@@ harm@@ ac@@ o@@ therapeu@@ tic gro@@ up@@ : oral blood glu@@ c@@ ose lo@@ wering dru@@ gs@@ ; Thi@@ az@@ oli@@ d@@ ine@@ di@@ on@@ es@@ ; AT@@ C co@@ de@@ :
A@@ 10 B@@ G 0@@ 3.
9 Pi@@ o@@ gli@@ ta@@ zone effects may be medi@@ ated by a reduction of insu@@ lin resi@@ st@@ anc@@ e@@ .
Pi@@ o@@ gli@@ ta@@ zone appears to act via activ@@ ation of specific nuclear rec@@ ep@@ tors (@@ per@@ ox@@ is@@ ome proli@@ fer@@ ator activ@@ ated rec@@ ep@@ tor gam@@ ma@@ ) leading to increased insu@@ lin sensi@@ tivity of li@@ ver@@ , fat and sk@@ el@@ et@@ al muscle cells in anim@@ al@@ s.
Tre@@ at@@ ment with pi@@ o@@ gli@@ ta@@ zone has been shown to reduce he@@ pati@@ c glu@@ c@@ ose output and to increase peri@@ pher@@ al glu@@ c@@ ose dispos@@ al in the case of insu@@ lin resi@@ st@@ anc@@ e@@ .
Fast@@ ing and post@@ pran@@ di@@ al g@@ ly@@ ca@@ e@@ mic control is improved in patients with type 2 diabetes mel@@ li@@ t@@ us@@ .
The improved g@@ ly@@ ca@@ e@@ mic control is associated with a reduction in both fa@@ sting and post@@ pran@@ di@@ al p@@ las@@ ma insu@@ lin conc@@ entra@@ tions@@ .
A clinical trial of pi@@ o@@ gli@@ ta@@ zone vs. gli@@ cla@@ zi@@ de as mon@@ o@@ therapy was extended to two years in order to assess time to treatment failure (@@ defined as appearance of H@@ b@@ A@@ 1@@ c ≥ 8@@ .0@@ % after the first six months of therap@@ y@@ )@@ .
Kap@@ lan@@ -@@ Meier analysis showed shor@@ ter time to treatment failure in patients treated with gli@@ cla@@ zi@@ de@@ , compared with pi@@ o@@ gli@@ ta@@ z@@ one@@ .
At two ye@@ ar@@ s@@ , g@@ ly@@ ca@@ e@@ mic control (@@ defined as H@@ b@@ A@@ 1@@ c < 8@@ .0@@ %@@ ) was sustained in 69@@ % of patients treated with pi@@ o@@ gli@@ ta@@ z@@ one@@ , compared with 50@@ % of patients on gli@@ cla@@ zi@@ de.
In a two@@ -@@ year study of combination therapy compar@@ ing pi@@ o@@ gli@@ ta@@ zone with gli@@ cla@@ zi@@ de when added to met@@ for@@ min@@ , g@@ ly@@ ca@@ e@@ mic control measured as mean change from bas@@ eline in H@@ b@@ A@@ 1@@ c was similar between treatment groups after one ye@@ ar@@ .
The rate of deterior@@ ation of H@@ b@@ A@@ 1@@ c during the second year was less with pi@@ o@@ gli@@ ta@@ zone than with gli@@ cla@@ zi@@ de.
In a pla@@ c@@ eb@@ o controlled tri@@ al@@ , patients with in@@ adequate g@@ ly@@ ca@@ e@@ mic control despite a three month insu@@ lin opti@@ mis@@ ation period were rand@@ o@@ mis@@ ed to pi@@ o@@ gli@@ ta@@ zone or pla@@ c@@ eb@@ o for 12 mon@@ th@@ s.
Pati@@ ents receiving pi@@ o@@ gli@@ ta@@ zone had a mean reduction in H@@ b@@ A@@ 1@@ c of 0.@@ 45@@ % compared with those continuing on insu@@ lin al@@ one@@ , and a reduction of insu@@ lin dose in the pi@@ o@@ gli@@ ta@@ zone treated gro@@ up@@ .
HO@@ MA analysis shows that pi@@ o@@ gli@@ ta@@ zone impro@@ ves bet@@ a cell function as well as increasing insu@@ lin sensi@@ tiv@@ it@@ y@@ .
T@@ wo@@ -@@ year clinical studies have shown maintenance of this effec@@ t.
In one year clinical tri@@ al@@ s@@ , pi@@ o@@ gli@@ ta@@ zone consistently gave a stati@@ st@@ ically significant reduction in the alb@@ umin@@ / cre@@ at@@ in@@ ine ratio compared to bas@@ el@@ ine@@ .
The effect of pi@@ o@@ gli@@ ta@@ zone (@@ 45 mg mon@@ o@@ therapy vs. pla@@ c@@ ebo@@ ) was studied in a small 18@@ -@@ week trial in type 2 di@@ abe@@ tic@@ s.
Pi@@ o@@ gli@@ ta@@ zone was associated with significant weight ga@@ in@@ .
Vis@@ cer@@ al fat was significantly decre@@ as@@ ed@@ , while there was an increase in extra@@ -@@ ab@@ dom@@ inal fat mass@@ .
Simi@@ lar changes in body fat distribution on pi@@ o@@ gli@@ ta@@ zone have been accompanied by an improvement in insu@@ lin sensi@@ tiv@@ it@@ y@@ .
In most clinical tri@@ al@@ s@@ , reduced total p@@ las@@ ma trig@@ ly@@ c@@ eri@@ des and free fat@@ ty aci@@ ds@@ , and increased H@@ DL@@ -@@ chol@@ ester@@ ol levels were observed as compared to pla@@ c@@ ebo@@ , with sm@@ all@@ , but not clin@@ ically significant increases in L@@ DL@@ -@@ chol@@ ester@@ ol level@@ s.
In clinical trials of up to two years dur@@ ation@@ , pi@@ o@@ gli@@ ta@@ zone reduced total p@@ las@@ ma trig@@ ly@@ c@@ eri@@ des and free fat@@ ty aci@@ ds@@ , and increased H@@ DL chol@@ ester@@ ol level@@ s@@ , compared with pla@@ c@@ ebo@@ , met@@ form@@ in or gli@@ cla@@ zi@@ de.
Pi@@ o@@ gli@@ ta@@ zone did not cause stati@@ st@@ ically significant increases in L@@ DL chol@@ ester@@ ol levels compared with pla@@ c@@ ebo@@ , whilst re@@ ductions were observed with met@@ form@@ in and gli@@ cla@@ zi@@ de.
In a 20@@ -@@ week stu@@ dy@@ , as well as reducing fa@@ sting trig@@ ly@@ c@@ eri@@ des@@ , pi@@ o@@ gli@@ ta@@ zone reduced post pran@@ di@@ al hyper@@ trig@@ ly@@ c@@ eri@@ da@@ emi@@ a through an effect on both absor@@ bed and he@@ pati@@ cally syn@@ the@@ si@@ sed trig@@ ly@@ c@@ eri@@ des@@ .
These effects were independent of pi@@ o@@ gli@@ ta@@ z@@ one@@ ’ s effects on g@@ ly@@ ca@@ emi@@ a and were stati@@ st@@ ically significant different to gli@@ ben@@ cla@@ mi@@ de.
In P@@ RO@@ ac@@ ti@@ ve@@ , a cardi@@ ov@@ as@@ cular outcome stu@@ dy@@ , 5@@ 2@@ 38 patients with type 2 diabetes mel@@ li@@ tus and pre@@ -@@ existing major mac@@ ro@@ v@@ as@@ cular disease were rand@@ o@@ mis@@ ed to pi@@ o@@ gli@@ ta@@ zone or pla@@ c@@ eb@@ o in addition to existing anti@@ di@@ abe@@ tic and cardi@@ ov@@ as@@ cular therap@@ y@@ , for up to 3.5 ye@@ ar@@ s.
The study population had an average age of 62 ye@@ ar@@ s@@ ; the average dur@@ ation of diabetes was 9.@@ 5 ye@@ ar@@ s.
Ap@@ pro@@ xim@@ ately one third of patients were receiving insu@@ lin in combination with met@@ form@@ in and@@ / or a sul@@ ph@@ on@@ y@@ lu@@ re@@ a.
To be eligible patients had to have had one or more of the follo@@ w@@ ing@@ : m@@ yo@@ cardi@@ al inf@@ ar@@ c@@ tion@@ , stro@@ ke@@ , per@@ cut@@ an@@ e@@ ous cardi@@ ac intervention or cor@@ on@@ ary ar@@ tery b@@ yp@@ ass gra@@ ft@@ , ac@@ ute cor@@ on@@ ary syn@@ dro@@ me@@ , cor@@ on@@ ary ar@@ tery dise@@ as@@ e@@ , or peri@@ pher@@ al ar@@ ter@@ ial ob@@ stru@@ ctive dise@@ as@@ e@@ .
Almost half of the patients had a previous m@@ yo@@ cardi@@ al inf@@ ar@@ ction and approximately 20@@ % had had a stro@@ ke@@ .
Ap@@ pro@@ xim@@ ately half of the study population had at least two of the cardi@@ ov@@ as@@ cular history entry cri@@ teri@@ a.
Almost all subjects (@@ 9@@ 5@@ %@@ ) were receiving cardi@@ ov@@ as@@ cular medic@@ ations (@@ bet@@ a blo@@ cker@@ s@@ , AC@@ E in@@ hi@@ bit@@ or@@ s@@ , an@@ gi@@ ot@@ ens@@ in II ant@@ agon@@ ist@@ s@@ , cal@@ ci@@ um channel blo@@ cker@@ s@@ , nit@@ rat@@ es@@ , di@@ ure@@ tic@@ s@@ , asp@@ ir@@ in@@ , stat@@ ins@@ , fi@@ br@@ at@@ es@@ )@@ .
10 Although the study failed regarding its primary end@@ poin@@ t@@ , which was a com@@ posite of all@@ -@@ cause mort@@ al@@ it@@ y@@ , non@@ - fatal m@@ yo@@ cardi@@ al inf@@ ar@@ c@@ tion@@ , stro@@ ke@@ , ac@@ ute cor@@ on@@ ary syn@@ dro@@ me@@ , major leg amp@@ ut@@ ation@@ , cor@@ on@@ ary rev@@ as@@ cul@@ ar@@ isation and leg rev@@ as@@ cul@@ ar@@ is@@ ation@@ , the results suggest that there are no long@@ -@@ term cardi@@ ov@@ as@@ cular concerns regarding use of pi@@ o@@ gli@@ ta@@ z@@ one@@ .
Ho@@ we@@ ver@@ , the inci@@ den@@ ces of oe@@ de@@ ma@@ , weight gain and heart failure were increas@@ ed@@ .
No increase in mort@@ ality from heart failure was observ@@ ed@@ .
5.@@ 2 P@@ harm@@ ac@@ ok@@ ine@@ tic properties
Ab@@ sor@@ p@@ tion@@ :
Following oral administ@@ ration@@ , pi@@ o@@ gli@@ ta@@ zone is rapidly absor@@ bed@@ , and peak p@@ las@@ ma conc@@ ent@@ rations of un@@ changed pi@@ o@@ gli@@ ta@@ zone are usually achieved 2 hours after administ@@ ration@@ .
Pro@@ por@@ tional increases of the p@@ las@@ ma concentration were observed for d@@ oses from 2 – 60 m@@ g.
Ste@@ ady state is achieved after 4@@ – 7 days of d@@ os@@ ing@@ .
Re@@ pe@@ ated d@@ osing does not result in accum@@ ulation of the compound or met@@ aboli@@ tes@@ .
Ab@@ sor@@ ption is not influ@@ enced by food in@@ take@@ .
Absol@@ ute bio@@ availability is greater than 80@@ %@@ .
Distri@@ bu@@ tion@@ :
The estimated volume of distribution in humans is 0.@@ 25 l@@ / k@@ g.
Pi@@ o@@ gli@@ ta@@ zone and all active met@@ aboli@@ tes are exten@@ sively bound to p@@ las@@ ma protein (@@ > 99@@ %@@ )@@ .
Met@@ aboli@@ sm@@ :
Pi@@ o@@ gli@@ ta@@ zone under@@ goes extensive he@@ pati@@ c met@@ aboli@@ sm by hydro@@ x@@ y@@ lation of ali@@ ph@@ atic meth@@ yl@@ ene gro@@ up@@ s.
This is pre@@ domin@@ antly via cy@@ to@@ ch@@ rome P@@ 450 2@@ C@@ 8 although other is@@ o@@ forms may be involved to a less@@ er de@@ gre@@ e@@ .
